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ABSTRACT 
 
 Inducing the heat shock response (HSR) through Hsp90 inhibition augments heat shock 
protein (Hsp) support and may improve several aspects of neurodegenerative phenotypes.  
Several Hsps serve as molecular chaperones that assist in the folding of nascent polypeptides 
(client proteins) into their mature conformations.  They also act as intracellular triage units 
that refold damaged proteins, stabilize protein complexes, solubilize protein aggregates, and 
help clear irreparable proteins.  A confounding issue surrounding Hsp90 inhibitors is their 
inability to generate therapeutic windows that dissociate cytotoxic client protein degradation 
from HSR induction.  Our novel C-terminal Hsp90 inhibitor, KU-32, induces the HSR while 
divesting client protein degradation, thus expanding the dose range for neuroprotection. 
 After 16 weeks of streptozotocin (STZ)-induced Type 1 diabetes in Swiss-Webster mice, 
KU-32 was intraperitoneally injected weekly at a dose of 20 mg/kg KU-32 (~ 43 mM 
Captisol/saline vehicle) for 10 weeks.  Untreated diabetic mice developed significant 
reductions in motor and sensory nerve conduction velocities and worsening thermal and 
mechanical hypoalgesia.  KU-32 intervention time-dependently restored these deficits back 
to untreated non-diabetic levels, without adversely affecting non-diabetic mice.  Further, 
untreated diabetic mice exhibited a 31% reduction in hindpaw intraepidermal nerve fiber 
(iENF) density by 16 weeks, which remained consistent until study completion.  KU-32 
improved diabetic iENF density to within 11% of non-diabetic levels by 26 weeks.   
 To assess mitochondrial function, a 96-well Extracellular Flux (XF96) Analyzer was 
used to measure oxygen consumption rates (OCRs) for lumbar (L4-L6) dorsal root ganglia 
(DRG) isolated and cultured upon study completion at 26 weeks.  Treatment with the ATP 
synthase inhibitor oligomycin reduced diabetic OCRs by ~ 80%, indicating that diabetic 
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DRG devote most of their basal oxygen consumption to ATP synthesis.  This is over twice 
that of untreated non-diabetic DRG at ~ 35%.  KU-32 treatment in STZ-diabetes improved 
OCR reductions to ~ 40%, signifying vast improvements to ATP synthesis efficiency.  Upon 
protonophore injection, DRG from KU-32-treated diabetic mice exhibited a much higher 
rebound in OCRs compared to diabetes alone, suggesting possible improvements in 
resiliency to prolonged metabolic stress.  Overall, these data suggest that the neuroprotective 
effects of KU-32 at more chronic stages of diabetic peripheral neuropathy (DPN) may stem 
from  ability to improve mitochondrial function and nerve fiber innervation.  
 KU-32 pharmacokinetic (PK) analyses were also performed on DPN-relevant tissues to 
verify successful drug distribution and elimination from these tissues after intraperitoneal 
(IP) or oral gavage (OG) treatments.  The results showed that KU-32 was rapidly absorbed 
and distributed to DPN-relevant tissues within 30 minutes of IP treatment and one hour of 
gavage.  Temporal PK analyses suggested that 99.9% of KU-32 distributed to these tissues 
was eliminated within ~ 30 hours of treatment.  This was consistent with findings from an 
8-week intervention study, which showed virtually no detectable levels of KU-32 present in 
diabetic and non-diabetic tissues one week after final treatment.  In support of the ongoing 
hypothesis that inducible Hsp70 is essential for KU-  neuroprotective effects in DPN, we 
showed that drug distribution to DPN-relevant tissues were indistinguishable between 
wild-type C57BL/6 and Hsp70 KO mice.  OG also increased drug elimination half-lives for 
all examined tissues compared to IP treatments, suggesting that OG drug delivery may 
beneficially increase drug exposure duration.   
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CHAPTER I:  INTRODUCTION 
 
SECTION 1.  DIABETES MELLITUS 
1.1.  Epidemiology of Diabetes Mellitus 
 By 2030, diabetes mellitus will affect over 550 million people worldwide, or one in 
every ten adults.1-3  Diabetes mellitus is a heterogeneous group of metabolic disorders 
characterized by persistent hyperglycemia that results from dysfunctional insulin signaling.4  
This non-communicable disease accounts for 8% of global mortality in adults (ages 20-79), 
and will presumably become the seventh leading cause of death by 2030.1-2, 5  Diabetes has 
reached epidemic levels, generating serious international health concerns and igniting public 
health awareness initiatives by the United Nations and its member states (most notably the 
United States, China, India, the Russian Federation, Brazil, and Mexico).2, 6-8   
The International Diabetes Federation (IDF) affirms that half of the approximate 371 
million adults currently living with diabetes are undiagnosed and unaware of their 
condition.1  This is partially attributed to the reality that 80% of all diabetics live in low- and 
middle-income regions.1-2, 9-10  Financial hardships, lack of insurance coverage, 
socioeconomic barriers, uncoordinated care, and shortages in healthcare professionals often 
hinder the timely acquisition of appropriate health care in these regions.8-13  In countries 
undergoing rapid urbanization and development, increases in population, lifespan, and 
sedentary lifestyles often boost the number of Type 2 diabetic patients flooding the local 
medical treatment facilities.3, 5, 7-11, 14-15  While Type 1 diabetes typically requires lifesaving 
medical interventions and diagnosis early in life, Type 2 diabetes generally develops much 
later and may take several years from disease onset to reach a clinical diagnosis (discussed 
in-depth in Classification of Diabetes Mellitus).4, 9, 14, 16-20  Besides the occasional periodic 
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health assessment, the detection of Type 2 diabetes ultimately requires the patient to 
recognize health abnormalities and to willingly seek out medical attention.4, 9, 14  For these 
reasons, diabetes prevalence estimates must consider the likely lag in clinical diagnoses.  
As alluded to previously, the global burden of diabetes is not evenly distributed.  While 
the top ten most populated countries account for ~ 63% of adult diabetes cases (ages 20-79), 
it is the smaller countries that are experiencing the worst of the epidemic.1-3, 5, 7-11  In fact, 
the highest comparative prevalence  of diabetes lies in the Middle East (Kuwait, Bahrain, 
Saudi Arabia, and Qatar at 22-24%) and several Pacific island states [Federated States of 
Micronesia , Kiribati, Nauru, Tuvalu, Vanuatu, and the Marshall Islands at 22-37%].1  
Comparative prevalence in these regions is often two to three times greater than any other 
region (e.g. United States at 9.4%, Mexico at 15.6%, India at 9.0%, and China at 8.8%).1   
In the United States, diabetes affects about 7% of the total population, with 2012 reports 
confirming at least 22.3 million cases.12  In U.S. adults (ages 20-79), clinically diagnosed 
diabetics account for ~ 8% of the subpopulation, while another 3% remain presumably 
undiagnosed.1-2  This prevalence will likely exceed 25% by 2050.21  With this dreary 
forecast, the economic burden of diabetes in the United States has not gone unrealized.12, 21   
Medical treatments for diabetes mellitus cost the United States nearly $176 billion in 
2012, a 30% increase since 2007.12  Over one-quarter of these expenditures were attributed 
to prescription medications.12  In fact, while U.S. medication costs reached $286 billion in 
2012, $50 billion worth of this medication went to treat diabetes.12  The average U.S. 
diabetic spends ~ 2.3 times more each year on medical care than the typical non-diabetic.12, 
21  
                                                 
 In contrast to national prevalence, comparative prevalence alleviates region-specific variations in age by 
normalizing to world population age profiles, thereby ensuring more appropriate comparisons   
 The Federated States of Micronesia is the global leader with 37.2% comparative prevalence 
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 deterioration not only impacts 
members and friends.12-13, 20, 22  Premature mortality can also decimate household incomes 
and family savings.  During these economically challenging times in the Untied States, the 
untimely deaths of 246,000 diabetics amounted to $18.5 billion in lost productivity in 
2012.12  These societal burdens will continue to grow as the diabetes foothold strengthens. 
Despite its global prevalence and societal burdens, there is still a pressing need to 
develop new drugs that effectively treat diabetes and its associated complications.  Although 
controlled insulin therapy significantly decelerates the rate of progression of diabetes, 
complications still develop and represent a significant risk to the overall deterioration of a 
person 23-25  Unfortunately, medicinal treatment options for diabetic complications 
are limited in that they typically offer monosymptomatic relief or target single pathogenic 
mechanisms commonly associated with hyperglycemia.26  This is especially true in the 
treatment of diabetic peripheral neuropathy (DPN).26  DPN patients commonly exhibit 
multiple clinical symptoms that lead physicians to prescribe several medications to address 
individual symptoms.27  This partially drives diabetes medication costs and increases the 
potential risks for drug-drug, drug-nutrient, and drug-disease interactions.12, 27  For these 
reasons, DPN could benefit from a more multifaceted therapeutic approach. 
Herein, an examination of diabetes mellitus and its substantial burden upon the nervous 
system will be conducted.  Further discussion will emphasize the development of DPN 
(SECTION 2), modern pharmacotherapeutics (SECTION 3), and the therapeutic potential 
associated with targeting heat shock proteins (SECTION 4).  Preliminary work (2010 
ill also be summarized in SECTION 4.28 
 
 4 
1.2.  Clinical Diagnosis and Classification of Diabetes Mellitus 
 To better understand the modern consensus concerning the classification and clinical 
diagnosis of diabetes mellitus, a short historical review regarding their derivation follows.  
This review introduces the condition of prediabetes alongside present-day clinical diagnostic 
measurements.  Modern clinical diagnostic criteria and classifications will be discussed 
subsequently in their respective sections. 
1.2.1.  Historical Prelude   
In 1979, the National Diabetes Data Group (NDDG) published the first widely accepted 
classification system and clinical diagnostic criteria for diabetes mellitus.29-30  The 
publication elicited prompt support by the World Health Organization (WHO) and sparked a 
global push for standardization amongst the clinical diabetes community.29, 31  The NDDG 
and WHO collectively established what became commonly known as insulin-dependent 
diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM), gestational 
diabetes mellitus (GDM), and malnutritional diabetes.29-32  These categories were based 
largely upon clinical manifestations and pharmacologic requirements, such as insulin-
dependency.29-32  Over time, diabetes mellitus became a label used to describe several 
disorders that merely shared hyperglycemic phenotypes, but were otherwise etiologically 
distinct.29-32  With advancements in diabetes etiology imminent, this classification system 
became obsolete by the turn of the century.29   
In contrast, clinical diagnostic criteria utilized metabolic screening techniques that have 
been largely preserved in the clinic today [i.e. 2-hour oral glucose tolerance test (OGTT) and 
fasting plasma glucose (FPG) measurements].29-32  These diagnostic parameters enabled 
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differentiation between diabetes, non-diabetes, and impaired glucose tolerance in children as 
well as pregnant and non-pregnant adults.29-32   
1.2.2.  Establishment of Prediabetes  
 After nearly two decades of etiological advancements in diabetes, committees were 
established by the American Diabetes Association  (ADA) and the WHO  to modernize 
diabetes diagnostic criteria and classifications.29, 33-34  These committees expanded upon the 
impaired glucose tolerance condition previously outlined by the NDDG and WHO.29-31, 33-34  
They recognized the presence of an intermediate metabolic state that manifests between 
normal glucose homeostasis and the lower diagnostic limits for clinical diabetes.29, 33-34  
Although this intermediate state is not a clinical entity per se, it serves as an important 
biomarker for patients at serious risk of developing diabetes and associated cardiovascular  
complications.4, 18-20, 29, 33, 35-36  ular 
metabolic anomalies:  impaired glucose tolerance and/or impaired fasting glucose.29-32, 34, 36 
1.2.3.  Impaired Glucose Tolerance and Impaired Fasting Glucose 
Impaired glucose tolerance (IGT) is determined using the 2-hour OGTT in accordance 
with WHO standards.31, 37  Venous plasma glucose levels are measured two hours after the 
oral administration of 75 g anhydrous glucose (dissolved in water).4, 29, 31, 33, 35, 37  Plasma 
glucose levels of 140-199 mg/dl (7.8-11.0 mM) are considered positive for IGT.4, 29, 33, 35   
Impaired fasting glucose (IFG) was introduced by the ADA in 1997 and requires venous 
FPG measurements after eight hours of caloric restriction.29, 33, 38  According to 2003 ADA 
standards, patients with FPG levels of 100-125 mg/dl (5.6-6.9 mM) are positive for IFG.4, 29, 
33, 35  
                                                 
 Expert Committee on Diagnosis and Classification of Diabetes Mellitus; 1997 and 2003 
 WHO Consultation; 1998 
 Microvascular deterioration is often already underway 
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Instead, they retain use of the original IFG lower cutoff of 110 mg/dl (6.1 mM) established 
back in 1997.29, 33, 35  Both of these metabolic anomalies, IGT and IFG, are elevated in 
patients with clinical diabetes (discussed below). 
1.2.4.  Glycated Hemoglobin 
 In addition to IFG and IGT, the detection of glycated hemoglobin (HbA1C) enables 
physicians to assess long-term changes in blood-glucose levels over an 8-12 week period.4, 
38-42  HbA1C represents a group of naturally occurring, non-enzymatic, post-translational 
modifications known as advanced glycation end-products (AGEs), whose levels become 
exacerbated during prolonged periods of hyperglycemia [discussed in-depth in Advanced 
Glycation End-Products].39, 41-48  HbA1C levels are generally expressed as a percentage of 
total hemoglobin within a collected whole blood sample using a standard A1C meter.40-42  
Prediabetes HbA1C levels generally range between 5.7-6.4%.4, 40-41  Based upon HbA1C and 
FBG data from 2005-2008, prediabetes presumably affects ~ 35% of the current U.S. adult 
population over 20 years of age and 50% of the elderly over 65 years.20  After much debate 
concerning test standardization, availability, and storage, an international consensus was 
finally achieved in 2009 regarding the clinical use of HbA1C for diagnosis.35, 40-41   
1.2.5.  Clinical Diagnosis of Diabetes Mellitus 
1.2.5.1.  Diagnostic Criteria for Diabetes Mellitus 
 In addition to prediabetes screening, IFG, IGT, and HbA1C metabolic tests provide the 
diagnostic parameters required for the clinical diagnosis of diabetes.4, 29, 33-35, 38-41  Simply 
put, individuals with IFG, IGT, or HbA1C results that exceed the prediabetes parameters 
described above meet the clinical diagnostic criteria for diabetes.4, 29, 33-35, 38-41  Conversely, 
individuals with test results below prediabetes parameters are non-diabetic.4, 29, 33-35, 38-41  
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Test selection is ultimately time-, resource-, and physician-dependent.  In dire situations, a 
patient displaying classic hyperglycemia symptoms can be clinically diagnosed by a random 
plasma glucose measurement of 200 mg/dl (11.1 mM) or greater.4, 38  While these diagnostic 
criteria address most types of diabetes, gestational diabetes mellitus remains an exception.   
1.2.5.2.  Diagnostic Criteria for Gestational Diabetes Mellitus 
 In determining gestational diabetes mellitus (GDM), women are administered the 75 g 
OGTT at 24-28 weeks of pregnancy.4, 49  After an 8-hour overnight fast, venous plasma 
glucose levels are measured immediately before glucose ingestion (FPG) and again 1-hour 
and 2-hours later (OGTT).4, 49  GDM is diagnosable if any of the following criteria are met:  
FPG > 5.1 mM; 1-hour OGTT > 10.0 mM; or 2-hour OGTT > 8.5 mM.4, 49  These criteria 
were established by the 2008-2009 International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) with input from several international obstetrical and diabetes 
organizations, including the ADA.4  In 2013, the WHO adopted this criteria as well.49 
1.2.6.  Classification of Diabetes Mellitus 
 ADA and WHO modernization efforts near the turn of the century produced the more 
appropriate, etiology-based diabetes classification system in use today.29, 33-35, 49  
Dysfunctional insulin signaling underlies all types of diabetes mellitus.  The main types of 
diabetes mellitus include:  Type 1, Type 2, and gestational diabetes mellitus.   
1.2.6.1.  Type 1 Diabetes Mellitus (T1DM) 
1.2.6.1.1.  Epidemiology of T1DM 
 Type 1 diabetes mellitus (T1DM), formerly known as insulin-dependent diabetes 
mellitus (IDDM) or, comprises 5-10% of all diabetic cases.20  T1DM is the third most 
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common chronic childhood disease , affecting an estimated 490,000 children (ages 0-14) 
worldwide in 2011.1, 50  This global prevalence is increasing by an average of 3% each 
year.20  Significant differences in geographic distribution also exist.  Northern European 
nations, such as Sweden, Norway, Finland, and the United Kingdom, are amongst the world 
leaders in T1DM prevalence in children (ages 0-14 years).1, 50  As one travels south to Italy, 
Spain, and France, these incidents taper down to nearly half.1, 50  In contrast, the United 
much more evenly dispersed.50  
This is likely attributed to the inherent, widespread ethnic diversity of the United States.50   
 Type 1 diabetes affects an estimated 970,000 Americans, or 0.34% of the total U.S. 
population.51  Approximately 20%  of these Type 1 diabetics are children and young adults 
(0.24% of Americans under 20 years).51-52  Furthermore, T1DM accounts for over 80% of all 
new diabetes cases in children and young adults (under 20 years).20, 50  Age, race, and sex 
have no noticeable impact upon T1DM prevalence.1, 51    
1.2.6.1.2.  Pathogenesis and Natural History of T1DM 
T1DM is a relapsing-remitting autoimmune disease 
islets of Langerhans and/or circulating insulin are selectively targeted through immune-
mediated elimination.53-56  This res
insulin supply and a lifelong dependence upon exogenous insulin.55  The pathogenesis and 
natural history of T1DM are reviewed herein.    
A revolutionary T1DM pathogenic model was proposed by Eisenbarth in 1986.57-58  
observed in patients prior to clinical disease onset, are linked to the additional polyendocrine 
                                                 
 Asthma and obesity are the most common 
 Extrapolation from 2010 (1) T1DM prevalence (0.24%) and (2) population census (82,267,556) reporting for 
Americans under 20 years of age. 
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deficiencies and the chronic autoimmunity [islet-cell cytoplasmic autoantibodies (ICAs)] 
also observed in these patients.57-58  This was reinforced by clinical immunosuppressive 
therapies (i.e. antithymocyte globulin and cyclosporine A) of the time, which favorably 
hindered Type 1 diabetes progression.57-60  Unfortunately, the specific mechanisms and 
putative stimuli responsible for triggering this autoimmunity and the r
insulin are progressively and selectively targeted remain unclear to this day.53, 61-65   
Clinical T1DM generally manifests as the functional integrity and/or viability of a 
-20%.53, 66  Hence, there is a distinct 
delay between the initial onset of autoimmunity and the development of overt diabetes.53  
This prediabetic period can vary in duration from weeks to several years before ultimately 
developing into clinical T1DM.62, 65-66  
autoantibodies does not necessarily guarantee that a patient will always develop clinical 
Type 1 diabetes.62, 66-67  For a long time it was thought that this autoimmune assault occurs 
uninterrupted and at a constant rate until all 53, 57  Although complete 
within 2-3 years of clinical onset, it is now 
53, 67-70  Also, the 
pathological development of T1DM progresses more realistically in waves of autoimmune 
bombardment as opposed to previous notions of a more constant, full frontal assault.53-54, 56 
 Autoimmunity in T1DM is a cyclic process.53-54, 56, 65  Under normal conditions, 
peripheral tolerance is afforded by regulatory T lymphocytes (Treg cells) that suppress 
autoreactive helper T lymphocytes (autoreactive Th cells) that manage to escape negative 
selection in the thymus (i.e. central tolerance).53, 65, 71  In most T1DM cases, a gradual 
disequilibrium between these two groups develops over time.53, 65  This leads to the 
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accumulation of autoreactive Th cells that can infiltrate the pancreatic islets most likely via 
the pancreatic lymph nodes.53, 64-65  During early pathogenic stages, a trailing upsurge of Treg 
cell production usually restores homeostatic restraint over the autoreactive Th cells until the 
next influx occurs.53, 65  Unfortunately, the effectiveness of each successive Treg cell ramp up 
lessens over time until eventually the Treg cells are unable to contain the amplifying number 
of autoreactive Th cells.65, 67, 71  These autoreactive Th cells bind to autoantigen-presenting 
65, 71  Consequently, cytotoxic T 
lymphocytes ( -generated autoantibodies are 
recruited to the islets, where inflammation (insulitis) ensues.65, 71     
 
process.69-70  This is presumed to be a compensatory mechanism (negative feedback) 
triggered in response to diminished insulin support. 52, 64, 65  Alas, these attempts only 
intensify subsequent autoimmune cycles by increasing 53, 56, 69-70, 72  
 As insulitis develops, malnutrition and hyperglycemia set in.56  This forces a patient to 
either undergo exogenous insulin-replacement therapy or risk death.56  Within weeks of 
initiating subcutaneous insulin therapy, patients frequently experience a phenomenon known 
-to-complete correction of hyperglycemia can 
occur.56, 70, 72  During this short-lived period, the amount of required insulin usually drops to 
less than 0.5 units of insulin/kg/day.73  It has been proposed that this supplementation 
temporarily reduces glucotoxicity to the point that some recovery of endogenous insulin 
secretion is able to take place.72  70  
Although only half of T1DM children experience a significant honeymoon phase, this phase 
 
 11 
can last up to two years.56, 74-75  Regardless, hyperglycemia inevitably returns, bringing with 
it an increased requirement for exogenous insulin and the risk for chronic complications.56    
1.2.6.1.3.  Risk Factors for T1DM 
 Although the underlying factors associated with T1DM autoimmunity remain elusive, 
several exogenous factors are known to encourage autoimmune progression.53, 63, 65, 76  These 
entail both hereditary and environmental risk factors.53, 63, 65, 76   
1.2.6.1.3.1.  Hereditary Risk Factors for T1DM 
 There is a strong genetic basis for the development of T1DM.  The risk of developing 
T1DM increases nearly 15-fold (~ 5%) in Americans with Type 1 diabetic siblings or 
parents.51, 77  Concordance rates in dizygotic (fraternal) twins are slightly higher at 6-10%.77  
Interestingly, while children of Type 1 diabetic mothers have about a 2% chance of 
developing Type 1 diabetes, children of diseased fathers are higher at around 7%.77  This 
suggests some sex-linked genetic tendencies.  Since monozygotic twins share nearly 
identical genotypes and associated phenotypes (e.g. disease susceptibility and development), 
identical twin studies are generally used to distinguish exclusive genetic predisposition from 
environmental contributing factors in disease etiology.  Although T1DM concordance rates 
historically range between 30-50%, a more recent U.S. study has shown that more long-term 
observations increase disease concordance rates to ~ 65% by 60 years of age.78-82  In this 
same study, T1DM concordance rates were only 15-20% by 20 years of age.82  Hence, while 
clinical disease onset in identical twins may be more discordant early on, concordance rates 
increase over time.82  Collectively, these data refute an exclusive genetic basis for T1DM.   
 Linkage analyses between two T1DM first-degree relatives (especially between siblings) 
have identified several broad, genomic regions that contribute to overall T1DM risk.58  The 
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identification of these inherited risk factors has been significantly accelerated with the recent 
advent of genome-wide association studies (GWAS).83-84  Collectively, over 50 genomic loci 
have been identified to affect T1DM development.84-86  Nearly all of these regions encode 
genes involved in immunity, insulin production, and metabolism.53, 84  However, most of 
these identified risk factors have only marginal impacts upon T1DM development.85  
Therefore, only the four most well-established, high risk loci will be addressed.    
1.2.6.1.3.1.1.  Human Leukocyte Antigen  
 The strongest region of the genome associated with T1DM development is found on the 
short arm of chromosome 6 (locus 6p21.3), a large region encoding components of the 
human leukocyte antigen (HLA) system.53, 76, 83-84  The HLA system is the major 
histocompatibility complex (MHC) in humans.87  These HLA genes encode a wide variety 
-
or impending pathogenic threats.62, 67, 76, 87-88  The HLA region of chromosome 6 contains 
over 200 genes that are susceptible to massive amounts of genetic polymorphisms; some of 
these genes have over a hundred alleles. 62, 67, 76, 87-88 
 Several HLA alleles have been shown to either accelerate or protect against pancreatic 
autoimmunity.4, 62, 67, 76, 87, 89  For instance, HLA class II-derived proteins are found only on 
the surfaces of cells rooted in bodily defense mechanisms (e.g. macrophages, dendritic cells, 
B lymphocytes, and islet epithelial cells).76   These membrane proteins present proteolytic 
fragments of endocytosed pathogens/short viral peptides as antigens for targeted elimination.  
The HLA class II gene variants HLR-DR and HLA-DQ confer 40-50% of known inherited 
T1DM risk.62, 90  In contrast, some class II HLA-DR and HLA-DQ alleles (e.g. DRB1*0403, 
DRB1*1401, and DQB1*0602) may actually protect against disease progression.91-93   
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 Several HLA class I alleles can also accelerate (e.g. HLA-A*24, A*30 and B*18) or 
protect (e.g. HLA-A*01, A*03, A*28, B*14, and B*56) against T1DM progression.62, 94  
HLA class I-derived proteins, which are found on nearly all cells, present proteolytic 
fragments from infiltrating pathogens and viruses for immune-mediated elimination.62, 76, 87  
Although HLA class I gene variants have historically been regarded as secondary to class II 
variant disease associations, evidence of their role in T1DM progression is increasing.62  
Nevertheless, how HLA class I and class II variants specifically thwart or facilitate central 
or peripheral tolerance is not fully understood.4, 62, 76, 83, 87     
1.2.6.1.3.1.2.  Lymphoid Tyrosine Phosphatase  
 Another gene implicated in T1DM risk is PTPN22 (tyrosine-protein phosphatase non-
receptor type 22) on chromosome 1p13.62, 84, 95  This encodes lymphoid tyrosine phosphatase 
(LYP), which negatively regulates T cell receptor (TCR) signaling.62, 84, 95  TCR signaling is 
what causes naïve CD4+ T cells to differentiate into Treg and autoreactive Th cells in the 
thymus if they are autoantigen-reactive.95  This results in the termination of autoreactive Th 
cells and the dispatch of policing Treg cells to the periphery.95  Naïve CD4+ T cells that 
survive the thymic screening process then enter circulation in search of antigen-presenting, 
HLA-derived proteins.71, 95  In the periphery, TCR signaling triggers naïve CD4+ T cell 
differentiation as well as an adaptive immune response.71, 95    
 TCR signaling initiates once antigen-presenting HLA-derived proteins bind to TCRs.95  
This activates a complex network of kinases, adaptor proteins, and phosphatases.95  TCR 
signaling also prompts LYP to dissociate from its inhibitory complex with C-terminal Src 
kinase (CSK) to begin dephosphorylating regulatory tyrosine residues on TCR signaling 
-Chain (TCR) associated protein kinase-70-kDa (ZAP-70); lymphocyte cell-
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specific protein-tyrosine kinase (LCK); cluster of differentiation-3 (CD3); and Vav 1 
guanine nucleotide exchange factor (Vav1 GEF).83-84, 95  Hence, LYP antagonizes TCR 
signaling.  Many Type 1 diabetics possess a single nucleotide polymorphism (SNP) within 
the encoding region of the PTPN22 gene (C1858T).84, 96  This corresponds to an arginine 
substitution for tryptophan at residue 620 (R620W), which disrupts normal LYP:CSK 
interactions, thus increasing LYP activity.84, 96-97  If autoantigen-reactive naïve CD4+ T cells 
fail to differentiate in the thymus due to TCR signal inhibition, then they can escape to the 
periphery.96-97  Why these cells later activate in the periphery remains unknown.96-97   
 Additionally, this particular SNP is often accompanied by a significant increase in 
proinsulin:C-peptide ratios, suggesting impairment in insulin processing or a surge in 
systemic insulin demand (discussed further in Zinc Transporter-8 Autoantibodies and 
Zinc in Insulin Processing).84, 98-99  Thus, this SNP may not only aids naïve CD4+ T cell 
escape, but may also somehow compromise the functional integrity of the  
1.2.6.1.3.1.3.  Cytotoxic T-Lymphocyte Antigen-4  
 The CTLA4 (cytotoxic T-lymphocyte antigen 4) gene on chromosome 2q33 is also 
implicated in T1DM risk.62, 83  This same region is also implicated in several autoimmune 
disorders, including:  Rheumatoid Arthritis; Celiac Disease; Multiple Sclerosis; and 
autoimmune endocrinopathies (e.g. Autoimmune Add
100-105  CTLA4 encodes a glycoprotein co-receptor that 
translocates to the cell membrane in response to TCR signaling in activated CD4+ T cells.106  
CTLA4 reduces TCR signaling through its interactions with homodimeric CD80 and/or 
CD86 on antigen-presenting cells.106  It is thought that this docking inhibits TCR signaling 
by enhancing phosphatase activity, competing with co-stimulatory CD28 for ligands, and 
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disrupting lipid raft and ZAP-70 microcluster formation in CD4+ T cells.106  Hence, these 
s. 
 The CTLA4 SNP +49A/G, which results in an alanine substitution for threonine at 
residue 17 (A17T) of the leader sequence, is strongly associated with T1DM risk.107-109  It is 
-translational processing in the 
endoplasmic reticulum (ER), thus hindering its glycosylation and vesicular integration.108  
thresholds and increasing the likelihood of autoimmunity.109 
1.2.6.1.3.1.4.  Insulin  
 Finally, genetic variations in the insulin gene itself (INS on chromosome 11p15.5) have 
naturally been suspected in T1DM development.83  However, genetic polymorphisms and 
variable number of tandem repeats (VNTRs) upstream of INS 
autoimmunity.62, 76, 84, 96, 110  With that said, insulin autoantibodies (IAAs) are usually the 
first detectible autoantibodies to appear in children.111  Since INS risk genotypes generally 
weaken insulin expression in the thymus, it is possible that screening for insulin-reactive 
CD4+ T cells is compromised.62, 112  Hence, INS genetic variants are more likely to affect 
tolerance to circulating insulin versus the 62, 85, 112-113   
1.2.6.1.3.2.  Environmental Risk Factors for T1DM 
 Environmental factors, including infectious agents, dietary and nutritional influences, 
and even psychological stressors, have been proposed to trigger pancreatic autoimmunity in 
T1DM.58  These environmental risks and associated hypotheses are discussed below. 
 Infectious agents, such as viruses, bacteria, and parasites, may contribute to T1DM 




reactivity.53, 58  Of these infectious agents, viruses are the most strongly implicated. 
1.2.6.1.3.2.1.  Viruses 
 Human enterovirus B species (HEV-Bs) have long been implicated as possible conduits 
for inducing autoimmunity in T1DM.  The HEV-B coxsackievirus B4 (CVB4) produces 
protein 2-C (P2-C), which closely resembles glutamic acid decarboxylase (GAD), a 
common enzyme in many neurons -depth in Glutamic 
Acid Decarboxylase Autoantibodies).76, 114  It is thought that this mimicry could either 
mask the virus from immune-mediated elimination or cause the immune system to target 
GAD instead.76  Furthermore, in response to nearby HEV-B (CVB and Echovirus) infections 
and replication, pancreatic islets secrete proinflammatory cytokines [e.g. tumor necrosis 
factor- - -6 (IL-6)] and chemotactic proteins [e.g. IL-8, interferon- -
inducible protein-10 (IP-10), macrophage inflammatory protein (MIP)-1a, and MIP-1b].115-
117  As a result, close proximity HEV-B infections cause the pancreatic islet cells to draw 
non-specific inflammation back towards the islets themselves, resulting in insulitis.117   This 
114, 118 
1.2.6.1.3.2.2.  Parasites  
 
pathogens, such as parasitic worms, through public health measures may actually counteract 
protective immunomodulation normally afforded by the parasite for survival.114, 119  In other 
words, a decline in parasitic infestation may actually increa
diabetes.114, 119  This is supported by trend analysis studies with the human helminth 
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Enterobius vermicularis.120  Infestations involving this pinworm, which used to infect nearly 
half of the U.S. and European childhood population in the 1950s, has declined steadily over 
the past few decades with improvements in personal hygiene.120  This pinworm can 
modulate the development of the mucosal immune system and promote a more humoral 
immune responsive-type (versus cell-mediated) to better ensure its own survival.120  
Consequently, this reduces overall T cell expression.120  With T1DM prevalence on the rise 
and pinworm infections in decline, this supports the hygiene hypothesis.120  Of course, good 
hygiene has also been argued to prevent T1DM.121  Regardless, this hypothesis raises 
questions as to whether tiny parasites can trigger T1DM autoimmunity. 
1.2.6.1.3.2.3.  Gut Microbiota 
 Inflammatory bowel diseases (e.g. 
microbiota to severely impact the immune system and to modulate autoimmunity.114, 122-123  
Although the disruption of gut microbiota affects T1DM development in mice, examining 
these effects in humans is still in its infancy.58, 114, 122, 124  However, preliminary evidence 
suggests that such a disruption might exist in early childhood T1DM cases.114, 124  In these 
T1DM cases, bacterial biodiversity in the gut diminishes over time and becomes less stable, 
suggesting a possible disease link.124  Further, autoreactive Th cells, which also originate in 
i.e. mucosal lymphoid tissue) during early 
development, can disrupt peripheral tolerance and increase 125-126  Even so, 
more studies are needed to explore these pathological implications in human T1DM.  
1.2.6.1.3.2.4.  Dietary Factors 




pancreatic 114, 127  Further, exposures to certain dietary factors at early stages in life 
(neonate, infant, and toddler) can affect T1DM risk.114  For example, breastfeeding reduces 
the risk of islet autoimmune development by supplying essential Zn2+ ions, nicotinamide, 
and vitamins C, D, and E.114  Given the high permeability and immunological profile of the 
neonate/infant/toddler gut, it has been proposed that the early introduction of high caloric 
demands and disrupt peripheral tolerance.76, 114, 125, 128-130  As the immune system matures 
and the gut thickens, intestinal permeability and immune reactions to these dietary factors 
decrease.125  Hence, it is likely that these early developmental stages are more susceptible to 
the pathogenic effects of dietary factors than adults.114   
Evidence of dietary factor influences upon autoantibody expression in T1DM patients is 
mounting.  In the Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes 
-based 
hydrolyzed formula (WHF), or WHF without bovine insulin for the first six months of life 
(whenever breast milk was not available).131  By three years of age, the prevalence of 
seropositivity for at least one autoantibody in these children was:  6.3% (CMF-fed);  4.9% 
(WHF-fed), and 2.6% (WHF without bovine insulin-fed).131  While human and bovine 
insulin only differ by three amino acids (two in the A-chain and one in the B-chain), it is not 
surprising that antibodies developed against bovine insulin might cross-react with human 
insulin.131-132  This suggests that if bovine insulin induces an adaptive immune response, the 
developed antibodies may double as IAAs to increase T1DM risk.61, 131   
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Perhaps more interesting is the Finnish Type 1 Diabetes Prediction and Prevention 
Project (DIPP), wherein infants possessing genetic polymorphisms for INS, PTPN22, or 
CTLA-4 were screened for autoantibody expression.133  In this study, infants were 
introduced and given CMF either before or after six months of age.133  While both PTPN22 
(C1858T) and INS (-A23T) genotypes demonstrated autoantibody development [IAA, ICA, 
and insulinoma-associated protein-2 autoantibody (IA-2A)] in children receiving CMF 
before six months of age, only the INS (-A23T) genotype exhibited autoantibody expression 
with CMF introduction after six months.133  These INS (-A23T) genotypes, but not PTPN22 
(C1858T), also developed autoantibodies against GAD (GADAs) independent of CMF 
introduction timelines.133  An additional study combining dietary and hereditary risk factor 
assessments was the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study.134  In 
this study, infants possessing high risk HLA alleles were either administered CMF or a 
casein hydrosylate formula alternative.134  CMF-fed infants developed a significantly higher 
level of autoantibodies than infants fed casein hydrosylate formula.134   
In summary, there appears to be significant interplay between genetic and environmental 
factors affecting autoimmune development in T1DM.  These data suggest that autoimmune 
development is fed by multiple mechanisms that converge to increase T1DM risk.  These 
risk factors ultimately encourage an adaptive immune response with autoantibodies that 
-mediated immunity has 
been addressed, autoantibody influences on T1DM development are reviewed below. 
1.2.6.1.4.  Autoantibodies in T1DM 
 Autoantibodies are present in 70-80% of newly diagnosed Type 1 diabetic patients.135  
As such, the serological detection of autoantibodies (i.e. autoantibody titers and definitive 
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autoantibody counts) has become a powerful indicator of autoimmune development in 
preclinical stages.4, 62, 136  This is especially true for patients that possess high-risk HLA 
alleles, children, and young adults.53, 136  In the previously mentioned identical twin study, 
the 65% T1DM concordance rate also corresponded to an autoantibody detection 
concordance rate of 78% by the same age (60 years).82  This suggests a partial genetic basis 
for autoantibody development and supports the validity of this biomarker later in life.  In 
this regard, the diagnosis of Latent Autoimmune Diabetes in Adults (LADA), a subtype of 
T1DM that develops later in life, is largely based on autoantibody seropositivity.89 
  There are currently over two dozen autoantibodies associated with T1DM.53, 137  Among 
these autoantibodies, the most prevalent are the islet-cell cytoplasmic autoantibodies (ICAs) 
and insulin autoantibodies (IAAs), as well as autoantibodies against glutamic acid 
decarboxylase-65-kDa (GADAs), insulinoma-associated protein-2 (IA-2As), and zinc 
transporter-8 (ZnT8As).137-143  The risk of developing T1DM increases significantly with 
each additional type of autoantibody developed.  In the European Nicotinamide Diabetes 
Intervention Trial (ENDIT), 10-34-year old patients expressing only ICAs had a 2.2% risk 
of developing T1DM within the next five years.135, 144  This risk increased to 17%, 39%, and 
70% with the appearance of one, two, or three additional autoantibody(ies), respectively.135, 
144  Furthermore, the Diabetes Autoimmunity Study in the Young (DAISY) revealed that 
89% of the children that express two or more islet-related autoantibodies developed 
T1DM.145  This suggests that age signif
While each of the above types of autoantibodies will be discussed shortly, the processing 









Figure 1.  Structures of preproinsulin (all), proinsulin, and insulin.  Arrow indicates the 
histidine residue at position B10 that coordinates with either one of two Zn2+ ions to form 
hexameric proinsulin.  The signal peptide (green) and the C-peptide (orange) are cleaved 
during insulin processing.  (Adapted from Kanatsuna et al.)146   
   
1.2.6.1.4.1.  Zinc Transporter-8 Autoantibodies and Zinc in Insulin Processing 
 -specific zinc transporter that localizes to the membrane of 
intracellular insulin secretory granules.147  By regulating Zn2+ ions, ZnT8 serves a critical 
role in processing, storage, and secretion of insulin.147  Insulin originates as the 110-amino 
acid precursor known as preproinsulin (Figure 1).146, 148-149  Upon 
signal sequence in the ER, monomeric proinsulin is transported into the Golgi apparatus 
where it is folded.  Histidine at position B10 coordinates with either one of the two central 
Zn2+ ions to form hexameric proinsulin.148-149  The prohormone convertases PC1/3 and PC2 
and exoprotease carboxypeptidase E (CPE) then excise the C-peptides to produce hexameric 
insulin while en route to insulin secretory granules.148-149  The two Zn2+ ions are co-secreted 
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with hexameric insulin via exocytosis and dissociate upon reaching the higher pH of the 
blood (~ 7.4).148  These Zn2+ ions then inhibit KATP 
membranes to prevent glucagon secretion and glucagon-associated glycogenolysis in the 
liver.150  Given that T1DM patients are hypoinsulinemic, it is not surprising that Type 1 
diabetics also exhibit unusually high basal systemic glucagon levels.150  This feeds systemic 
hyperglycemia even further and complicates insulin therapy.  Hence, Zn2+ ions not only 
provide structural stability for insulin during its processing and secretion, but these cations 
also help regulate glucagon secretion. 
 Nearly 30% of Type 1 diabetic patients that test negative for all other known disease-
associated autoantibodies test positive for ZnT8As.138  Since the discovery of ZnT8As in 
2007, these autoantibodies have been found in 55-65% of all new-onset T1DM cases.143, 151  
However, ZnT8A concentrations usually decrease after diagnosis to the point that they are 
only detectible in ~ 25% of patients 50 years later.151-153  With this in mind, the functional 
importance of ZnT8 in T1DM etiology has not gone unexplored.138  Most ZnT8As recognize 
the intracellular C-terminus of ZnT8.137-138  Accordingly, the effects of SLC830A8 (ZnT8 
-terminal structure and 
associated disease susceptibility have been assessed.86, 137-138  Interestingly, while SLC830A8 
SNPs increase Type 2 diabetes risk, Type 1 diabetes is unaffected.137-138, 154-155  Although 
two additional loci [FCRL3 (Fc receptor-like 3) gene on chromosome 1q23.1 and HLA class 
I regions] have been linked with ZnT8A seropositivity, SNP assessments at these loci have 
no impact upon T1DM risk as well.153  Hence, while ZnT8As may serve as effective 




1.2.6.1.4.2.  Insulin Autoantibodies 
 IAAs are found primarily in children below five years of age.145-146  In this age group, 
children that persistently express IAAs nearly always develop T1DM within the next six 
years.145  
T1DM within ten years.145  Hence, the level of IAA persistency in children can predict the 
age at which T1DM will most likely occur.145   
 As previously mentioned, genetic variations in INS reduce thymic insulin levels, thus 
crippling the autoreactive screening process for insulin and allowing naïve CD4+ T cells to 
enter circulation.  With that said, anything 
e.g. insulin, proinsulin, and C-peptide) by HLA-derived 
proteins.146  Evasive autoreactive naïve CD4+ T cells descend upon these presented antigens 
to induce cell-mediated and humoral immune responses.146  The humoral immune response 
generates a multitude of autoantibodies, including IAAs.146  Furthermore, autoreactive B 
lymphocytes that also manage to escape the negative selection process can also trigger 
immunopathogenesis.146  Upon finding an antigenic match, B lymphocytes recruit Th cells to 
help induce its differentiation into autoantibody-producing plasma cells.146  In either case, 
plasma cells still generate IAAs, which bind to (pro)insulin A and B chains.146, 156  HLA 
class I and class II-derived proteins can also bind (pro)insulin A and B chains as well as C-
peptide.146, 157-158  This could also elicit a humoral and/or cell-mediated immune response.   
1.2.6.1.4.3.  Glutamic Acid Decarboxylase Autoantibodies 
 Glutamic acid decarboxylase autoantibodies (GADAs) are detectible in 70-80% of new-
onset T1DM patients and tends to persist throughout most of their lives.137  About half of the 
patients that survive fifty years of T1DM still test positive for GADAs.137, 151  These GADAs 
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primarily target the 65-kDa isoform (GAD-65) over the 67-kDA isoform (GAD-67).137  
GAD normally catalyzes the conversion of glutamate to the inhibitory neurotransmitter -
regeneration.159-163  
viability.  GADAs are also the predominate autoantibody found in LADA patients, where its 
extended presence arguably helps distinguish it from Type 2 diabetes mellitus.89   
1.2.6.1.4.4.  Insulinoma-Associated Protein-2 Autoantibodies  
 IA-2As are found in 60-70% of new-onset T1DM cases.137, 151, 164-165  However, these 
IA-2As are detectible in only ~ 6% of the diabetic population after 50 years of T1DM.151  
IA-2 is an inactive tyrosine phosphatase found in the membranes of neuroendocrine 
secretory granules.164  Despite IA-  
proliferation, the physiological functions of this enzyme are still unknown.53, 164, 166   
1.2.6.1.4.5.  Islet-Cell Cytoplasmic Autoantibodies 
 -2As, GADAs, IAAs, and ZnT8As) described 
above have islet autoantigens that have been specifically identified and cloned.53, 137  In 
contrast, ICAs have no identified autoantigens other than the islet cells themselves.137  
Seropositivity for these polyclonal ICAs is determined using epifluorescent microscopy, 
-group O) pancreatic 
tissue samples.137  Although ICAs are present in 70-80% of new-onset Type 1 diabetes, they 
are only detectible in ~ 5% in of Type 1 diabetics after ten years.137  Nevertheless, ICAs 
were the first autoantibodies discovered in T1DM, and despite their seemingly ambiguous 
137   
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1.2.6.1.5.  Idiopathic T1DM 
 Idiopathic Type 1 diabetes mellitus is ambiguous by definition.  Although idiopathic 
diabetics clearly develop stages of hypoinsulinemia, they are devoid of any evidence of 
autoimmunity.4, 167  The natural history for this sect differs from other T1DM patients in that 
initial insulin therapy normally renders these diabetics normoglycemic for several years 
without any additional need for exogenous insulin treatment, so long as they watch their diet 
and maintain use of other glucose-regulating agents (discussed in-depth in Targeting 
Hyperglycemia).167  167  
Subsequent exogenous insulin requirements are generally only needed on a periodic basis.4  
Besides intermittent hyperglycemia, idiopathic diabetes is best characterized by sporadic 
167  DKA is a life-threatening event that 
usually only arises during the first manifestation of the disease or during periods of extreme 
insulin deficiency (discussed in-depth in Targeting Hyperglycemia).4, 167  In idiopathic 
diabetics, DKA arises without warning when insulin levels plummet.4, 167  Despite strong 
signs of genetic inheritance, no genes have been linked to idiopathic diabetes.4, 167 
1.2.6.2.  Type 2 Diabetes Mellitus (T2DM) 
1.2.6.2.1.  Epidemiology of T2DM 
 Type 2 diabetes mellitus (T2DM), formerly known as non-insulin-dependent diabetes 
mellitus (NIDDM) or adult-onset diabetes, comprises 90-95% of all diabetic cases.4, 20, 168-169  
Hence, the epidemiological statistics presented in the introductory section mostly pertain to 
T2DM.  However, there are specific T2DM demographic trends that should be noted.   
 While T2DM has historically been considered a disease that affects the middle-aged and 
169-176  In 2003, the 
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prevalence of T2DM in U.S. children (under 20 years) surpassed that of T1DM in several 
ethnic/racial groups, including:  African Americans at 19.0:15.7 (T2DM:T1DM incidents 
per 100,000 children) and Asian/Pacific Islanders at 12.1:7.4 (T2DM:T1DM incidents per 
100,000 children).169, 172-177  In American adolescents (ages 15-19), the frequency of T2DM 
(per 100,000) is:  49.4 (Native Americans); 22.7 (Asian/Pacific Islanders); 19.4 (African 
Americans); 17.0 (Hispanics); and 5.6 (Non-Hispanic Whites).176  This is thought to be 
partially linked to rising trends of childhood obesity, which increases T2DM risk.171, 178-179   
 There are also significant ethnic/racial differences in T2DM prevalence in adults.  For 
instance, the highest documented prevalence of T2DM in the world is found in the Pima 
Indians of modern-day Arizona.180-182  As of 2003, the prevalence of T2DM in these Native 
Americans culminated at 58% (ages 55-64), with an average body mass index (BMI) of 27.7 
kg/m2 (men) and 30.1 kg/m2 (women).182  Although overweight (BMI:  25-29.9 kg/m2) and 
obese (BMI > 30 kg/m2) phenotypes  are generally associated with increased T2DM risk, 
these BMI:T2DM risk correlations are only applicable within a particular race/ethnicity and 
do not necessarily hold true when comparing other groups.180, 183 
 Over 35% of the global Type 2 diabetic population resides in the Western Pacific, with a 
significant portion in East Asia.3, 184-185  Although the population BMI for East Asians is far 
less than those of European descent, T2DM prevalence is still comparable to that of the 
United States.3, 184-185  This is thought to be the result of higher visceral adiposity in Asian 
populations, which is thought to be more metabolically adverse (i.e. contributes more to 
lipotoxicity and insulin resistance).184  These BMIs are consistent with Asian Americans as 
well.186  However, despite lower BMIs, Asian Americans (i.e. Asian Indians, Filipinos, 
Vietnamese, Japanese, Koreans, and Chinese) are 30-50% more likely to develop T2DM 




versus non-Hispanic White Americans.186  Furthermore, regardless of BMI, the prevalence 
of T2DM in African Americans, Mexican Americans, and Puerto Ricans in the United States 
is 3-4% higher than non-Hispanic White Americans.187-188  Hence, BMI affects T2DM risk 
differently within each race/ethnicity, and this risk is subject to environmental influence.     
1.2.6.2.2.  Pathogenesis and Natural History of T2DM 
 T2DM is characterized by a progressive loss of pancreatic -
resistant individuals.4, 35, 170, 178, 189-191   While both of these features develop well before the 
clinical onset of T2DM, the relative contributions of these factors have been the source of 
much controversy.170  However, a study in the Pima Indians at the turn of the century helped 
put this debate to rest.170, 180-181  The study showed that declining glucose tolerance in 
since overall insulin responsiveness did not change.170, 180  This was later supported by the 
United Kingdom Prospective Diabetes Study (UKPDS), which showed that tightly 
maintaining normoglycemia pharmacologically does not prevent the deterioration of glucose 
regulation in developing Type 2 diabetics.192-193  Hence, 
of T2DM pathogenesis.  However, insulin production and secretion are partially driven by 
plasma glucose levels.149, 170   This means that anything that disrupts glucose clearance, 
149, 
170, 191  This hyperactivity can amplify previously discrete anomalies, eventually causing 
dysfunction and deat 149, 170, 191  As such, the relative contributions of 
As a prelude, an imperative review of the glucose-mediated feedback system governing 
insulin production and secretion has been conducted. 
 
 28 
1.2.6.2.2.1.  Glucose Transport, Insulin Secretion, and Onset of Hyperglycemia 
 
glucose and other monosaccharides, free fatty acids, and amino acids.149  However, glucose 
is the primary stimulus for insulin secretion.149  Since DPN results from dysfunctional 
affect on glucose transport and its feedback mechanisms are discussed below.44, 194-195 
 Glucose is absorbed from the intestinal lumen by sodium-dependent glucose transporter-
1 (SGLT-1), a cotransporter expressed on the apical membrane of enterocytes.196  Glucose 
transporter-2 (GLUT-
exports glucose into the blood for circulation.44, 196-197  
constitutively expressed GLUT-1 (humans) and GLUT-2 (rodents) permit glucose to flow 
44, 149, 197-202  The initiation of glucose 
-limiting step) 
for insulin secretion.149, 198-201  Increases in intracellular ATP levels then inhibit ATP-
sensitive potassium channels.149, 198-201  This depolarizes the cell membrane and induces Ca2+ 
ion influx via voltage-dependent calcium channels (VDCCs).149, 198-201  This causes insulin 
secretory granules to the cell membrane and secrete hexameric insulin.148-149, 198-201  
 Upon dissociation in the blood, monomeric insulin docks to insulin receptors on the cell 
membranes of muscle, adipose, and liver cells.148, 203-207  This induces phosphatidylinositol 
3-kinase/protein kinase-B (PI3K/Akt-)-mediated GLUT-4 vesicle translocation to the cell 
membrane, where it docks, fuses with the cell membrane, and facilitates glucose uptake.207-
209  Hence, dysfunctional insulin signaling causes these insulin-sensitive tissues to become 
malnourished, which jeopardizes their function and viability.44  
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 On the other hand, the nervous system and pancreas can not afford to endure sustained 
periods of glucose deprivation.  As such, neurons and endothelial cells of the blood-brain 
barrier (BBB) employ constitutively expressed, insulin-insensitive GLUT-3 and GLUT-1, 
respectively, for nutritional support.44, 197, 210-212  -1 for nutritional 
support since they are the primary source of insulin supply.44, 197, 202  Hence, GLUT-1 and 
GLUT-3 are open corridors for glucose influx.  If insulin signaling is compromised and 
muscle, adipose, and hepatic tissues fail to assist in glucose clearance, there are no flood 
gates that can close to prevent glucose from entering 
glucotoxicity in neurons and the pancreas, which is often followed by lipotoxicity.149  
Glucotoxicity is further complicated by glucagon-induced hepatic glycogenolysis.44, 150  
44  These hepatic actions collectively increase 
glucose entry into the blood.  Hence, hyperglycemia feeds upon itself. 
 Overall, dysfunctional insulin signaling disrupts normal glucose transport, thus resulting 
in muscle, adipose, and hepatic malnourishment, systemic hyperglycemia, and detrimental 
bombardment.4  In contrast, T2DM has historically been considered a metabolic disease.4  
However, islet-reactive Th cells and autoantibodies have been found in various subgroups of 
T2DM patients.213-218  This has given rise to new questions and concerns, primarily:  (1) how 
pathogenically distinct are T1DM and T2DM and (2) how accurate is the current etiological 
classification system?213  Nevertheless, the development of dysfunctional insulin signaling 
in Type 2 diabetes mellitus (as currently understood) is reviewed below.  
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1.2.6.2.2.2.   
 
production and secretion.191  
At autopsy, the pancreatic islets of T2DM patients often contain lesions with clear signs of 
inflammation and apoptosis (Figure 2).219-222  These reductions can be as high as 60%.222   
 
 
Figure 2.  Inflammation in human islets.  Double immunohistochemical staining for the 
macrophage marker CD68 (brown; arrows) and insulin (red) in non-diabetic (left) and Type 
2 diabetic (right) islet sections indicate insulin depletion and immunologic infiltration.220  
  
 Figure 3).223  
This results from the aggregation of islet amyloid polypeptide (IAPP), or human amylin, a 
37-amino acid polypeptide that is co-packaged and co-secreted with insulin.224-226  IAPP 
normally fine-tunes the actions of insulin and glycemic control by suppressing glucagon 
secretion and slowing gastric emptying.224-226  Why these IAPP aggregates form in T2DM 
patients is not well understood.226  It is possible that an increase in insulin demand, while in 
the midst of worsening hyperglycemia and insulin resistance, boosts IAPP levels beyond the 
226  It is also unknown whether this aggregation occurs inside the 
secretory granule or in the interstitial space after secretion.226  Regardless, these aggregates 





Figure 3.  Islet amyloid deposition in human islets.  Thioflavin S staining of islets from a 
Type 2 diabetic patient; islet amyloid deposition appears white (Bar = 50 µm).223     
 
  autoimmunity.  In adults with classic 
phenotypic T2DM h 
cells.215  Age also significantly impacts the manner by which this autoimmunity develops.215, 
228-229  For instance, the prevalence of autoreactive Th cells is ~ 64% in adults with T2DM 
versus ~ 42% in newly diagnosed children (ages < 18 years).215, 229  On the other hand, 
autoantibody prevalence is much higher in Type 2 diabetic children (70-75%) than in it is in 
adults (~ 48%).215, 228-229  Why these age-related differences occur is not well understood.  
Despite etiologic similarities between T1DM and this T2DM sect, there is reason to believe 
that some of the molecular targets, as well as the prevalence of shared autoantibodies, differ 
between these diseases.214-215, 217, 230  It is also conceivable that autoimmunity in T2DM 
could be linked to phenotypic risk factors, such as obesity, which is uncharacteristic in 
T1DM.  This notion partly stems from the propensity of obese individuals to develop 
123, 217, 231-233    
                                                 
 Diagnosis at ages 35-70 years and no history of DKA, ketonuria, or insulin therapy 
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1.2.6.2.2.2.1.   
 T2DM is affected by multiple genetic loci that collectively contribute to over 70% of 
T2DM risk.234-236  In monozygotic twin studies, disease concordance rates of 17% and 76% 
were reached by 1 year and 15 years, respectively, following initial diagnosis of the first 
twin.236  IGT concordance reached 96% by 15 years.236  These data suggest a strong genetic 
influence upon T2DM development.   
 etic variants often affect glucose metabolism and insulin 
biosynthesis, processing, and secretion.  For example, mutations in PC1/3 can hinder 
proinsulin processing in insulin secretory granules.191, 237  In the gut, genetic polymorphisms 
in TCF7L2 (transcription factor 7-like 2) reduce the expression of the incretin GLP-1 
(glucagon-like peptide-1).238  This hormone normally binds to GLP-1 receptors (GLP-1Rs) 
A (cAMP/PKA) signaling.239  Of the 40+ -cell function 
in T2DM, TCF7L2 SNPs have the strongest T2DM-associated risk to date.169, 237, 240   Other 
examples of susceptible loci include SLC2A2 (GLUT-2), SLC830A8 (ZnT8), and GCK 
(glucokinase).169, 237, 240  It is estimated that only 10% of the total genetic influences thought 
169   
 
 Environmental factors can influence genetic expression during fetal and neonatal 
169, 234  Epigenetics is the 
study of how the environment interacts with the genome to chemically alter DNA and DNA-
associated proteins and modify gene expression.169, 234, 241-243  
169, 234, 241-243  
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Examples of epigenetic marks include:  DNA modifications (e.g. methylation); histone post-
translational modifications (e.g. acetylation and phosphorylation); alternative nucleosome 
positioning; microRNAs; and oxidative/nitrosative damage.234, 241  All of these epigenetic 
marks serve to translate environmental cues into lifelong epigenetic states.234   
 Epigenetic programming can adversely impact 
weight control, and promote oncogenesis.169, 244  Examples of contributing prenatal and early 
postpartum environmental factors include:  xenobiotic chemicals, behavioral cues, low-dose 
radiation, and nutritional supplements.243   Although the specific epigenetic factors and 
mechanisms governing intrauterine pancreatic programming are unclear, children of mothers 
with GDM exhibit a higher risk of developing obesity, glucose intolerance, and T2DM than 
children of obese mothers.245-246  Conversely, it has also been proposed that if a newborn is 
equipped for a life of low-energy intake, he/she may face problems later in life with the 
adoption of high-energy diets and a more sedentary lifestyle.169  Hence, the embryonic and 
neonatal environment can predispose a child to future disease development.   
 Epi
autoimmunity.242, 247  DNA methylation profiling of pancreatic islets from T2DM donors has 
shown differential DNA methylation within the promoter regions of over 250 genes relative 
to non-diabetic donor tissues or high-glucose-treated islet explants.247  These disruptions in 
and inflammation.247  Whether or not these epigenetic alterations are the cause or an effect 
of T2DM remains to be determined.  Epigenetic alterations in autoimmunity in T1DM are 
gaining momentum and may doubly apply to T2DM as well.  Epigenetic marks in T1DM 
notably include:  hypermethylation and hypomethylation of several genes in macrophages 
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and B lymphocytes as well as unfavorable alterations in microRNA levels of Treg cells and 
the pancreas (affecting insulin exocytosis, development, and apoptosis).242  Hence, 
epigenetics may have a critical role in T1DM and T2DM development. 
1.2.6.2.2.3.  Insulin Resistance and Associated Risk Factors 
 Insulin resistance is a major hallmark of T2DM.248-250  Insulin resistance mainly results 
from hyperlipidemia and associated lipotoxicity.248-250  Although mutations or defects in the 
insulin signaling machinery can exist and do affect insulin resistance, these cases are usually 
more rare.249  Nonetheless, key mutations affecting insulin signaling and hyperlipidemic 
pathogenic contributions are reviewed below.  Although the molecular components of the 
insulin signaling cascade are superficially introduced below, they will be covered more in-
depth in the Altered Insulin-Associated Neurotrophism in Diabetes Mellitus section. 
Adipocytes normally regulate systemic free fatty acid (FFA) circulation in the blood.  
However, high caloric intake and diminished physical activity can alter systemic FFA 
distribution and utilization.  At the cellular level, protection against lipotoxicity is generally 
afforded by the storage of FFAs as triacylglycerides in small lipid droplets.248-250  Under 
hyperlipidemic conditions in non-adipose cells (especially muscle cells), the intracellular 
storage capacities quickly depletes.250  This results in the intracellular accumulation of FFAs 
and the production of adverse lipid products, such as diacylglycerol (DAG) and ceramide.248, 
250-253  DAG and ceramide activate select protein kinase C (PKC) isoforms that disrupt 
insulin signaling by phosphorylating and inhibiting insulin receptor substrate-1 (IRS-1), 
IRS-2, and Akt.248-254  Inhibitory phosphorylations of IRS-1 and IRS-2 are also executed by 
the stress kinases JNK (c-Jun N-terminal kinase) and IKK- -




implicated in the development of insulin resistance.248-249, 254  These phosphorylations also 
inhibit PI3K/Akt-mediated GLUT-4 vesicle translocation.  In addition, JNK and IKK-
phosphorylate and activate AP-1 (activating-protein-1) and NF- , respectively.248-249, 254  
This induces the expression of additional cytokines and perpetuates inflammation.248-249, 254   
 Only a few genetic variations have been linked to insulin resistance in T2DM.  One of 
these gene products, PPARG (encoding PPAR- -activated receptor-
Targeting Hyperglycemia).255  
FFAs and eicosanoids (prostaglandins and leukotrienes) bind to PPAR-
expression of genes associated with adipocyte differentiation and glucose homeostasis.256  
Thus, inducing PPAR- roving adipocyte proliferation, 
viability, and preventing the release of detrimental FFAs and cytokines, such as TNF- 169   
 Other risk factors for insulin resistance include genetic variants for IRS-1, IRS-2, and 
IGF-I (insulin-like growth factor-I).240, 257-259  The impact of these alterations will become 
evident in the future discussion on Altered Insulin-Associated Neurotrophism in Diabetes 
Mellitus.  Finally, while over 40 gene variants have been linked to obesity, only variants in 
FTO (fat mass and obesity-associated) have been able to link BMI with T2DM risk.191, 258, 
260  Hence, the development of insulin resistance is more closely associated with obesity and 
sedentary lifestyle versus a  
1.2.6.3.  Gestational Diabetes Mellitus 
 
178, 261  With the rise in obesity in women of childbearing age, this 
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distinction differentiates GDM from pre-GDM (women that are already/almost diabetic), 
which accounts for ~ 15% of diabetic pregnancy complications.4, 261-262   
 In the United States, GDM affects ~ 7% of all pregnancies (~ 200,000 cases each year), 
with the lowest rates occurring in African Americans (4%) and the highest rates occurring in 
Asian Americans (8.6%).4, 262  GDM prevalence increases almost linearly as a woman ages 
from ~ 1% (ages 15-19) to ~ 16% (ages 45-beyond).262  If GDM persists without 
intervention, the patient may likely develop clinical T2DM during the pregnancy or 
postpartum, posing serious health risks to both mother and child.4, 20, 34, 49  The maternal risk 
of developing T2DM increases from 5-10% immediately after childbirth to 35-60% in the 
next 10-20 years.20  This further supports age and BMI as risk factors for T2DM.   
 As previously mentioned, in utero epigenetic modifications can increase the risk of 
obesity, glucose intolerance, T1DM, and T2DM in the child if successful intervention is not 
achieved.242, 245-246  In most cases, GDM is not diagnosed until 24-28 weeks of pregnancy 
unless it is caught at the initial visit with the physician.261  This is partly attributed to the fact 
that most women with GDM have no apparent symptoms.22  Exceptions to this screening 
frequency include women at high risk of GDM, such as patients with marked obesity, 
glycosuria, a personal history of GDM, or a strong family history of diabetes.263   
 Overall, despite their different etiologies, each type of diabetes induces hyperglycemia, 
clinical symptoms and complications.  
1.3.  Symptoms and Complications of Hyperglycemia 
Although the Ebers Papyrus arguably describes the first reported symptoms of diabetes 
mellitus about 3,500 years ago, the first indisputable symptomatic and treatment accounts 
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were recorded by the ancient Greek physician Aretaeus (81-138 AD).264-267  It was Aretaeus 
diabaínein -
 
Diabetes is . . . a melting down of the flesh and limbs into urine . . . 
life is disgusting and painful; thirst, unquenchable; excessive 
drinking, which, however, is disproportionate to the large quantity 
of urine, for more urine is passed; and one cannot stop them either 
from drinking or making water.264  
          - Aretaeus, the Cappadocian 
  
 Hyperglycemic symptoms of diabetes mellitus include:  frequent urination (polyuria); 
excessive thirst (polydipsia); increased appetite (polyphagia); blurred vision; unusual weight 
fluctuations; extreme fatigue; nausea; and slowly healing cuts or bruises.4, 268  In addition, 
results from the Diabetes Control and Complications Trial (DCCT, 1983-1993) support the 
hypothesis that hyperglycemia contributes to the pathological progression of more chronic 
diabetic complications, such as diabetic neuropathy, cardiovascular disease, retinopathy, and 
nephropathy.23, 44, 197  While our research mainly focuses on DPN, these other complications 
can foster neuropathic development.  Thus, they will be addressed briefly in the context of 
DPN.  The physiologic effects of acute diabetic complications will be addressed in the 
context of mismanaged insulin therapy in Targeting Hyperglycemia. 
SECTION 2.  DIABETIC PERIPHERAL NEUROPATHY 
 Diabetic peripheral neuropathy (DPN) is the overall attrition of peripheral nerve fibers 
that results from diabetes.23, 46, 269-276  Affecting over half of the diabetic population, DPN is 
the most prevalent of the chronic complications.271-272  These neuropathies mainly manifest 
as distal, symmetric, sensorimotor polyneuropathies, which entail both small and large nerve 
fiber deterioration in the extremities, partly resulting in progressive sensorimotor deficits.271, 
277  These sensorimotor deficits, combined with diminished microvascular support, promote 
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the development of non-healing foot ulcerations and gangrenous infections that ultimately 
require traumatic, lifesaving surgeries.278  Incidentally, DPN is the leading cause of non-
traumatic lower limb amputation in the United States, averaging ~ 82,000 each year.20, 278  
Sadly, over 85% of these amputations are thought to be preventable with early detection and 
proper therapeutic intervention.20, 278  
increased likelihood of accidental injury (e.g. fractures, burns, contusions, lacerations, and 
frostbite) that often accompanies insensate neuropathies.43   
 Despite recent advances in DPN etiology, its prevalence, and its overall impact upon a 
-being, there are few therapeutic options available to 
effectively treat DPN.  In order to properly introduce modern pharmacotherapeutics and the 
need for new and effective drug treatment strategies, an examination of DPN pathogenesis 
follows.  Herein, the morphological alterations and clinical manifestations that accompany 
DPN are reviewed and will be followed by an extensive look at the molecular mechanisms 
implicated in diabetic sensorimotor polyneuropathy (DSPN), the focus of this research.    
2.1.  Morphological and Clinical Manifestations in Diabetic Neuropathy 
There are several forms of diabetic peripheral neuropathy.  These neuropathies differ 
according to their symptoms, patterns of neurological involvement, course, risk factors, 
progression, and etiology.274-276, 279  Although several DPN classification systems have been 
developed based upon various clinical manifestations or developmental patterns, the system 
proposed by Thomas and later adapted by Boulton and the Toronto Expert Panel on Diabetic 
Neuropathy (2009) is widely accepted today.274-276, 279  This system divides DPN into focal 




2.1.1.  Focal and Multifocal Neuropathies  
Focal and multifocal neuropathies are generally asymmetric neuropathies that develop 
mostly in older T2DM patients.270  Diabetic focal neuropathies consist of nerve entrapment 
and mononeuropathies.270  The most common form of nerve entrapment is carpal tunnel 
syndrome (CTS), wherein compression of the median nerve in the wrist causes numbness, 
tingling or burning sensations, weakness, muscular atrophy, and potentially paralysis in the 
hands and fingers.270, 280  Over one-third of the diabetic population is affected by CTS.280-281  
Other forms of entrapment involve the ulnar and radial nerves, the lateral cutaneous nerve of 
the thigh, and the peroneal and tibial nerves.280  Tibial nerve entrapment can cause what is 
known as tarpal tunnel syndrome, wherein CTS-like symptoms develop in the feet.280   
In contrast to the gradual progression of nerve entrapment, mononeuropathies develop 
abruptly as a result of localized vasculitis (inflammation of the blood vessels) and associated 
ischemia.280  These mononeuropathies typically affect the peripheral nerves (median, ulnar, 
femoral, sciatic, sural, and peroneal), thoracic nerves, and, on more rare occasions, the 
cranial nerves (CN III, CN IV, CN VI, and CN VII).270, 280  Mononeuropathic symptoms 
closely resemble those associated with nerve entrapment.  
Multifocal neuropathies, as implied, affect multiple nerves at one time.270, 274-275  These 
include the development of multiple mononeuropathies as well as cervical, thoracic, or 
lumbosacral radiculoplexopathies.273-275  Lumbosacral radiculoplexopathy (also known as 
diabetic amyotrophy, proximal motor neuropathy, or Bruns-Garland Syndrome) entails 
neurodegeneration in the thighs, hips, legs, and/or buttocks presumably due to regionalized 
microvasculitis and ischemia.273  This ultimately leads to muscular fatigue, atrophy, and 
diminished motor skills.273   
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2.1.2.  Generalized Symmetric Polyneuropathies 
The majority of DPN cases involve generalized, symmetric polyneuropathies.  These 
include diabetic autonomic neuropathy, impaired glucose tolerance neuropathy, acute 
sensory neuropathy, and diabetic sensorimotor polyneuropathy.276, 279   
2.1.2.1.  Diabetic Autonomic Neuropathy 
Diabetic autonomic neuropathy (DAN) is the most dangerous and least understood of the 
diabetic neuropathies.282-283  Although usually diffuse, DAN can localize to particular 
visceral organ(s) and compromise their functional integrity.283  DAN is further complicated 
by the fact that many visceral organs are dually innervated by both the parasympathetic and 
sympathetic nervous systems. .282-283  This increases relative susceptibility of these organs to 
neurodegeneration and associated autonomic dysfunction.282-283  As such, DAN can directly 
283   
Although the pathogenesis of DAN is not fully understood, evidence strongly suggests 
that autonomic neural imbalance results from chronic hyperglycemia and is multifactorial in 
nature.282-283  DAN also appears to be length-dependent in that it initially targets the longest 
nerve fibers first.282-283  This is extremely problematic given that the longest nerve of the 
autonomic nervous system (ANS), the vagus nerve (CN X), accounts for over 75% of all 
parasympathetic activity.283-284   
DAN occurs in ~ 53% of T1DM and ~ 74% of T2DM patients.285  Roughly 15% of these 
cases are considered moderate-to-severe.285  DAN clinical symptoms can go unnoticed for a 
long time and can take years to develop.282-283  Its symptoms ultimately depend upon which 
organ(s) have been affected.283  DAN can cause myocardial ischemia, hypotension, cardiac 
arrhythmia, and cardiac infarction, which complicates hyperlipidemic and cardiovascular 
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complications already associated with diabetes.282-283  DAN can cause:  gastrointestinal 
irregularities (e.g. diarrhea, constipation, loss of bowel control, gastroparesis, heartburn, 
difficulty swallowing, nausea, and vomiting); genitourinary problems (e.g. erectile 
dysfunction, female sexual dysfunction, and loss of bladder sensation/control); improper 
sudomotor function (e.g. gustatory sweating, dry skin, heat intolerance); sleep apnea; 
irregular pupil constriction/dilation; and an overall unawareness of hypoglycemia.282-283  
 
2.1.2.2.  Impaired Glucose Tolerance Neuropathy 
 
for IGT.276, 286-289  It is thought that these occurrences are the early stages of DPN.276, 287  To 
test this hypothesis, the Impaired Glucose Tolerance Neuropathy (IGTN) study assessed 
whether lifestyle intervention (diet and exercise) could improve these neurodegenerative 
phenotypes.287  The study was modeled after the Diabetes Prevention Program (DPP), which 
showed that intense diet and exercise can reduce IGT progression to T2DM by ~ 58%.287, 290  
In the IGTN study, diet and exercise partly restored cutaneous innervation (described 
shortly), which improved neuropathic pain.287  This suggests that neuropathy can initiate 
before the clinical onset of diabetes and that lifestyle intervention is beneficial early on.    
2.1.2.3.  Acute Sensory Neuropathy 
Acute sensory neuropathy is best described as an abrupt, intense, neuropathic pain.270  
-like sensation (sharp, stabbing pains) in the lower 
extremities.270  Frequent complaints include deep aching pains, constant burning sensations 
in the feet, and severe paresthesias (abnormal skin sensations).270  Weight loss, depression, 
and sexual dysfunction are also common.270, 279  These neuropathies are thought to result 
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from diverted microvascular support, which results due to poor glycemic control.270, 279  
Pharmacologic treatments for acute sensory neuropathy usually entail various analgesics.270  
Although this type of neuropathic pain usually resolves within a year, this is not usually the 
case in diabetic sensorimotor polyneuropathy (DSPN).270, 274-275  
2.1.2.4.  Diabetic Sensorimotor Polyneuropathy (DSPN) 
DSPN is the most common type of diabetic neuropathy in the somatic nervous system 
and the focus of this research.270, 273-275  DSPN is a symmetric neurodegenerative process 
that initiates in the more distal regions of small-caliber nerve fibers and progresses up the 
extremities (towards the midline).270, 274-275    This compromises the functional integrity and 
viability of longer somatic nerves, thus leading to multiple clinical manifestations.270   
2.1.2.4.1.  Clinical Manifestations of DSPN 
 Generalized symmetric polyneuropathies are divided into atypical and typical subgroups 
to rule out non-diabetic sources of neuropathy in epidemiological and clinical research 
studies.274-275  Atypical DPNs includes the acute sensory neuropathies and DANs, which 
develop intermittently throughout diabetes and have generally monophasic or relapsing 
courses.275  In contrast, typical DPNs (DSPN) entail the development of chronic pain and 
sensorimotor deficits.274-275  Given that atypical DPN diagnostic parameters are still 
underway and that our research is concerned with DSPN, only the diagnostic criteria for 
DSPN will be addressed.274-275   
2.1.2.4.1.1.  Electrophysiological and Sensory Assessments for DSPN 
  DSPN diagnostic criteria are based on electrophysiological and quantitative sensory 
threshold (QST) assessments.274-275  Electrophysiological assessments generally entail both 
motor (MNCV) and sensory nerve conduction velocity (SNCV) measurements, which are 
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based on compound muscle action potentials (CMAPs) and sensory nerve action potentials 
(SNAPs), respectively.  In human peroneal and sural nerves, DSPN gradually slows MNCV 
by approximately 0.5 m/s each year.270, 291  DSPN reduces SNCV in the peroneal and sural 
nerves by 0.2 and 0.4 m/s each year, respectively.270, 292  Although these deficits may appear 
minor at first, this becomes increasingly troublesome.  
QST testing is a psychophysical type of analysis that measures somatosensory thresholds 
in response to incremental changes in stimulus intensity.270  QST ultimately enables non-
invasive assessments of both small- and large-fiber sensory function (discussed in-depth in 
Somatosensory Nerve Fibers).293  QST diagnostic tools include:  Biothesiometers to 
determine vibration perception thresholds; Semmes-Weinstein monofilaments (human 
version of von Frey monofilaments) for assessing mechanical hypoalgesia; and computer-
driven thermal analyzers to measure temperature hypoalgesia.293-294   QST ultimately 
enables progressive monitoring disease-induced changes in sensations.   
2.1.2.4.1.2.  Symptoms of DSPN 
 DSPN is characterized by both positive and negative symptoms that manifest primarily 
in the toes, feet, and legs.274  Positive symptoms typically include paresthesias, which are 
constricting-like sensations.43, 274  Tactile allodynias may also develop, causing typically 
non-noxious stimuli to be perceived as painful (e.g. brush of bed sheets or clothing draped 
over the skin).43  These painful symptoms can lead to insomnia and physical injury as a 
patient attempts to avoid further aggravatio  
 Physical injury can also result with the development of sensorimotor deficits, which 
comprise the negative symptoms of DSPN. 270  Although easily dismissible at first, these 
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deficits become increasingly problematic.270, 295  Sensory deficits are commonly described as 
-like perception of sensory loss and can lead to imbalance and 
physical injury.270, 278  This increases the likelihood of  developing non-healing foot 
ulcerations and gangrenous infections.278  Although muscle weakness is much less common 
early on, atrophy can eventually occur in the small muscles of the feet and hands.270, 272  
Clinical signs of motor impairment often include diminished or absent ankle reflexes and 
occasionally (rare) loss of patellar reflexes.270 
2.1.2.4.1.3.  Clinical Diagnostic Criteria for DSPN 
DSPN is divided into stages of progression based on QST and nerve conduction velocity 
(NCV) results.274-275  Patients with possible DSPN either have positive symptoms, negative 
symptoms, or aberrant motor reflexes.274-275  In probable DSPN, patients exhibit positive or 
negative symptoms and aberrant motor reflexes.274-275  In confirmed DSPN, patients that 
meet the criteria for probable DSPN also have NCV deficits.274-275  Finally, in subclinical 
DSPN, only NCV deficits are present.274-275 
2.1.2.4.1.4.  Alternative Small Fiber Neuropathy Assessments for DSPN 
 Small fiber neuropathy assessments can be used in the absence of NCV deficits in 
probable DSPN patients where DSPN is highly suspected.275  In this regard, morphological 
assessments, such as skin punch biopsies and corneal confocal microscopy, are emerging as 
minimally invasive techniques to assess small sensory nerve fiber loss in patients.275, 296  In 
skin biopsies, immunohistological analyses of intraepidermal nerve fiber (iENF) densities 
are used to assess changes in cutaneous innervation (i.e. C-fibers; discussed shortly).275, 296  
Recent studies show that iENF densities are significantly reduced in diabetic patients that 
still have normal NCVs.297-298  These reductions are further exacerbated in patients 
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displaying clinical symptoms or signs of DSPN.297  Intriguingly, assessments of small 
sensory corneal nerve fibers via corneal confocal microscopy strongly correlate with iENF 
loss and DSPN severity.298  Hence, corneal confocal microscopy is gaining ground as a 
surrogate, non-invasive biomarker for DSPN.298 
 As a therapeutic side note, compounds that generally improve NCV and sensory deficits 
in rodents historically fail to exhibit clinical efficacy.296, 299  Alternatively, morphological 
assessments, such as iENF density analysis or corneal confocal microscopy, may be more 
adept to predicting clinical efficacy since they can alleviate interspecies mechanistic 
differences.296  Hence, iENF density analysis has been used as a morphological assessment 
to monitor both disease progression and drug efficacy in this research. 
2.1.2.4.2.  Somatosensory Nerve Fibers and Pain in DSPN 
 To better understand the development of somatosensory deficits in DSPN as well as the 
behavioral measurements used in this research, somatosensory nerve fibers are reviewed 
below.  Since our research examines the effects of drug intervention upon thermal and 
mechanical hypoalgesia in STZ-diabetic mice, a special emphasis has been placed upon 
nociception (encoding/processing of potentially damaging, noxious stimuli) and pain. 
2.1.2.4.2.1.  Somatosensory Nerve Fibers  
Somatosensory information is relayed to the central nervous system (CNS) by dorsal 
root ganglia (DRG).300  DRG are pseudounipolar sensory neurons whose soma (cell bodies) 
lie clustered (in ganglia) in the intervertebral foramena of the spinal column.300  These 
neurons have single axons (nerve fibers) that extend from peripheral tissues, such as the 




- - -, and C-fibers.302  Each type of fiber 
differs in its degree of myelination, conduction velocity, and type(s) of information it 
transmits.300, 302-303  The thickness of the protective, dielectric myelin sheathe depends on 
neurotrophic signaling between myelinating Schwann cells (SCs) and the axons.304-307  As 
myelin thickness increases, NCV also increases.300, 302, 304-307  -fibers are the most thickly 
myelinated fibers (12-20 µm in diameter) and the fastest conductors at 72-120 m/s.300, 302  
-fibers are more thinly myelinated (6-12 µm in diameter) and slower (6-72 m/s).300, 302 
- -fibers mainly transmit touch and proprioceptive information.300, 302  The thinly 
-fibers (1-6 µm in diameter) transmit thermal and nociceptive information at 
4-36 m/s.300, 302  C-fibers are entirely unmyelinated, with diameters between 0.2-1.5 µm.300, 
302  C-fibers also transmit thermal and nociceptive information, but at a slower rate (0.4-2.0 
m/s).300, 302  C-fibers alternatively receive neurotrophic support from non-myelinating SCs, 
which surround multiple C-fibers to form Remak bundles.305 
2.1.2.4.2.2.  Nociception and Pain 
 Pain is a complex interpretation (percept) of sensory outputs combined with emotional 
experiences.300-301, 303, 308  Although emotion does certainly influence pain, it is the relay of 
nociceptive information that is mainly compromised in DSPN.  As such, it is important to 
distinguish between normal responses to non-noxious and noxious stimuli.  
 Thermal receptors and nociceptors are found at the free nerve endings of -fibers and 
C-fibers.301, 303  At normal skin temperature (34ºC), warm receptors on C-fibers and cool 
rec -fibers fire continuously at 2-5 spikes/s.300, 302  These thermal receptors fire 
most vigorously at 45ºC (warm receptors) and 25ºC (cool receptors).300, 302  As temperatures 
fluctuate around these optimal temperatures, the firing rates decrease, altering the frequency 
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of transmissions to the CNS.300, 302  As temperatures exceed 45ºC or fall below 5ºC, thermal 
-fibers) and cold nociceptors (C-fibers) activate.300, 
302  Acute thermal pain tolerance can be measured in animals using the hot plate and cold 
plate tests, which assess hindpaw withdrawal latencies after abrupt exposures to extreme 
temperature changes.308  Polymodal nociceptors on C-fibers also respond to noxious thermal 
stimuli.300, 302  However, while heat and cold nociceptors typically evoke sharp painful 
sensations, polymodal nociceptors result in a slow, dull burning sensation.300, 302  The latter 
can be measured using the Hargreaves behavioral test, which applies gradual, intensifying 
amounts of radiating heat to determine withdrawal latencies.309 
Mechanical nociceptors respond to intense pressure.300-302, 308  While polymodal 
nociceptors on C-fibers detect noxious blunt stimuli (e.g. pressing and pinching), 
-fibers sense pricking stimuli.302, 310  Pricking pain thresholds 
can be assessed in animals by applying von Frey monofilaments to the plantar surface of the 
hindpaw and measuring withdrawal latencies.303, 308  Hence, the von Frey and Hargreaves 
behavioral tests allow for -fiber and C-fiber nociceptive functions to be individually 
assessed.  Both of these behavioral tests have been used in our research.  
Thermal and nociceptive information is relayed to the primary somatosensory cortex by 
the anterolateral system (ALS).300-302, 311  These sensory impressions are shunted through the 
secondary somatosensory cortex on to the somatosensory association cortex, where an 
overall perception of the stimuli is generated.  In the case of pain, this oversimplification 
does not address the emotional contributions, the effects of ascending feeds to other regions 
of the brain, or the inhibitory effects of the descending periaqueductal gray (PAG) pathway.  
- and C-fiber 
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deterioration in DSPN compromises the initial sensing of noxious stimuli, which derails the 
perception of pain and results in hypoalgesia or hyperalgesia.  The molecular mechanisms 
implicated in this deterioration are described below. 
2.2.  Neuropathogenesis in Diabetes Mellitus 
DSPN is a multifactorial neurodegenerative disorder that arises from biochemical insults 
associated with glucotoxicity, altered neurotrophism, and ischemia.44, 271, 275, 307  Although 
this discussion primarily focuses on the biochemical insults associated with DSPN, it should 
be noted that these mechanisms likely contribute to the development of all generalized 
symmetric polyneuropathies, especially DAN. 
2.2.1.  Glucotoxicity 
As mentioned, dysfunctional insulin signaling disrupts normal glucose transport, thus 
resulting in adipose, muscle, and hepatic tissue malnourishment, systemic hyperglycemia, 
and excessive glucose influx into neurons.  This abundance of glucose causes what is best 
Figure 4).  In an attempt to metabolize and clear 
excess glucose, neurons employ alternative metabolic pathways that drain intracellular 
coenzyme and antioxidant resources.  This forces neurons to reroute critical supplies in an 
attempt to support more crucial, life-sustaining functions.  Unfortunately, chronic exposure 
to high glucose ultimately leads to a collapse in these critical functions and cell death.  
Glucotoxicity results from prolonged increases in metabolic flux through:  glycolysis; 
Tricarboxylic Acid (TCA) Cycle; polyol pathway; hexosamine pathway; diacylglycerol-
protein kinase C (DAG-PKC) pathway; non-enzymatic post-translational modifications 
(AGEs); and mitochondrial dysfunction.  The neuropathological contributions for each of 



















Figure 4.  Conflicting metabolic demands in neurons during hyperglycemia.  
Overlapping regions indicate coenzyme (hashed) use by competing metabolic pathways, 
mitochondria, or glutathione reductase (solid) in glucose metabolism; reduced glutathione 
(GSH, hashed) replenishment is needed to effectively neutralize mitochondria (red)-derived 
reactive oxygen (ROS) and reactive nitrosative species (RNS).43-46, 312-313 
 
2.2.1.1.  Glycolysis and Tricarboxylic Acid Cycle 
 Diabetes-induced hyperglycemia can cause up to a fourfold increase in neuronal glucose 
levels.44  The neuronal response to glucose accumulation is to up-regulate the primary and 
alternate metabolic pathways.  In this regard, glycolysis and the TCA Cycle are the first line 
of defense against glucotoxicity.  Several of these metabolic steps use the oxidizing 
coenzymes NAD+ (nicotinamide adenine dinucleotide, oxidized) and FAD (flavin adenine 
dinucleotide, oxidized), which reduce to NADH and FADH2, respectively.312  Each glucose 
molecule yields roughly ten NADH and two FADH2, which are then subjected to oxidative 
phosphorylation to collectively produce 26-28 molecules of ATP.312  However, the 
metabolic capacity of hexokinase (rate-limiting step) is overwhelmed in diabetic nerves, 
intensifying metabolic demands upon the mitochondria and depleting NAD+ and FAD 
levels.44  Consequently, excess glucose must be shunted to alternative metabolic routes.   
2.2.1.2.  Polyol (Sorbitol) Pathway 
The polyol (sorbitol) pathway provides the bulk of reinforcing metabolic support 
(Figure 5).  When hexokinase is overwhelmed, glucose levels quickly approach the KM of 
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aldose reductase (AR; Kd:  AR >> hexokinase).44  AR reduces glucose to sorbitol using 
NADPH (nicotinamide adenine dinucleotide phosphate, reduced).43-44, 46  This coenzyme is 
also used by glutathione reductase to convert oxidized glutathione (GSSH) back to reduced 
glutathione (GSH), for use as an antioxidant.   Consequently, cellular antioxidant defenses 
are weakened.43-45   
 
Figure 5.  Polyol (sorbitol) pathway.  (Adapted from Tomlinson and Gardiner)44  
Sorbitol is normally oxidized to fructose by sorbitol dehydrogenase and NAD+.46  
However, NAD+ depletion in glycolysis and in the TCA Cycle hinder this conversion.46  
This causes the build-up of impermeable, hydrophilic sorbitol, which results in hypertonicity 
and the efflux of numerous osmolytes, including myo-inositol (MI).43-45, 314  MI also serves 
as a metabolic precursor to phosphatidylinositol (PI), whose various phosphorylation states 
serve as important secondary messengers in multiple signaling cascades.314  In the sciatic 
nerves of experimental Type 1 diabetic steptozotocin (STZ)-induced rats, significant 
reductions in MI concentrations, Na+/K+-ATPase activity, and MNCV have been noted after 
only 2-4 weeks of diabetes.315-316  MI supplementation can prevent the reductions in Na+/K+-
ATPase activity and MNCV.315  Both AR genetic deletions and pretreatments with 
Fidarestat (aldose reductase inhibitor) prevent GSH depletion and reductions in MNCV and 
SNCV in STZ-diabetic mice.317  These conditions also suppress superoxide levels and 
related DNA damage in these diabetic mice.317  This is encouraging for the pharmacologic 




Figure 6.  O-GlcNAcylation and the hexosamine pathway.44-45, 318-319 
2.2.1.3.  Hexosamine Pathway 
 Augmented metabolic support is also provided through the hexosamine pathway, which 
consumes the fructose 6-phosphate intermediate from glycolysis (Figure 6).44-45, 318-319  
Shunting of fructose 6-phosphate via the hexosamine pathway leads to an over-production 
of UDP-O-GlcNAc (uridine diphosphate-N-acetyl-D-glucosamine).44-45, 318-319  O-GlcNAc 
transferase (OGT) uses this metabolite to post-translationally modify (O-GlcNAcylate) key 
regulatory sites (serine/threonine residues) of transcription factors and signaling proteins.44-
45, 318-319  These modifications usually serve as an adaptive response to various stressors, 
such as heat, hypoxia, and heavy metals.319-322  -
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O-GlcNAcylation and phosphorylation tightly regulate gene transcription, translation, and 
protein trafficking and degradation.319-322  O-GlcNAcylation and phosphorylation can either 
work together to fine-tune protein activity or antagonize each other.319-322   
 Disrupting the fine balance between O-GlcNAcylation and phosphorylation can have 
devastating effects.  In fact, alterations to the hexosamine pathway, protein kinase activity, 
and regulatory site mutations have been implicated in the pathological progression of 
numerous diseases, including cancer and diabetes.323-327   
 In cancer, the transcription factor c-Myc is often up-regulated and phosphorylated to 
enhance pro-survival protein expression.325-327  O-GlcNAcylation of c-
prevents phosphorylation and activation at this same site.327  In contrast, when the tumor 
suppressor p53 (mutated in about half of human cancers) is O-GlcNAcylated at Ser(149), 
phosphorylation at Ser(155) is blocked.325, 328  This prevents p53 proteolytic degradation and 
promotes pro-apoptotic gene transcription.328  Thus, O-GlcNAcylation and phosphorylation 
can either promote or inhibit gene transcription. 
 In diabetes, cardiovascular complications are partially linked to the transcription factor 
Sp1.45, 271, 329  O-GlcNAcylation activates Sp1, which permits the expression of several 
glucose-induced housekeeping genes, such as plasminogen activator inhibitor-1 (PAI-1) and 
transforming growth factor- - 45, 271, 329  PAI-1 inhibits tissue plasminogen 
activator (tPA) and urokinase, thereby impeding fibrinolysis and promoting microvascular 
thrombosis (blood clotting) and nerve ischemia.45  Increases in PAI-1 activity have been 
noted in sural nerve biopsies from T2DM patients, where tPA levels in epineurial and 
endoneurial microvessels were reduced nearly sixfold.330  In vitro studies in rat DRG have 
shown that TGF- -
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elevated in the DRG and sciatic nerves of 12-week STZ-diabetic rats.331  Hence, Sp1 O-
GlcNAcylation in diabetes likely enhances nerve ischemia and disrupts neuritogenic efforts. 
 O-GlcNAcylation can also contribute to the development of insulin resistance.  High 
levels of O-GlcNAc in adipocyte-like 3T3-L1 cells can increase O-GlcNAcylation of IRS-1 
and IRS-2.324  This prevents IRS-1 and IRS-2 phosphorylation and associated PI3K/Akt-
dependent GLUT-4 vesicle translocation (discussed in-depth in Altered Insulin-Associated 
Neurotrophism in Diabetes Mellitus).324  While the functional implications are currently 
unclear, several insulin signaling components can be O-GlcNAcylated, including:  
of the insulin receptor, Akt-1, Akt-2, GSK- -
(phosphoinositide-dependent kinase-1), PI3K, and endothelial GLUT-1.324  Furthermore, 
insulin signaling normally causes PIP3 (phosphatidylinositol 3,4,5-triphosphate) to recruit 
OGT from the nucleus to the plasma membrane.332  These data suggest that OGT has a 
critical role in normal insulin signaling and DSPN pathogenesis.  
 To summarize, O-GlcNAcylation can alter gene transcription and protein expression, 
trafficking, and degradation, which can favor or hinder cell viability.  This is especially true 
for diabetic neurons that endure massive amounts of metabolic flux through the hexosamine 
pathway.  However, non-enzymatic protein glycosylation (glycation) also contributes. 
2.2.1.4.  Advanced Glycation End-Products 
Glycation is a naturally occurring process that simply becomes amplified with diabetes-
induced hyperglycemia.  Advanced glycation end-products (AGEs) significantly affect the 
pathological progression of DSPN.46  These AGEs result from the degradation of early 




Figure 7.  Formation of early glycation adducts.  R1 = remainder of lysine.335-337  
 
2.2.1.4.1.  Formation of Early Glycation Adducts 
Early glycation adducts form via the Amadori rearrangement.39, 43-46, 335-336  During this 
process, the anomeric carbon of glucose is attacked by the -amino group of lysine or the 
-guanidino group (Figure 7).  This results in the protonation of 
335-336  Nitrogen 
lone pair electrons then establish a Schiff base with the anomeric carbon, causing further 
protonation of the anomeric oxygen, the release as H2O, and deprotonation of the imine.335-
336  Deprotonation at the C-2 position then gives the 1,2-enolamine.335-336  This tautomerizes 
- -fructosyl- -fructosyl-arginine), which can 
cyclize to form pyranose or furanose ring structures for added stability.335-337  The most 
well-known of these complexes is glycated hemoglobin.  Since HbA1C remains detectible for 
up to 120 days (lifespan of most erythrocytes), it makes a great biomarker for physicians to 
assess long-term changes in plasma glucose levels and to diagnose diabetes.39, 337-338   
2.2.1.4.2.  Formation of AGEs  
Amadori complexes are readily oxidized by iron-containing enzymes, phosphates, 
nitrates, reactive oxygen species (ROS), and reactive nitrosative species (RNS) (discussed 
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in-depth in Mitochondrial Dysfunction and Oxidative and Nitrosative Stress).333-334, 339  
- -(carboxymethyl)lysine (CML) or 3-(N- -
lysine)-lactic acid (Figure 8).333-334, 339-341  These AGEs are produced with the pH-dependent 
oxidation of the 2,3-enediol intermediate of the Amadori complex.333-334, 339-340   
 
 
Figure 8.  Structures of advanced glycation end-products.  R1 = remainder of lysine.333-
334, 339-341 
 
-oxoaldehydes.  For 
example, C-2 deprotonation and C-3 dehydroxylation of acyclic glucose gives the 2,3-enol, 
which tautomerizes to yield 3-deoxyglucosone (3-DG).334  Retroaldol reactions between the 
C-3 and C-4 positions of the 2,3-enol forms 2-hydroxy-propenal (and glyceraldehyde), 
which tautomerizes to methylglyoxal.334  Deprotonation at C-2 can also give the 1,2-
enediol, which undergoes monosaccharide autoxidation to form glucosone and H2O2.334  
Finally, retroaldol reactions between the C-2 and C-3 positions of acyclic glucose generates 
glyoxal and erythritol or glycolaldehyde and erythrose.334  In the latter case, glycolaldehyde 
further oxidizes to produce glyoxal and H2O2.334  -oxoaldehydes are highly 





2.2.1.4.3.  Impact of AGEs on Peripheral Nerves 
 Hyperglycemia accelerates AGE production, and disrupts homeostasis.343  In neurons, 
AGEs can affect cytoskeletal proteins (e.g. tubulin, actin, and neurofilaments) as well as 
Na+/K+-ATPase, thus impairing axonal transport, neurite outgrowth, and NCV and 
promoting axonal atrophy.344-345  AGEs involving extracellular matrix proteins (e.g. laminin, 
fibronectin, and collagen) can also impair neurite outgrowth/regeneration.43, 271, 344-345  AGEs 
involving the myelin structural proteins P0 and myelin basic protein (MBP) are also thought 
to contribute to demyelination.344-345  Furthermore, AGE formation can alter vasoreactivity 
by quenching the vasodilator nitric oxide, thus enhancing nerve ischemia.43, 344-345 
 Plasma protein AGEs serve as extracellular ligands for AGE receptors (RAGEs) found 
on macrophages, smooth muscle cells, vascular endothelial cells, DRG, and SCs.271, 344-345  
In DRG, RAGE signaling induces ROS production, DNA degradation, caspase-3 activation, 
and apoptosis.271, 347  RAGE signaling also triggers nuclear factor- -
to the nucleus.271, 347  NF- interleukin- -
and TNF- expression, which are linked to hypoalgesia in DSPN.344, 346  This is further 
supported by diabetes studies in RAGE knockout mice, wherein hypoalgesia, NCV deficits, 
and axonal atrophy are blunted as compared to wild-type diabetic counterparts.271, 346-347  
Finally, NF-
thrombosis in the blood vessels of the epineurium and the dermal vasa nervorum.  This 
compromises essential blood support to the peripheral nerves.344  Hence, diabetes-induced 
hyperglycemia can significantly increase AGE concentrations, which can have grave 




2.2.1.5.  Diacylglycerol-Protein Kinase C Pathway 
Dysfunctional insulin signaling causes starvation in adipose tissues, thereby inducing 
lipolysis and unregulated FFA entry into the blood.348  The resulting hyperlipidemia 
compromises neuronal viability in two ways.  First, it promotes atherosclerosis through the 
deposition of small lipoproteins, such as low-density lipoprotein (LDL)-cholesterol, forming 
hardened plaques in the vasculature that reduce blood flow.349  Second, it promotes de novo 
1,2-diacylglycerol (DAG) synthesis in non-adipose tissues, which inhibits IRS-1 and IRS-2 
phosphorylation and subsequent insulin signaling.248, 250-253  This exacerbates neuronal 
glucotoxicity.  DAG also affects blood flow to the nerves via PKC.     
 DAG activates several PKC isoforms.348  Once primed by PDK1, PKCs remain auto-
inhibited until secondary messengers bind to the C1/C2 domains or the proper stimulus is 
encountered.350  -sensitive C1 domains and 
Ca2+-sensitive C2 domains.350  It is the PKC-
DSPN.350  Overactivation of PKC-
altering the expression of PAI-1, TGF- NF- , and vascular endothelial growth factor 
(VEGF), a pro-angiogenic.46, 271, 351-352  PKC- -mediated nitric oxide 
release and vasodilation.353  Hence, PKC-
development (discussed in PKC- ) 
In contra
are DAG- and Ca2+-insensitive.350  Although the endogenous ligands for novel PKCs remain 
elusive, recent neuronal studies suggest that activating PKC- -sensitive PKC-


























Figure 9.  Mitochondrial respiration and generation of superoxide.  Electron transfer 
(red) and proton transport (blue) are denoted by hashed arrows.  Single electrons (e-) lost 
from complex I and coenzyme Q/complex III converge (red/black hashed lines) and react 
with O2 to generate superoxide (O2 -).  Blue and red charges along the membrane depict an 
established electrostatic gradient.  (Adapted from Figueroa-Romero et al.)45 
 
2.2.1.6.  Mitochondrial Dysfunction and Oxidative and Nitrosative Stress  
Increased metabolic demands impose significant stress upon the mitochondria, which 
jeopardizes neuronal function and survival.  During mitochondrial respiration, a single pair 
of electrons are transferred from the reducing substrates NADH and FADH2 to respiratory 
complexes I and II, respectively (Figure 9).45  These electrons are transported through the 
respiratory complexes, establishing an electrochemical (proton) gradient across the inner 
mitochondrial membrane.45  Upon reaching complex IV, the electrons are used to reduce O2 
to H2O in the matrix.45  As the protons are released back into the matrix, the proton motive 
force supplies the energy needed to drive ATP synthesis via ATP synthase.45    
About 1-4% of O2 fails to completely reduce to H2O at complex IV, which generates the 
free radical ROS superoxide (O2 -) (Figure 9).44-46  Superoxide is thought to arise due to a 
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reverse single electron transfer (e-) at complex I or the autoxidation of the ubisemiquinone 
radi 45  Superoxide dismutase (SOD) converts 
superoxide to H2O2, where it is reduced to H2O and O2 by catalase.45  The breakdown of 
H2O2 is normally augmented by glutathione peroxidase.44-46  However, this enzyme requires 
reduced glutathione (GSH) to convert H2O2 to H2O.44-45  As NADPH and GSH resources 
deplete and respiratory demands increase with chronic hyperglycemia, superoxide and 
hydrogen peroxide levels increase. 
Superoxide is highly reactive and can generate a chain reaction that produces additional 
44-45  This chain reaction 
has become known as the Haber-Weiss reaction.358  It initiates with the reduction of Fe(III) 
to Fe(II) by superoxide, which restores O2 (Equation 1).358  H2O2 then reacts with Fe(II) to 
replenish Fe(III) and to give the ROS hydroxyl radical -) 
(Equation 2).358  The net reaction is shown in Equation 3 2) can 
also react with superoxide to produce the highly unstable RNS peroxynitrite (ONOO-).  
Peroxynitrite also forms when superoxide reacts with endogenous nitric oxide.44-45   
 
 
Figure 10.  Haber-Weiss Reaction. (Adapted from Haber and Weiss)358   
  
ROS and RNS can severely damage any encountered protein, membrane lipid, or DNA 
molecule in the mitochondria, compromising the functional integrity of the mitochondria 
and thereby promoting pro-apoptotic signaling (i.e. cytochrome C release).45-46  Recent 
studies in excised STZ-diabetic and high-glucose-treated DRG and SCs have shown 
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significant alterations to the mitochondrial proteome, mitochondrial membrane potentials, 
respiratory chain activities, and bioenergetics.359-363  Although ROS and RNS can not readily 
diffuse across mitochondrial membranes, permeability transition pores may likely permit 
free radicals to exit the outer mitochondrial membrane and enter the cytosol.45  This can 
drastically impair other neuronal and SC functions.  Common indicators of oxidative and 
nitrosative stress include:  4-hydroxynonenal, a lipid peroxidation product; nitrotyrosine, a 
peroxynitrite nitrosylation product; and carbonylation, which results from the oxidation of 
amino acid side-chain hydroxyl groups.46, 364   
Interestingly, somatic nerve fibers become increasingly dependent upon mitochondrial 
sources of ATP as one travels distally down the nerve.45  Hence, hyperglycemia-induced 
mitochondrial dysfunction, alongside aforementioned nerve ischemia, may partly explain the 
























   
Figure 11.  Poly(ADP-ribose) polymerase (PARP) and DNA repair.  PARP flags nicked 
DNA for base excision repair with poly(ADP-ribose), designated as the chains of [A].46, 313    
  
2.2.1.7.  Poly(ADP-ribose) Polymerase Pathway 
ROS and RNS can nick and severely damage DNA.  Poly(ADP-ribose) polymerase 
(PARP) helps repair single-strand DNA breaks (Figure 11).313, 365  PARP cannibalizes 
NAD+ to form ADP-ribose and nicotineamide, and then polymerizes these ADP-ribose 
metabolites to form poly(ADP-ribose), or PAR.46, 313  PAR is covalently attached to select 
nuclear proteins (e.g. histones) or displayed by PARP at the damage site.313  PARylation is 
an SOS beacon that triggers the recruitment of DNA repair enzymes for base excision repair 
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(BER).313  This process also depletes NAD+ stores during a time of metabolic crisis, which 
ironically intensifies oxidative/nitrosative stress and further DNA damage.45-46, 271, 313   
PARP hyperactivity has been implicated in NCV deficits, neurovascular dysfunction, 
thermal and mechanical hyper- and hypoalgesia, tactile allodynia, and demyelination in 
diabetic nerves.45-46, 271, 365  PARylated proteins are present after 4 weeks of STZ-diabetes 
and cultured human SCs.365  Recent evidence also suggests that PARP overactivation occurs 
before the development of diabetes-related oxidative/nitrosative stress, suggesting a more 
pivotal role in DSPN pathogenesis.46  This is further supported by the fact that mice devoid 
of PARP-1 do not develop small-fiber neuropathy with STZ-diabetes.46, 366-367  Hence, PARP 
may be a viable target for pharmacotherapy. 
In summary, diabetes-induced hyperglycemia drives peripheral nerves to the point of 
metabolic exhaustion while continuing to subject them to worsening ischemic conditions.  
Chronic exposure to metabolic stress depletes coenzyme stores and antioxidant defenses.  
This increases the likelihood of mitochondrial dysfunction, ROS/RNS production, DNA 
damage, pro-apoptotic signaling, aberrant post-translational modifications, and detrimental 
alterations in molecular trafficking.  However, this metabolic distress is accompanied 
diminished neurotrophic support, which has a much more direct impact upon peripheral 
nerve function and viability.  The effects of this altered neurotrophism are reviewed below. 
2.2.2.  Altered Insulin-Associated Neurotrophism in Diabetes Mellitus 
In addition to regulating postprandial glucose uptake in muscle, adipose, and hepatic 
tissues, insulin signaling is required during early development to sustain neuronal viability 
and function throughout the nervous system.194-195, 269, 277, 368-371  These neurotrophic effects 
of insulin are normally augmented by insulin-like growth factor-I (IGF-I).368-371  However, 
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IGF-I signaling also diminishes in diabetes.372-378  Dysfunctional insulin and IGF-I signaling 
are also linked to the pathological progression of central neurodegenerative disorders, such 
269  While insulin and IGF-I do have 
critical roles in the CNS, only peripheral neurotrophic effects will be discussed below.  To 
better understand the impact of altered neurotrophism in DSPN, ligand bioavailability, 
receptor localization, and ligand-induced molecular signaling are reviewed herein. 
2.2.2.1.  Insulin and Insulin-Like Growth Factor (IGF) Bioavailability 
As previously discussed, peripheral insulin supply depends exclusively upon pancreatic 
-I is expressed in the 
DRG, the SCs, the sympathetic ganglia, the ventral horn of the spinal cord, and the targeted 
tissues.269, 368  Another IGF isoform, IGF-II, is also secreted by SCs and skeletal muscle cells 
to reinforce neurotrophic support.269, 368  These IGFs support nerve viability, neuronal 
migration, and neuritogenesis, which may promote nerve regeneration in DSPN.269, 368   
Table 1.  Insulin, IGF-I, and IGF-II IC50 values.  IC50 values in nM concentrations. (From 
Urban et al.; Adapted from Belfiore et al. and Benyoucef et al.)206, 269, 379 
 
Isoform Ligand (IC50, nM) 
IR-A  Insulin (0.2)     <     IGF-II (2.2)     <     IGF-I (9.0) 
IR-B Insulin (0.5)     <     IGF-II (10.0)   <     IGF-I (90.0) 
IGF-IR IGF-I (0.8)       <     IGF-II (4.4)     <     Insulin (>100) 
 
2.2.2.2.  Insulin and IGF-I Receptor Structure and Localization 
Insulin receptors (IRs) and IGF-I receptors (IGF-IRs) are tetrameric proteins that consist 
of two extracellular ligand-binding domains ( -subunits) and two receptor tyrosine kinase 
-subunits).206, 269  While insulin, IGF-I, and IGF-II can all bind to IGF-IR 
                                                 
 Receptor lacks exon 11, which enhances ligand binding affinity 
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and to both IR isoforms (IR-A and IR-B), differences in receptor compositions substantially 
(Table 1).206, 269, 379-380 
In adipose, muscle, and hepatic tissues, the metabolic effects of insulin are enhanced via 
selective expression of the IR-B isoform over the IR-A.206, 269  It is thought that alterations to 
these relative IR-B:IR-A expression ratios promotes insulin resistance.206  Conversely, IR-A 
is believed to be the dominant isoform in neurons, where it exhibits a much stronger binding 
affinity for all three ligands compared to IR-B.206, 379-380  In peripheral nerves, IRs primarily 
localize to the DRG and the sympathetic ganglia.368, 381  IGF-IRs are mainly expressed in 
- or C-fiber), motor neurons, sympathetic ganglia, and SCs.368, 
381  Most of these regions are implicated in DSPN and DAN, suggesting an etiologic link 
between DPN and dysfunctional insulin and IGF-I signaling.206, 269  
2.2.2.3.  Insulin and IGF-I Signaling 
Upon ligand binding, receptor autophosphorylation activates intrinsic RTK domains, 
which phosphorylate and activate regulatory effector proteins, such as IRS-1, IRS-2, Shc 
[Src (Rous sarcoma) homology 2 domain-containing], and Grb2 (growth factor receptor-
bound protein-2) (Figure 12).206, 269  This activation is ligand-, receptor-, and tissue-
dependent and essentially directs which signaling effects are induced.206, 269, 368   
2.2.2.3.1.  Metabolic Effects 
 The metabolic effects of insulin are mediated via induction of the PI3K/Akt pathway in 
IR-B-heavy tissues (Figure 12).206, 269  IRS-1/IRS-2 phosphorylation triggers the recruitment 
and activation of PI3K, which converts PIP2 (phosphatidylinositol 4,5-bisphosphate) to 
PIP3.206  This permits PDK-mediated Thr(308)Akt phosphorylation, or pThr(308)Akt.324  
pThr(308)Akt enhances GLUT-4 vesicle transit velocity, docking, and incorporation into the 
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cell membrane to facilitate glucose uptake.207-209, 324  As discussed, insulin resistance can 
develop through the deterioration of PI3K/Akt signaling.206  Again, this can result from 















































Figure 12.  Metabolic effects and cytoprotection via insulin and IGF-I signaling.  
Ligand binding triggers receptor autophosphorylation and RTK (red) activation, allowing for 
IRS-1, IRS-2, Shc, or Grb2 phosphorylation.  Mitogenic signaling pursues via Grb2-
mediated activation of the GEF son of sevenless (SoS), enabling Ras activation.  Ras 
initiates the MAPK/ERK pathway through Raf-1 phosphorylation and enhances 
mTOR/raptor signaling, collectively inducing cell growth, proliferation, protein expression, 
and viability.  Induction of the PI3K/Akt pathway in muscle, adipose, and hepatic tissues 
enhances GLUT-4 vesicle integration into the cell membrane, enabling glucose uptake.  
Hsp90 client proteins (SECTION 4 and CHAPTER II) are indicated with a pink bar and serve 
critical roles in regulating insulin and IGF-I signaling.  (Adapted from Urban et al.)269   
  
2.2.2.3.2.  Cytoprotective Effects 
Generalized cytoprotective effects are normally afforded by partial shunting through the 
MAPK/ERK (mitogen-activated protein kinase/extracellular-signal-regulated kinase) and 
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mTOR/raptor (mammalian target of rapamycin/regulatory-associated protein of mTOR) 
pathways (Figure 12).206, 269  Receptor-
MAPK/ERK pathway, which enhances transcription factors that promote proliferation, cell 
growth, and survival (e.g. c-Fos and c-Myc).206  Ras also induces mTOR/raptor signaling, 
which stimulates p70S6 kinase- and eIF4E (eukaryotic translation initiation factor-4E)-
regulated cell growth, autophagy, metabolism, ribosome biogenesis, and translation.206, 269  
The MAPK/ERK and mTOR/raptor signaling pathways also receive input from Akt.206, 
269  Akt phosphorylates TSC2 (tuberous sclerosis complex 2), which prevents the hydrolysis 
of Ras-bound GTP and signal termination (Figure 12).206  Further, Akt-mediated MDM2 
(murine double minute-2) phosphorylation allows p53 to be sequestered, ubiquitinated, and 
degraded.382  This reduces the expression of TSC2, IGFBP-3 (IGF-binding protein-3), and 
PTEN (phosphatase and tensin homolog).382  IGFBP-3 disrupts IGF-I:receptor interactions, 
whereas PTEN dephosphorylates PIP3.382  Hence, Akt enhances MAPK/ERK and 
mTOR/raptor signaling, which collectively promotes pro-survival transcription, translation, 
and cell proliferation in insulin/IGF-I-responsive cells.206, 269  However, the bulk of insulin 
and IGF-  
2.2.2.3.3.  Neurotrophic Effects 
 While the specifics of insulin signaling in peripheral nerves are still under investigation, 
several mechanistic clues suggest that insulin and IGF-I signaling share common 
neurotrophic signaling pathways.194, 206  These include:  (1) ligand interchangeability 
between receptors; (2) similar phenotypic improvements upon ligand treatment; and (3) 












































Figure 13.  Insulin and IGF-I neurotrophic signaling in dorsal root ganglia.  RTK (red)-
induced IRS-1/IRS-2 phosphorylation selectively induces PI3K/pSer(473)Akt and 
PI3K/PKC- PKC-
neuritogenesis, respectively.  Hsp90 client proteins (SECTION 4 and CHAPTER II) are 
indicated with a pink bar.194, 269, 350, 354-356, 361, 383-397   
 
In DRG, IGF-I selectively activates PI3K signaling over the MAPK/ERK and the 
mTOR/Raptor pathways (Figure 13).269, 383  Since IRS-2 mRNA levels in adult mouse 
lumbar DRG are ~ 27 times greater than IRS-1, it is conceivable that selective signaling via 
IRS-2 affords neurotrophic effects.195  Further, DRG from Type 1 (STZ-induced) and Type 
2 (ob/ob) diabetic mice demonstrate significant reductions in IRS-2 protein expression levels 
in conjunction with elevated IRS-2 inhibitory phosphorylations.195  These phosphorylations 
are thought to destabilize IRS-2:receptor associations, resulting in IRS-2 degradation and 
signal deterioration.195  However, these effects may likely be region-specific, given that 
peripheral nerve IRS-1 and IRS-2 mRNA levels in STZ-diabetic foot pads are unaffected.194   
In diabetic DRG, IR mRNA levels increase, which suggests possible attempts to increase 
insulin sensitivity.194  -IR mRNA and protein expression levels decrease 
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in diabetic DRG, but recover with insulin treatments.194, 375, 381, 391  This raises the question:  
does insulin have direct neurotrophic effects or does it merely act by increasing IGF-IR?  In 
this regard, DRG explants treated with insulin alone (no IGF-I) display vast improvements 
in mitochondrial function and neurite outgrowth, indicative of direct neurotrophic effects.361  
However, this does not rule out the possibility that insulin could act via IGF-IR nor does it 
negate possible synergistic or additive neurotrophic effects in the added presence of IGF-I.  
In any case, these neurotrophic effects appear contingent on PI3K signaling. 
2.2.2.3.3.1.  Effects on Mitochondria Bioenergetics and Neuronal Viability 
In DRG, IGF-I induced PI3K signaling triggers PDK1-mediated Akt phosphorylation at 
Ser(473) (Figure 13).  This enhances Akt
of pro-survival transcription factor CREB (cAMP-response element binding) as well as the 
nuclear exportation of forkhead and deactivation of GSK- -apoptotic effectors).361, 383-
388  Under high glucose conditions, pSer(473)Akt prevents the detrimental trafficking of 
permeabilizing Bim/Bax to DRG mitochondria and phosphorylates/deactivates caspase-9; 
both of these conditions prevent caspase-3 activation and apoptosis.383, 389-391  Similar effects 
have been seen in SCs, where IGF-I-induced pSer(473)Akt enhances SC motility and 
promotes myelination in SC-DRG co-cultures.398-406  IGF-I- and insulin-induced 
to nearly twofold that of untreated control DRG.361  Hence, insulin and IGF-I signaling can 
improve DRG and SC mitochondrial viability and function via pSer(473)Akt.361   
2.2.2.3.3.2.  Effects on Neuritogenesis 
It is thought that somatosensory nerve fibers remain in a state of perpetual growth, and 
that these nerve fibers can respond to local manipulation.194  Growth-associated protein-43 
 
 68 
(GAP-43) is an IGF-I- and insulin-r
neuronal growth cones and non-myelinating SCs during development and nerve fiber 
regeneration.194, 392-396  In DRG, GAP-43 promotes F-actin accumulation, morphogenic 
activity, and prevents growth cone retraction.397  GAP-43 reductions have been noted in the 
lumbar DRG and the foot pads of STZ-diabetic rats and in the nerve fibers of early Type 2 
diabetic skin biopsies.194, 407-412  IGF-I can improve distal somatosensory nerve fiber atrophy, 
iENF density, and attenuate SC vacuolization and peripheral nerve demyelination.369, 378   
GAP-43 is activated by PKC- - -mediated Ser(41) phosphorylation (Figure 13).  
This process initiates after PKC is phosphorylated and primed by PDK1.350, 354-356, 397  While 
neither PKC- - sion levels change in DRG from STZ-diabetics rats, 
pThr(505)PKC- 413-415  Further, PKC- -expression can restore 
neurite outgrowth in diabetic DRG.414  To the best of our knowledge, the effects of PKC-
phosphorylation [pThr(566) or pSer(729)] in DSPN are unexplored.355  However, data from 
PC12 cells suggests that PKC- -sensitive and can induce neuritogenesis and CREB 
phosphorylation when confronted with oxidative stress.355  Hence, targeting PKC-
PKC-  
Improvements in mitochondrial function and neuritogenesis likely contribute to insulin- 
and IGF-I-induced recoveries in MNCV, SNCV, thermal hypoalgesia, and mobility as well 
as the stabilization of mechanical hyperalgesia in STZ-diabetes.371, 378, 416  However, these 
recoveries may also benefit from improvements in synaptic plasticity.   
2.2.2.3.3.3.  Effects on Synaptic Plasticity  
Insulin deprivation can significantly affect nociceptive signaling.  In painful neuropathy 
studies involving STZ-diabetic rats, nociceptive DRG over-express metabotropic glutamate 
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receptors (mGluR5) at presynaptic terminals.417  This enhances glutamate (N-methyl-D-
aspartic acid, or NMDA) release and amplifies nociceptive signaling to postsynaptic neurons 
in the spinal cord.417  Postsynaptic NMDA receptor (NMDAR) phosphorylation also 
increases in the lumbar spinal cords of STZ-diabetic rats, which potentiates nociceptive 
signaling.418  Reductions in GABAB (GABA class B) receptor expression also occur in the 
lumbar spinal cords of STZ-diabetic rats, suggesting that GABAergic inhibitory signaling 
needed to suppress nociceptive transmission is compromised.419  Overall, these data suggest 
that insulin deprivation alters synaptic plasticity and deregulates nociceptive signaling.  
In summary, dysfunctional insulin and IGF-I signaling causes numerous hyperglycemic 
and neurotrophic insults, which compromise the functional integrity and survival of the 
peripheral nerves and the relay of nociceptive information.  Thus, DSPN is a multifaceted 
neurodegenerative disorder that demands a multifaceted therapeutic approach.  
SECTION 3.  MODERN PHARMACOTHERAPEUTIC APPROACHES FOR DSPN 
The Diabetes Control and Complications Trial (DCCT, 1983-1993) demonstrated that 
while controlled insulin therapy does significantly decelerate the rate of progression of 
diabetes, DSPN and other complications still develop.23-25  Modern pharmacotherapeutic 
approaches for DSPN are limited in that they mainly target single pathogenic mechanisms 
associated with hyperglycemia or provide monosymptomatic relief for positive symptoms.26  
Current drug treatment options for managing diabetes and DSPN are reviewed herein.     
3.1.  Targeting Hyperglycemia 
3.1.1.  Insulin 
By 1920, the best therapeutic options for diabetes mellitus were purgation and extreme 
dieting, which were techniques utilized by Aretaeus ~ 3,500 years ago.264-265  Consequently, 
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diabetic complications (Figure 14A).265, 420  Sadly, a T1DM diagnosis at that time was 
essentially a death sentence, with most patients dying within a year.265, 420  Luckily, that 
changed with the discovery and administration of extracted pancreatic insulin by Banting, 
McCleod, Best, and Collip in 1922.55  Exogenous insulin administration induced profound 
physiological improvements in Type 1 diabetics, which appreciably enhanced patient 
survivability (Figure 14B).55, 265, 420  This marked the first major pharmacotherapeutic 
breakthrough for diabetes and its associated complications.55, 265, 420-421   
 
Before (December 15, 1922  Age: 3 years; Weight: 15 lbs) and    
(B) after insulin treatment (February 15, 1923  Age: 3 years; Weight 29 lbs).265 
 
neuroglycopenia, which deprives the brain of essential glucose.422  This can cause fatigue, 
confusion, seizure, temporary loss of consciousness, or even coma or death.422  Conversely, 
-oxidation in the liver, which generates 
-hydroxybutyrate i.e. acetoacetate and acetone).423  
-hydroxybutyrate (~ 4.7) and acetoacetate (~ 3.6) result in near complete 
deprotonation in blood (pH ~ 7.4), thus increasing blood acidity.423  This overwhelms the 
bicarbonate buffering system and causes diabetic ketoacidosis (DKA).423  DKA can also 




insulin therapy can have dire consequences.  These issues are further convoluted by varying 
pharmacodynamic effects associated with different insulin preparations (rapid-, short-, 
intermediate-, and extended-acting), insulin mimetics (e.g. L-783,281), and adjunctive 
therapies for postprandial glucose management.424 
3.1.2.  Insulin Secretagogues 
Insulin secretagogues are prescribed as an adjunct to insulin therapy.27  These drugs 
T2DM.425  These mainly consist of first-generation (e.g. tolbutamide, chlorpropamide, 
tolazamide, and acetohexamide) and second-generation (e.g. glyburide, glipizide, gliclazide, 
and glimepiride) sulfonylureas.27, 424-425  Both of these generations block ATP 
channels, causing membrane depolarization, Ca2+ ion influx, and insulin secretion.426  These 
drugs also inh ATP channels alongside secreted Zn2+ ions to prevent 
glucagon release.150, 424-425  Alternatively, the third-generation sulfonylurea, glimepiride, 
mainly acts by enhancing GLUT-4 vesicle translocation in muscle, adipose, and liver 
tissues.425  Although structurally dissimilar to sulfonylureas, repaglinide (meglitinide) and 
nateglinide also block pancreatic KATP channels.424-425  However, these insulin secretagogues 
are generally more fast-acting than sulfonylureas.424-425   
3.1.3.  Biguanides 
Metformin is the only Food and Drug Administration (FDA)-approved biguanide 
available for use in the United States due to lactic acidosis dangers associated with other 
biguinides.424-425, 427  As opposed to altering pancreatic secretions, metformin enhances 
AMP- -
oxidation and decreasing gluconeogenesis.424-425, 427  Metformin also reduces intestinal 
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glucose absorption and improves insulin signaling in muscle and fat.424-425, 427  With that 
 
3.1.4.  Thiazolidinediones 
Thiazolidinediones (e.g. rosiglitazone, pioglitazone, and troglitazone), which are 
common -
agonists.255, 424-425  PPAR-
differentiation and glucose/FFA metabolism, thus increasing viability and preventing the 
release of pro-inflammatory cytokines and FFAs.169  PPAR- -4 
expression in adipose and skeletal muscle tissues.428  Hence, these drugs are mainly intended 
to improve insulin resistance in Type 2 diabetic patients.  
3.1.5.  -Glucosidase Inhibitors 
-Glucosidase inhibitors, such as acarbose and miglitol, reduce intestinal glucose 
absorption by slowing the hydrolysis of starch, dextrin, and various disaccharides.424-425  
These sugar mimics essentially blunt the postprandial plasma glucose spikes that are 
characteristically experienced in all diabetics.424-425 
3.1.6.  Other Glucose-Regulating Agents 
Postprandial plasma glucose levels can also be managed by enhancing GLP-1-mediated 
insulin secretion and by suppressing glucagon release.  Both of these goals can be 
accomplished using GLP-1R agonists (e.g. exenatide, liraglutide, lixisenatide, albiglutide, 
langlenatide, and dulaglutide).429  Similar effects can also be attained by slowing GLP-1 
degradation with diaminopeptidase-4 (DPP-4) inhibitors (e.g. vildagliptin, sitagliptin, 
saxagliptin, linagliptin, and alogliptin).429  Further, glucagon can also be suppressed with 
pramlintide, a non-aggregating, human recombinant amylin.430  GLP-1Rs are also found on 
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DRG and SCs.431  In STZ-diabetic rodents, exenatide treatment can strangely improve 
MNCV and iENF density without affecting plasma glucose levels (as intended).431  
more, STZ-diabetes intervention with the DPP-4 inhibitor PKF275-055 also improves 
MNCV, Na+/K+-ATPase activity, and nociceptive thresholds.432  Hence, GLP-1 may have 
neuroprotective effects in peripheral nerves that are independent from glucose regulation.  
To conclude, the inability to prevent DSPN via targeting hyperglycemia alone has led 
many researchers to pursue alternative pharmacotherapeutic approaches that directly 
improve nerve viability and function in diabetes.  This includes targeting single, putative 
pathogenic mechanisms associated with hyperglycemia. 
3.2.  Targeting Hyperglycemia-Associated Pathogenic Mechanisms 
3.2.1.  Aldose Reductase Inhibitors 
 As mentioned, pretreatment with the ARI fidarestat prevents MNCV, SNCV, and GSH 
reductions in STZ-diabetic mice and suppresses superoxide accumulation.317  As such, 
diverting metabolic flux away from the polyol pathway via ARIs has become an attractive 
therapeutic approach.  ARIs mainly consist of:  acetic acid compounds (e.g. epalrestat); 
spirohydantoins (e.g. sorbinil and fidarestat); and succinimides (e.g. ranirestat).433  However, 
due to undesirable/unsafe side effects from most of the acetic acid compounds, only 
epalrestat is in use today (only in Japan).433  Despit
433  While ranirestat 
has recently completed Phase III clinical trials in the United States, the results have not been 
published.434  Nonetheless, earlier clinical studies with ranirestat showed vast improvements 
in MNCV after 52 weeks of treatment in T1DM and T2DM patients.  However, SNCV 
results in this study were questionable due to placebo effects.434-435 
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3.2.2.  PKC-  
PKC-
support.351, 414  Selective PKC-
(LY333531) and JTT-010, have been shown to improve MNCV and SNCV deficits in STZ-
diabetic rats.351, 436-438  In DSPN patients (T1DM and T2DM), ruboxistaurin can improve 
neuropathic pain scores.439  Even so, the current status for advancing ruboxistaurin and other 
PKC-  
3.2.3.  PARP Inhibitors 
Genetic deletion studies suggest that PARP-1 significantly contributes to DSPN in STZ-
diabetic mice.46, 366-367  In this regard, PARP inhibitors, such as 3-aminobenzamide, 1,5-
isoquinolinediol, PJ34, GPI-15427, and nicotinamide, have been shown to improve 
neurovascular support, NCV deficits, and metabolic activities in STZ-diabetic rats.366-367  
Furthermore, intervention with the PARP inhibitor GPI-15427 can improve thermal 
hypoalgesia, mechanical hyperalgesia, tactile allodynia, and iENF density in STZ-diabetic 
rats.440  Although PARP inhibitors have entered clinical trials as cancer treatments, their use 
in treating DSPN is still in preclinical stages.434 
3.2.4.  Antioxidants 
Since hyperglycemia compromises endogenous antioxidant defense mechanisms, 
antioxidants could be therapeutically beneficial.  In this regard, oral administration of the 
antioxidant -lipoic acid can reduce neuropathic pain scores by as much as 50%.441  Further, 
-Lipoic acid is already sold as a dietary supplement in the United States and is approved for 
DSPN treatment in Germany.271  The antioxidant QR333 (containing quercetin, ascorbyl 
palmitate, and vitamin D) has recently completed Phase II clinical trials for DSPN 
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treatment.434, 442  Studies have shown that t
feet can improve NCV deficits.442  The antioxidant properties of taurine can also improve 
mechanical hyperalgesia.440  Finally, the carotenoid lycopene (commercially available 
dietary supplement) can improve thermal hyperalgesia presumably through the inhibition of 
TNF- -diabetic mice.443  These data suggest that increasing 
resilience to hyperglycemia-induced oxidative/nitrosative stress can improve DSPN.  
3.2.5.  Hexosamine Pathway Inhibitors 
While there are no current inhibitors for the hexosamine pathway, fructose-6-phosphate 
can be shunted away from glycolysis towards the pentose phosphate pathway via thiamine-
dependent activation of transketolase.271  Curiously, both thiamine and transketolase levels 
are reduced in diabetic patients.271  In this regard, the combination therapy of thiamine plus 
pyridoxine can improve neuropathic pain scores in DSPN patients.444  Benfotiamine, a lipid-
soluble thiamine derivative that also improves DSPN-associated neuropathic pain, is 
currently awaiting Phase III clinical trials to assess its therapeutic influence upon iENF 
density in DSPN.434, 445  It is thought that these neuroprotective effects arise by diverting 
glucose away from the hexosamine pathway and restoring normal O-GlcNAcylation.271 
3.2.6.  Antihypertensive Agents 
Given the compromised state of neurovascular support in DSPN, various FDA-approved 
antihypertensive agents are being prescribed.  Angiotensin-converting enzyme (ACE) 
inhibitors (e.g. enalapril) can slow the renal conversion of angiotensin I to angiotensin II, 
which can prevent angiotensin II-induced vasoconstriction.424-425  Antihypertensive therapies 




3.3.  Targeting Growth Factors 
Intervention with exogenous growth factors, such as nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3), have had limited success 
in clinical trials despite promising preclinical results.307, 446  NGF can significantly enhance 
neuritogenesis, collateral branching, and viability in STZ-diabetic rodent DRG.446  However, 
clinical trials was terminated due to injection site hyperalgesia.446  In contrast, IGF-I has 
never entered clinical trials for DSPN management, even though it inhibits hyperalgesia in 
rodents.  Hence, boosting endogenous IGF-I signaling may be a viable therapeutic approach 
(discussed in-depth in SECTION 4).   
3.4.  Targeting DSPN Symptoms 
 Monosymptomatic treatments are a large part of modern DSPN pharmacotherapy.  Since 
there are no FDA- , this section will 
focus entirely upon drugs prescribed for pain management.     
3.4.1.  Non-Steroidal Antiinfammatory Drugs 
Non-steroidal antiinfammatory drugs (NSAIDs) inhibit select cyclooxygenases, thereby 
slowing the production of pro-inflammatory prostaglandins and reducing inflammatory-
related pain.424-425  In this regard, several COX inhibitors are frequently used to manage 
pain, including:  aspirin (COX-1 inhibitor); ibuprofen (non-selective COX-1 and COX-2 
inhibitor); and acetaminophen (COX-2 inhibitor). 
3.4.2.  Opioids 
Opioid analgesics alter the perception of pain.  Activation of various opioid receptors in 
the descending inhibitory neurons of the periaqueductal gray (PAG) antagonizes nociceptive 
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transmissions relayed from the DRG to the dorsal horn lamina of the spinal cord.300  This 
blunts the perception of pain.  Several opioids (e.g. morphine, oxycodone, tapentadol, and 
tramadol) can effectively mitigate pain in DSPN.271  However, these drugs are typically 
plagued by numerous side effects, including gastrointestinal irregularities, nausea, vertigo, 
and drug tolerance and dependence.424-425  Hence, this type of therapy is usually a last resort. 
3.4.3.  Anticonvulsants 
Anticonvulsants are sometimes used for pain management since they can reduce 
neuronal hyperactivity.  In hyperalgesic DSPN cases, nociceptive signaling may include 
excessive glutamatergic signaling from nociceptive DRG.  Anticonvulsants essentially blunt 
this signaling.  Commonly prescribed anticonvulsants for pain management include 
gabapentin (Neurontin) and pregabalin (Lyrica).447  These anticonvulsants block presynaptic 
VDCCs, thus preventing Ca2+ ion influx required for neurotransmitter secretion.300, 424-425, 447  
Other commonly prescribed anticonvulsants include the voltage-gated sodium channel 
blockers (e.g. oxcarbazepine, lamotrigine, lacosamide, valproate, and topiramate ).300, 424-425, 
447  These drugs temporarily prevent neuronal depolarization and the generation of action 
potentials, thus inhibiting the relay of nociceptive information.300, 424-425   
3.4.4.  Antidepressants 
 As mentioned, pain is a complex interpretation of sensory outputs combined with 
emotional experiences.300-301, 303, 308  Nociceptive signaling feeds into the limbic system via 
the paleospinothalamic tract.300  These limbic 
components of pain.300  These drugs are thought to provide analgesic effects by improving 
descending inhibitory neurons of the PAG.300, 424-425   
                                                 
 Also activates postsynaptic ionotropic GABAA receptors, which enables Cl- influx into the neurons, resulting 
in hyperpolarization and inhibition 
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Selective serotonin reuptake inhibitors (SSRIs) prevent the presynaptic reuptake of 
serotonin, which increases its synaptic cleft dwell time and promotes postsynaptic 
signaling.300, 424-425  Similarly, serotonin-norepinephrine reuptake inhibitors (SNRIs) prevent 
the reuptake of serotonin and norepinephrine.300, 424-425  In this manner, SSRIs and SNRIs 
perception of pain.300, 424-425, 448  The PAG receives stimulatory serotoninergic and 
noradrenergic input from the raphe nuclei and the locus coeruleus, respectively.  Again, this 
blunts nociceptive signaling.  While SNRIs (e.g. duloxetine and venlafaxine) can reduce 
pain scores by as much as half, SSRIs (e.g. fluoxetine, paroxetine, and citalopram) are 
usually slightly less effective.448  Of these antidepressents, duloxetine is the only drug that is 
specifically FDA-approved for treating pain management in DSPN.271, 448 
3.4.5.  Topical Analgesics 
The topical analgesics lidocaine and capsaicin are also used for pain management in 
DSPN.  Lidocaine is a voltage-gated sodium channel blocker.271, 448  Capsaicin (extracted 
from chili peppers) depletes substance P, another neurotransmitter in nociceptive DRG.271, 
448  Both lidocaine and capsaicin patches are FDA-approved for neuropathic pain.271, 448 
 In conclusion, medicinal treatment options for DSPN are problematic in that they mainly 
target single, pathogenic mechanisms associated with hyperglycemia or simply help manage 
pain.  There are no FDA- 26, 
296  Compounds that improve sensorimotor and NCV deficits in STZ-diabetic animals 
usually fail to exhibit clinical efficacy.296, 299  Hence, morphological assessments may be 
more adept to predicting clinical efficacy since they can alleviate interspecies mechanistic 
differences.296  For these reasons, DSPN could benefit from a more multifaceted therapeutic 
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approach that impacts psychophysical, electrophysiological, and morphological indices.  
Targeting heat shock proteins improves all three.  
SECTION 4.  TARGETING HEAT SHOCK PROTEINS (HSPS) 
4.1.  Prelude 
Several heat shock proteins (Hsps) serve as molecular chaperones that assist in the 
folding of nascent polyp 269, 449-
452  These chaperones also assist in the refolding of damaged proteins that arise under 
various cellular stressors, such as heat shock, nutrient deprivation, oxidative and nitrosative 
stress, and other various insults to the cell.449-452  These Hsps also serve as intracellular 
triage units that tag irreparable proteins for proteolytic degradation, stabilize protein 
complexes, solubilize protein aggregates, and facilitate intracellular trafficking.449-453   
The neuroprotective qualities of Hsps have led to new treatment paradigms for several 
neurodegenerative disorders.269  Pharmacologic Hsp induction can help mitigate proteotoxic 
(HD); amyotrophic lateral sclerosis (ALS); multiple sclerosis (MS); and spinal & bulbar 
muscular atrophy (SBMA).452  Although it is unlikely that the pathogenesis of DSPN is 
attributed to the accumulation of any one particular misfolded protein, diabetes-induced 
hyperglycemia does cause significant increases in ROS and RNS in diabetic nerves.46, 359, 454-
455  These reactive species can denature proteins and disrupt protein folding, refolding, and 
transport initiatives.44-46, 271, 359-363, 454-458  In support of this, recent studies have shown the 
myelin structural protein PMP22 (peripheral myelin protein 22) is extensively carbonylated 
and aggregated in the sciatic nerves of Type 2 diabetic mice, suggesting a direct oxidative 
link to demyelination and NCV deficits in DSPN.364  Intriguingly, in SC-DRG co-cultures 
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developed from PMP22 over-expressing mice, pharmacologic Hsp induction can improve 
PMP22 solubility and turnover in SCs.459  Hence, targeting Hsp expression may be a viable 
option in alleviating potential proteotoxic threats in DSPN. 
To better understand the therapeutic potential of augmented Hsp support in DSPN, the 
physiological roles of Hsps are reviewed herein with a special emphasis on pharmacologic 
induction of the heat shock response (HSR).  This chapter will conclude with a brief review 
rts the proof-of-principle that 
C-terminal heat shock protein 90 (Hsp90) modulators can be an effective therapeutic 
approach for DSPN.28  Objectives and hypotheses for the current work will also be covered. 
4.2.  Heat Shock Protein 90 
 Heat shock protein 90 (Hsp90) is a 90-kDa, homodimeric cytosolic protein that interacts 
with over 200 client proteins and roughly 50 co-chaperones.269, 449-451, 460-461  While the 
mechanistic details surrounding client protein folding remain unsolved, the folding 
machinery involved in this process has been established.    
4.2.1.  Hsp90 and Protein Folding 
Protein folding initiates with the co-chaperones Hsp70 and Hsp40, which recognize and 
bind select polypeptide substrates.269, 461  These are recruited into a larger, more stabilized 
heteroprotein complex with Hsp90 and HOP (Hsp70/Hsp90-organizing protein).461  This 
stabilized complex enables client protein transfer to the Hsp90 homodimer, thus permitting 
Hsp70, Hsp40, and (in some cases) HOP dissociation.461  Additional co-chaperones and 
immunophilins aid ATP binding within the N-terminal nucleotide-binding domain of Hsp90, 
which promotes N- 461  
Recruitment of the co-chaperone p23 further stabilizes the clamped protein complex and 
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461  AHA1 
(ATPase homologue 1) then initiates ATP hydrolysis to provide the energy needed for 
conformational changes (i.e. folding) and release.461   
N-terminal Hsp90 inhibitors block ATP-mediated dimerization and clamping of the 
client protein, thereby destabilizing the complex and resulting in premature release of the 
client protein.269, 462  Failure to produce mature client proteins is progressively cytotoxic as 
protein turnover surpasses production rates.461-462   
4.2.2.  Hsp90 and the Heat Shock Response 
Under normal conditions, Hsp90 binds to heat shock factor 1 (HSF1), and this complex 
prevents the induction of the pro-survival heat shock response (HSR) (Figure 15).269, 463-464  
Upon stress or heat shock, Hsp90 releases HSF1 and induces the HSR following its 
hyperphosphorylation, trimerization, and translocation into the nucleus.463-464  The HSR is 
characterized, in part, by the increased expression of Hsp90, Hsp70, Hsp40, Hsp27, and 
other genes.463-464  Small molecule Hsp90 inhibitors mimic cellular stress by disrupting the 
Hsp90:HSF1 complex.465    
 
Figure 15.  Hsp90 and HSR regulation.  (Adapted from Donnelly and Blagg)466  
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Table 2.  Hallmarks of cancer.  (As defined by Hanahan and Weinberg)467 
  
Hallmark Hsp90 Client Proteins 
Self-sufficient growth signals Raf-1, Akt, ErbB2, MEK, Bcr-Abl 
Insensitive to anti-growth signals Plk, Wee1, Myt1, CDK4, CDK6 
Evasion of apoptosis RIP, Akt, mutant p53, c-Met, Apaf-1, Survivin 
Limitless replicative potential Telomerase (h-Tert) 
Sustained angiogenesis FAK, Akt, Hif- -R, Flt-3 
Tissue invasion and metastasis c-Met, v-src 
 
4.3.  Targeting Hsp90 
4.3.1.  N-Terminal Hsp90 Inhibitors 
Therapeutically, the development of N-terminal Hsp90 inhibitors may provide effective 
chemotherapeutic strategies given that numerous Hsp90 client proteins are also oncoproteins 
(e.g. mutant p53, v-Src, Bcr-Abl, Akt, and ErbB2).269, 449-450, 468  As such, inhibiting Hsp90 
has become an attractive target for cancer therapy since it simultaneously targets multiple 
molecular components within all six hallmarks of cancer (Table 2).449, 467, 469  However, the 
chemotherapeutic potential for these inhibitors is often confounded by a narrow therapeutic 
window (Figure 16).450  N-terminal Hsp90 inhibitors, such as the benzoquinone ansamycin 
antibiotic geldanamycin (GDA) and the structural analog 17-(allylamino)-17-demethoxy 
geldanamycin (17-AAG), fail to effectively dissociate client protein degradation from HSR 
induction (Figure 16).450  Since HSR induction enhances pro-survival Hsp70 and Hsp90 
expression, these Hsps antagonize the desired endpoint of cytotoxicity in cancer cells by 
increasing oncoprotein folding.449-452, 469  These compounds have also exhibited hepatotoxic 
side effects in preclinical (GDA) and clinical (17-AAG) trials.450, 460  Other N-terminal 
inhibitors, such as celastrol, gedunin, and H2-gamendazole (Figure 16), also induce client 




Figure 16.  Differential Hsp90 inhibitors and HSR inducers.  Structures of N-terminal 
Hsp90 inhibitors [GDA (green), 17-AAG, Celastrol, Gedunin, and H2-Gamendazole];  
C-terminal Hsp90 inhibitors [KU-32 (inset; blue), KU-174 (red), and Novobiocin]; and  
chemical HSR inducer HSF1A.  Upper left graph depicts the differential effects of GDA 
(green), KU-174 (red), and KU-32 (blue) upon client protein expression (hashed) and HSR 
induction (solid) as a function of inhibitor concentration; blue shading represents the 
neuroprotective therapeutic window associated with KU-32.  KU-174 represents compounds 





(cell division cycle 37 homolog, S. cerevisiae).471  However, these inhibitors are also 
plagued by narrow therapeutic windows.471 
In contrast to selecting for cytotoxicity, it is thought that HSR induction can promote the 
disaggregation of misfolded proteins linked to several neurodegenerative disorders.269  In 
this regard, N-
prevent mutant huntingtin (mHtt) aggregation in HD, and improve motor function in 
SBMA.472-476  However, as with cancer therapies, selecting for neuroprotection ultimately 
requires a therapeutic window that minimizes the risk of cytotoxicity.  This can be 
accomplished with C-terminal Hsp90 inhibition. 
4.3.2.  C-Terminal Hsp90 Inhibitors 
The C-terminus of Hsp90 contains an additional nucleotide-binding domain that also 
binds the natural product novobiocin (Figure 16), an ATP-binding site inhibitor of DNA 
gyrase.269, 477  Although novobiocin is a poor inducer of client protein degradation and the 
HSR, higher affinity and more potent C-terminal Hsp90 inhibitors have been developed 
using its coumarin scaffold.477-478  Through structure-activity relationship studies, HSR 
induction and associated cytoprotection have been divested from client protein degradation 
and associated cytotoxicity, expanding the dose range for neuroprotection.  A representative 
example is KU-32 (Figure 16), or N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyl-tetrahydro-2H-pyran-2-yloxy)-2-oxo-2-methyl-chromen-3-yl)acetamide, which 
pr -induced death in cortical neurons, glucose-induced cell death in DRG, 
and agonist-induced demyelination of SC-DRG co-cultures.470, 479-480  Moreover, we have 
shown that KU-32 can effectively reverse NCV deficits and sensory hypoalgesia in STZ-
diabetes without any overt cytotoxicity (discussed in-depth in Preliminary Work).28, 470   
 
 85 
4.4.  Targeting the Heat Shock Response 
It should be noted that chemical induction of the HSR can also be achieved without 
pharmacologic Hsp90 inhibition.269  For example, HSF1A (Figure 16) induces the HSR 
presumably through interactions with the chaperonin TRiC [TCP1 (tailless complex 
polypeptide 1)-ring complex] independent of Hsp90 binding.481  In neuroprogenitor cells, 
riluzole (used to treat ALS) can reduce HSF1 turnover while boosting the expression and 
activation of HSF1 and glutamate transporters.482  The latter enhances presynaptic glutamate 
recovery, reducing the likelihood of excitotoxicity (implicated in painful DSPN, ALS, AD, 
PD, and HD).482  However, the mechanisms by which HSF1A and riluzole specifically 
induce the HSR remain under investigation.482  Finally, the flavonoid antioxidant quercetin 
can disrupt the DNA:HSF1 binding interface, thus preventing the transcription of Hsp 
mRNA (especially Hsp70).483 
4.5.  Heat Shock Factor 1 Roles in the Absence of Heat Shock 
HSF1 regulates several genes in the absence of heat shock.  For instance, siRNA-
mediated HSF1 down-regulation in cervical carcinoma cells modulates the expression of 
378 genes linked to cell cycle regulation and proliferation.269, 484  This suggests that HSF1 
maintains the expression of several proteins required for survival under stressful conditions 
(i.e. cancerous) in the privation of heat shock.464, 484  Under non-cancerous conditions, HSF1 
works with NFATC2 (nuclear factor of activated T-cells- -crystallin (small 
Hsp) expression and the scaffolding protein PDZK3 (PSD-95/Dlg-A/ZO-1 (PDZ) domain-
containing-3).485  -crystallin to disaggregate mHtt in over-expressing R6/2 
HD mice.485  In the insulin-like signaling pathway of C. elegans, the FoxO (forkhead box 
-16 (abnormal dauer formation-16) works with 
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HSF1 to regulate genes that promote life expectancy.463  Hence, HSF1 activation promotes 
cell survival under both normal and stressful conditions.       
4.6.  Targeting Hsp70, Hsp40, and Hsp27  
 Independent of Hsp90, Hsp70 and Hsp40 form heteroprotein complexes that offer 
additional neuroprotective attributes.269  J-domain-containing proteins (J proteins), such as 
activities of inducible Hsp70 (Hsp72) and the constitutively expressed Hsp70 isoform Hsc70 
(heat shock cognate 70).486  Although binding affinities differ between these isoforms, a 
degree of interchangeability exists with various J proteins.486  These specialized neuronal J 
protein:Hsp70 interactions can help facilitate synaptic vesicle protein repair, vesicle cycling 
(via calcium channel regulation and clathrin exchange), GEF activities with G-protein 
coupled receptors, toxic protein aggregate solubilization, and protein ubiquitination.486   
 Hsp70 and Hsc70 interact with BAG-1 (Bcl-2-associated athanogene) and CHIP (C-
terminus of Hsc70/Hsp70-interacting protein) to flag irreparable proteins with ubiquitin for 
proteolytic degradation.269, 458  Alternatively, BAG-2 enables Hsp70-mediated (ubiquitin-
independent) delivery of irreparable proteins directly to 20S proteasomes for degradation.487  
Upon Hsp70/BAG-2 saturation, clearance duties are reinforced by the Hsp70/BAG-1/CHIP 
complex.487  Such triage management has been implicated in tau clearance (AD), where 
effective Hsp70 chaperoning becomes exhausted.487  These data suggest that targeting select 
Hsp70 isoforms via chemical modulators could feasibly enhance desired neuronal J protein 
interactions and discourage unfavorable associations (e.g. tau triage), thus improving 
neuronal function.483, 488  Although selective Hsp70 inhibition provides promise as 
neuroprotective and chemotherapeutics, characterization of isoform-selective scaffolds that 
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modulate Hsp70 (e.g. dihydropyrimidines, polyamines, and ATP mimics) are still 
underway.483, 488     
4.7.  Preliminary Work  
We have demonstrated that Hsp70 induction with the KU-32 can effectively reverse 
several clinical indices associated with both small and large fiber dysfunction in DSPN.28, 470  
After 12 weeks of STZ-diabetes in C57BL/6 mice, weekly intraperitoneal (IP) injections of 
20 mg/kg KU-32 (~ 40 mM Captisol/saline vehicle) for 6 weeks progressively improved 
mechanical and thermal hypoalgesia and MNCVs and SNCVs back to control levels.28, 470  
These improvements occurred without affecting systemic insulin, FPG, or HbA1C levels, 
suggesting that KU- 28, 470   
To explore KU- -
inducible Hsps could negate KU-
progression of DSPN.28, 470  Since Hsp90 genetic deletion is lethal, we focused our attention 
on alternative knockout (KO) models.28, 470  We had shown (by immunoblotting) that KU-32 
dose-dependently increases Hsp70 expression in MCF7 (human breast adenocarcinoma) 
cells and sciatic nerves of KU-32-treated C57BL/6 mice.28, 470  This data, combined with 
Hsp90, led us to perform a 
nearly identical 12-week intervention study in Hsp70 double KO mice, in which both 
inducible Hsp70 genes in mice (Hsp70.1 and Hsp70.3) were removed.28, 470  While the 
pathological timeline of STZ-diabetes in Hsp70 KO mice was nearly identical to wild-type 
C57BL/6 mice, KU-32 was ineffective.28, 470  Hence, while inducible Hsp70 is required for 
KU- 28, 470  
However, this does not rule out compensatory support from other Hsp70 isoforms.  
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Overall, our preliminary studies provided proof-of-principal that C-terminal Hsp90 
modulators could improve psychophysical and electrophysiological aspects of DSPN in 
experimental T1DM animal models without affecting systemic metabolic control.  We 
concluded that hyperglycemia may adversely impact the folding and refolding capabilities of 
newly synthesized or mildly damaged proteins in diabetic peripheral nerves.   
4.8.  Objectives and Hypotheses 
4.8.1  Part 1 (Chapter II) 
Although the efficacy of KU-32 requires the expression of inducible Hsp70, little insight 
was gained in these early studies to determine how KU-32 specifically improves 
psychophysical and electrophysiological aspects of DSPN.  With that said, it should be 
reemphasized that compounds that improve sensory and NCV deficits in rodents historically 
fail to exhibit clinical efficacy.296, 299  Thus, morphological assessments, such as iENF 
density analyses, may likely alleviate interspecies mechanistic differences to expedite drug 
development.296  To better observe morphological alterations, an animal model capable of 
surviving more chronic stages of DSPN was needed.  Hence, we elected to use a more hardy 
strain of mice, the genetically out-bred Swiss-Webster (SW) mice, which enables better 
morphological comparisons that may be more comparable to human DSPN.  Also, given 
its 
implications in DSPN development, we assessed mitochondrial bioenergetic profiles to 
determine KU-32 affects upon metabolic resiliency.359-360   
4.8.1.1.  Objective 1 
The main objective of this research is to determine whether KU-32 can improve clinical 
indices of chronic DSPN and its effects on iENF density and mitochondrial bioenergetics.   
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4.8.1.2.  Hypothesis 1  
We hypothesize that KU-32 intervention will improve morphological, psychophysical, 
electrophysiological, and bioenergetic indices of DSPN at more chronic stages. 
4.8.2.  Part 2 (Chapter III) 
In our preliminary work, pharmacokinetic (PK) analyses demonstrated that a single 
intraperitoneal injection of KU-32 at a dose of 2 mg/kg (5% Captisol/saline vehicle) resulted 
in rapid drug absorption and distribution to the brain within 5 minutes.470  KU-32 was 
eliminated from the blood and the brain within ~ 8 hours.470  While these PK studies yielded 
promising results, they did not assess KU- -relevant tissues, such as the 
DRG, foot pads, and sciatic, tibial, and sural nerves.  Moreover, oral PK profiles have not 
been assessed.  Demonst
quality of life and expedite drug progression.  It would also help establish comparable dose 
ranges needed to initiate oral gavage (OG) intervention studies.  Therefore, PK profiles for 
IP and OG KU-32 treatments were assessed. 
4.8.2.1.  Objective 2 
The second objective of this research is to characterize the KU-
profiles in DSPN-relevant tissues after IP or OG administration.    
4.8.2.2.  Hypothesis 2 
We hypothesize that both intraperitoneal and oral KU-32 administration will result in 
successful drug delivery to DSPN-relevant tissues in a route-dependent manner.      
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CHAPTER II:  KU-32 IMPROVES CHRONIC EXPERIMENTAL DIABETIC NEUROPATHY 
 
SECTION 1.  MATERIALS AND METHODS 
1.1.  Animals 
 Male, six-week old, outbred Swiss-Webster (SW) mice were purchased from Harlan 
Laboratories (Indianapolis, IN) and acclimated for two weeks prior to starting the study.  All 
animals were maintained on a 12 hour light/dark cycle at 70°F and 70% humidity with ad 
libitum access to water and Purina diet 5001 chow.  All animal procedures (e.g. tagging, 
handling, fasting, blood draw, drug administration, euthanasia, and colony management) 
were performed according to Institutional Animal Care and Use Committee (IACUC) 
regulations and protocols as well as the standards and regulations for care and use of 
laboratory rodents established by the National Institutes of Health (NIH).   
1.2.  Induction of Diabetes 
 Streptozoticin [STZ, or 2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose; Sigma 
Aldrich, St. Louis, MO] was used to chemically induce experimental T1DM in select SW 
mice (Figure 17).  STZ is a nitrosourea alkyating agent whose glucose-moiety permits 
GLUT-2-mediated transport into rodent pancre 1-2  Upon entry, STZ methylates 
1-2  This 
destroys the majority of insulin- 1-3 
 Prior to inducing diabetes, all mice were designated into weight-matched, diabetic and 
non-diabetic treatment groups.  After a six hour fast, mice identified for diabetes were 
administered a single intraperitoneal injection of 100 mg/kg STZ in 200 µl sterile saline 
in solution, pre-weighed STZ was mixed with the saline vehicle immediately prior to each 
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injection.3  Fasted, non-diabetic mice received only the 200 µl saline vehicle.  All injection 
sites were cleaned with 70% ethanol prior to injection.  Food was reintroduced just after 
injection.  This entire process was repeated the next day.  Altogether, diabetes-designated 
mice received a total of 200 mg/kg STZ and all mice received a total of 400 µl saline 
vehicle.  Fasting blood glucose (FBG) levels were measured (as described below) one week 
after the final STZ injection.  Mice with FBG levels above 290 mg/dl were deemed diabetic 
and were admitted into the study.  FBG measurements were conducted at study completion 
e.  HbA1C levels (as described below) were also 




hydrolysis generates the DNA alkylating agent methanediazonium and the RNS nitric oxide.  




   
 In compliance with veterinary oversight and IACUC approval, a body condition score 
(BCS) was used to assess overall health deterioration in diabetic mice.4  BCS1 denotes 
advanced muscular atrophy and extreme loss of subcutaneous fat deposits, which causes 
prominent indentions between the vertebrae and sharp protuberances of spinal processes 
(ileum and sacrum).4  Throughout this study, a conscious effort was made to avoid BCS1.  A 
BCS1+ status was characterized by less severe fat loss and milder bony protuberances.4  
BCS1+ diabetic mice that exhibited a hunched posture, sunken or closed eyes, lethargy, and 
seemed unlikely to improve, were generally euthanized after veterinary consult. 
1.3.  Fasting Blood Glucose and Glycated Hemoglobin Measurements 
 Venous blood was drawn from the tip of the tail for all FBG and HbA1C measurements.  
FBG levels were determined using a commercial One-Touch Ultra glucometer (Lifescan, 
Milpitas, CA) following a 16-hour, overnight fast.  Percent HbA1C levels were measured 
using the A1C Now+ multi test A1C kit (Bayer Healthcare, Sunnyvale, CA).  HbA1C levels 
at or above 6.5% were considered diabetic (comparable to humans).5-7   
1.4.  Drug Formulation and Treatments 
 STZ-diabetic mice were designated into untreated (STZ + Veh) and KU-32-treated 
(STZ + KU-32) groups after 16 weeks of STZ-diabetes.  Non-diabetic mice were likewise 
divided into untreated (Veh + Veh) and KU-32-treated (Veh + KU-32) groups.  In both 
cases, mice were weight-matched and BCS-matched so as to alleviate treatment bias.   
 KU-32 [N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-
pyran-2-yloxy)-2-oxo-2-methyl-chromen-3-yl)acetamide] was synthesized and its structural 
purity was verified (> 95%) according to published procedures.8-10  To overcome solubility 
constraints, KU-32 was dissolved in 0.1 M Captisol (CyDex Pharmaceuticals, Lenexa, KS) 
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in sterile 1X phosphate buffered saline (PBS) (137 mM NaCl; 2.7 mM KCl; 100 mM 
Na2HPO4; 2 mM KH2PO4; pH 7.4).  0.1 M Captisol and 5 mg/ml KU-32 (0.1 M Captisol) 
stock solutions were prepared fresh and sterile-filtered the morning prior to injections. 
 After 16 weeks, all mice received weekly intraperitoneal injections of 20 mg/kg KU-32 
or a corresponding vehicle equivalent for 10 weeks.  Treatments were based on the mass of 
the specimen (kg) the day prior to injection.  Aliquots of 5 mg/ml KU-32 (0.1 M Captisol) 
stock needed for each 20 mg/kg dose were dispensed into sterile 1.7-ml microcentrifuge 
tubes.  200 µl of sterile 1X PBS was then added to help facilitate injections, giving a final 
working concentration of 20 mg/kg KU-32 in ~ 350 µl of ~ 43 mM Captisol.  Each injection 
was performed using a sterile 1-ml syringe fitted with a 27-gauge, 3/4-inch long hypodermic 
needle (BD, Franklin Lakes, NJ) at injection sites precleaned with 70% ethanol.  Control 
diabetic and non-diabetic mice were administered mass-dependent equivalents of 0.1 M 
Captisol with 200 µl of sterile 1X PBS, or ~ 350 µl of ~ 43 mM Captisol.   
1.5.  Assessment of Thermal Hypoalgesia 
 A Hargreaves Analgesiometer (Ugo Basile, Comerio, Italy) was used to assess responses 
to noxious thermal stimuli.11-13  Mice were placed under a 1 L glass beaker on a glass 
platform and allowed to acclimate for 30-40 minutes.  A focused beam of intensifying, 
radiating heat (0.3°C/s) was applied to the plantar surface of alternating hindpaws to 
determine paw withdrawal latencies (seconds).  Individual paw readings were collected 
every five minutes to avoid hyperalgesia.  Paw withdrawal latencies were measured 3-4 
times per animal and then averaged.  Hargreaves testing was conducted once during weeks 
5, 9, and 13, and then weekly from weeks 15 to 26.  The analgesiometer was calibrated prior 
at the start of each session using a heat flux radiometer (Ugo Basile).  As discussed, the 
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Hargreaves test measures behavioral responses to slow, dull burning sensations as detected 
by polymodal nociceptors located on unmyelinated C-fibers.13-15 
1.6.  Assessment of Mechanical Hypoalgesia 
 A Dynamic Plantar Aesthesiometer (Ugo Basile) was used to monitor responses to 
noxious mechanical stimuli.11-12, 16-17  Mice were acclimated for 30-40 minutes within a 
covered plastic cubicle, which rested upon a wire mesh platform.  The upward application of 
a stiff von Frey monofilament (0.5 mm diameter steel fiber fitted to a force actuator) to the 
plantar surface of alternating hindpaws was used to assess pricking pain thresholds.  As 
mentioned, pricking sensations are transduced by mechanical nociceptors found on thinly 
-fibers.14, 18  Preliminary experiments found that applying the monofilament 
with an upward force of 10 g and a ramp speed of 2 seconds was necessary to provide a 
sufficient dynamic range to detect mechanical hypoalgesia in diabetic SW mice.  Using 
these settings, a series of 5 recordings were collected roughly every 5 minutes per foot, 
measuring the force (grams) needed to trigger paw withdrawal and the latency associated 
with each response; these recordings were averaged for each animal.  Von Frey testing was 
conducted once during weeks 4, 8, and 12, and then weekly from weeks 15 to 26.  The 
anesthesiometer was calibrated using a 50 g steel weight prior to each testing session. 
1.7.  Nerve Conduction Velocity Measurements 
 NCV measurements were performed according to published procedures.11-12  These 
measurements were conducted at weeks 16 (benchmark) and 26 (study completion).  All 
mice were anesthetized via intraperitoneal injection of 100 mg/kg ketamine with 10 mg/kg 
xylazine.  Mice were only operated upon after general anesthesia was confirmed using toe 
pinch and eye blink reflex methods.  Electromyography for motor and sensory NCV 
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-EMG Monitoring System 
(Carefusion, San Diego, CA) with 12 mm subdermal disposable platinum/iridium bipolar 
needle electrodes (Cardinal Health Neurocare, Madison, WI).  Throughout this procedure, 
body temperature was monitored using a rectal probe and Physitemp TCAT-2DF Controller 
(Physitemp Instruments, Clifton, NJ) and was maintained at 37°C using a heat lamp.   
1.7.1.  Motor Nerve Conduction Velocity 
 To determine MNCV, electromyograms (EMGs) for proximal and distal compound 
muscle action potentials (CMAPs) were collected.11-12  A stimulatory electrode was inserted 
through either the sciatic notch (proximal) or just above the calcaneous between the Achilles 
tendon and the tibia/fibula (distal).  A recording electrode was embedded in the first plantar 
interosseous muscle.  Three additional electrodes were implanted in nearby skin and muscle 
tissues to improve the signal:noise ratio.  Electrical stimuli consisted of a 9.9 mA 0.05 ms 
duration square wave pulse.  Resulting waveforms were filtered with low (3 kHz) and high 
(10 kHz) settings.  Latencies were defined as the time between stimulus artifact and the 
onset of negative M-wave deflection.  Each distal EMG was followed by a proximal EMG.  
MNCV (m/s) was calculated by dividing the physical straight line distance between 
proximal and distal stimulatory electrodes by the time difference between proximal and 
distal latencies.  Three MNCV measurements were collected for each mouse and averaged. 
1.7.2.  Sensory Nerve Conduction Velocity  
 To determine SNCV, a series of 10 EMGs for sensory nerve action potentials (SNAPs) 
were collected and averaged to generate a single waveform.11-12  A stimulatory electrode 
was inserted into the tip of the second hind toe.  The recording electrode was emplaced just 
above the calcaneous between the Achilles tendon and the tibia/fibula.  Electrical stimuli 
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consisted of ten 2.4-3.0 mA 0.05 ms duration square wave pulses.  The resulting average 
waveform was filtered with low (3 kHz) and high (10 kHz) settings.  Latency was defined as 
the time difference between stimulus artifact to the onset of peak negative deflection.  
SNCV (m/s) was determined by dividing the physical straight line distance between 
stimulating and recording electrodes by the latency.  Since this was derived from an average 
of 10 SNAP EMGs, SNCV was calculated only once per animal. 
1.8.  Euthanasia and Tissue Harvesting 
 All mice were euthanized according to NIH guidelines and IACUC regulations and 
approved protocols.  Upon completing NCV measurements, animals were euthanized by 
cardiac excision and then decapitation.  Mice identified for euthanasia based upon BCS and 
veterinary consult were terminated using CO2 asphyxiation and then decapitation.  In all 
cases, select tissues and organs were harvested immediately thereafter.   
 Sciatic, tibial, and sural nerves were dissected and pooled from both hind limbs and cut 
into smaller segments in 200 µl mRIPA (modified radioimmunoprecipitation assay) buffer 
(50 mM Tris-HCl, pH 7.5; 1 mM EDTA; 1% Nonidet P-40; 0.5% deoxycholate; 0.1% SDS; 
150 mM Na3VO4; 0.5 mM Na2MoO4 -glycerophosphate) 
containing 1X complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) on 
ice.  Tissues were homogenized using a Polytron fitted with a micro tissue tearor and 
centrifuged at 10,000 x g at 4°C for 10 minutes.  The supernatant was collected, flash frozen 
on dry ice, and stored at  20°C.  With the exception of 3 representative mice from each 
treatment group at week 26, L4-L6 DRG were dissected from the lumbar intervertebral 
foramena for each mouse using a dissecting microscope (roots removed during extraction).  
DRG were processed in the same manner described for the nerves.  The remaining 12 mice 
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at week 26 were used to establish adult DRG cultures to assess mitochondrial bioenergetics 
(described in Establishment of Adult Sensory Neuron Cultures).     
 Blood serum was collected for future processing after cardiac excision.  Whole blood 
was vortexed with 50 µl of 0.3 M EDTA (ethylenediaminetetraacetic acid) containing 1X 
artificial anticoagulant.  Whole blood was centrifuged at 1,500 x g at 4°C for 15 minutes and 
the sera (supernatant) was collected, flash frozen on dry ice, and stored at  80°C.  Brain, 
liver, muscle, adipose, and kidney samples were also collected, flash frozen on dry ice, and 
stored at  80°C for future processing. 
 
Middleton, WI) overnight at 4°C.  All foot pads were washed 3 times with cold (4°C) PBS 
buffer with 3 mM NaN3 (pH 7.4) and dehydrated in 30% sucrose (cryoprotectant) overnight 
at 4°C.  These tissues were then embedded in Tissue-Tek optimal cutting temperature 
compound (OCT) (Sakura USA, Torrence, CA) on dry ice and stored at  80°C for 
cryosectioning.  Frozen foot 
Cryostat (Leica Biosystems, Buffalo Grove, IL).  Samples were collected on Fisherbrand 
Superfrost Plus microscope slides (ThermoFisher Scientific, Waltham, MA) that were coded 
to obscure treatment and then stored at  80°C until iENF density analysis. 
1.9.  Intraepidermal Nerve Fiber Density Analysis 
 For iENF density analysis, immunohistochemistry (IHC) was performed using rabbit 
anti-PGP 9.5 (ubiquitin C-terminal hydrolase) antibody (AbD Serotec, Oxford, UK) and a 
Vectastain Elite ABC-Peroxidase kit for rabbit IgG (Vector Laboratories, Burlingame, CA).  
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Slides were blocked in normal goat serum (NGS)-containing blocking buffer for 30 minutes 
and then incubated in a 1:1,000 dilution of anti-PGP 9.5 antibody in NGS-blocking buffer 
for 3 hours at room temperature.  Slides were rinsed with PBS, incubated with secondary 
antibody for 1 hour at room temperature, and then rinsed again with cold PBS.  The slides 
were then incubated in an avidin-biotin complex solution (ABC solution) for 1 hour at room 
temperature, rinsed with PBS, and then incubated with NovaRED peroxidase substrate 
solution (Vector Laboratories, Burlingame, CA) for 2-3 minutes.  Slides were counterstained 
with hematoxylin (Vector Laboratories, Burlingame, CA) and coverslipped with Permount 
(ThermoFisher Scientific, Waltham, MA).  Twelve digital images per animal were captured 
using a Zeiss Axioplan-2 light microscope (Carl Zeiss Microimaging, Thornwood, NY) with 
a color CCD digital camera (Diagnostic Instruments Inc., Sterling Heights, MI).  Single 
immunopositive nerve fibers crossing the dermal/epidermal junction were quantified by 
blinded observers (branching within the epidermis was disregarded).19  iENF density was 
calculated by dividing the number of fibers by the length of the dermal/epidermal junction 
(fibers/mm).  Treatment effects upon dermal nerve fiber density were also assessed by 
tracing individual PGP 9.5-immunopositive nerve fibers and summing fiber area using 
ImageJ software (http://imagej.nih.gov/ij/).  This was divided by the total dermal area to 
generate a percentage of fiber-occupied space in the dermis.   
1.10.  Measuring Mitochondrial Bioenergetics in Adult Sensory Neurons 
1.10.1.  Establishment of Adult Sensory Neuron Cultures  
 Three representative mice from each treatment group were used to establish adult 
sensory neuron cultures at 26 weeks.  This was conducted according to published protocols 
with minor modifications.20  Lumbar spinal columns were removed and transported in 1X 
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PBS to a sterile hood , where the spinal cord was dislodged using a gentle stream of sterile 
1X PBS delivered through a 10 ml syringe.  L4-L6 DRG were excised using a dissecting 
medium (Corning cellgro/Mediatech, Manassas, VA) containing 10% fetal calf serum (Atlas 
Biologicals, Fort Collins, CO) on ice.  After trimming the nerve roots and connective tissue, 
pooled DRG were transferred to 1 ml of serum-free F10 medium.  DRG were then 
dissociated by adding 1 ml of 1.25% collagenase (Gibco/Invitrogen, Carlsbad, CA) for 45 
minutes (37°C) and then adding 1 ml of 2% trypsin (Gibco/Invitrogen) for 30 minutes 
(37°C).  Cells were isolated from the media by centrifugation at 1,000 x g at 4°C for 5 
minutes, and the cell pellet was resuspended in serum-free F10 medium and triturated using 
a fire-polished glass pipette.  The cell suspension was carefully layered on top of a 10 ml 
gradient of iso-osmotic Percoll [0.9 ml of 10X PBS; 6.485 ml ddH2O; 2.615 ml Percoll 
(Sigma-Aldrich, St. Louis, MO)] and centrifuged at 800 x g at 4°C for 20 minutes to remove 
cell debris and myelin fragments.  The pellet was resuspended in 5 ml of serum-free F10 
medium and filtered 
was rinsed with 5 ml of fresh medium.  Sensory neurons were recovered by centrifugation 
and were resuspended in F10 (6.1 mM glucose) maintenance medium containing 50 ng/ml 
NGF (Harlan Biosciences, Indianapolis, IN), 1 ng/ml NT-3 (Harlan), and N2 supplement 
(Invitrogen) without insulin.   These neurons were seeded on a specialized 96-well plate 
[XF96 Cell Culture Microplate (Seahorse Biosciences, North Billerica, MA)] that was pre-
coated with poly-DL-ornithine (0.5 mg/ml overnight) and then laminin (2 mg/ml for 3 
hours).  For each treatment group, pooled neurons were plated on 4-5 wells at 5 x 103 
cells/well containing maintenance medium and maintained for 48 hours ex vivo (Figure 18). 
                                                 





Figure 18.  Neurite outgrowth in intact adult sensory neuron cultures.  Phase contrast 
image shows axons extending from large (e.g. thick arrow) and small (e.g. thin arrow) DRG 
after 48 hours in culture.  Examples of non-neurons are indicated by white arrowheads.   
 
1.10.2.  Assessment of Mitochondrial Bioenergetics  
The 96-well Extracellular Flux (XF96) Analyzer (Seahorse Biosciences) uses two 
calibrated optic sensors to non-invasively assess oxygen consumption rates (OCRs) in viable 
cells that remain attached to the bottom of the microplate wells.21  After 48 hours in culture, 
adult sensory neurons were incubated in bicarbonate-free DMEM (5.5 mM D-glucose) for 1 
hour at 37°C.  Basal OCR readings (teal; Figure 19) were collected in the XF96 Analyzer 
using 4 measurement loops that each consisted of a 2 minute mix and 5 minute measurement 
cycle.  These measurement loops were repeated after injecting each respiratory chain 




assessments of the respiratory chain [maximal respiratory capacity, or MRC (red)] were also 
conducted by depolarizing the mitochondrial inner membrane potential with 1 µM FCCP 
[carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone] (Sigma); protonophore effects 
were expressed as percent basal OCR.  Working oligomycin and FCCP concentrations 
(indicated above) were optimized in earlier experiments.  Spare respiratory capacity, or SRC 
(magenta), is the arithmetic difference between the MRC and the basal OCR and depicts 
how close the mitochondria are to operating at their bioenergetic limit.  Non-mitochondrial 
(green) OCRs values were obtained from other wells.  After respiratory measures, cells 
were harvested and rate values for each well were normalized to relative protein content.  To 
determine protein content, each well was washed three times with cold (4°C) 1X PBS and 
cells were lysed in cold (4°C) mRIPA buffer with 1X complete protease inhibitor cocktail 
on ice.  Protein levels were determined (in triplicate) using lysate aliquots and the DC 
Protein Assay (Bio-Rad, Berkeley, CA).   
 
Figure 19.  Schematic Seahorse XF96 Analyzer graph interpretation.  Abbreviations:  
OCR (oxygen consumption rate); SRC (spare respiratory capacity); MRC (maximal 
respiratory capacity); and FCCP [carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone].  
See text for in-depth description.  (Adapted from Brand and Nicholls).21    
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1.11.  Immunoblot Analyses 
 Immunoblotting (IB) was performed on tissue homogenates.  Protein samples were 
thawed on ice and quantified via DC Protein Assay to determine the sample volume needed 
for 10 
-mercaptoethanol; 4% SDS 
(sodium dodecyl sulfate); 0.5% bromphenol blue; and 6.25% 4X Upper Tris buffer (0.5 M 
Tris HCl; 4% SDS; pH 6.8)].  Samples were boiled at 100°C for 5 minutes, separated by 
SDS-PAGE (polyacrylamide gel electrophoresis), transferred to a nicrocellulose membrane 
overnight, and stored in PBS-T (PBS buffer with Tween-20) at 4°C.  Membranes were 
blocked with three 20-minute washes of 5% milk in PBS-T via gentle rocking; 5% bovine 
serum albumin alternatively used to detect phosphorylated proteins.  Membranes were then 
incubated with primary antibodies (diluted in blocking buffer) overnight (16-17 hours) at 
actin (two hours at room temperature).  These membranes were 
washed in 5% blocking buffer three times for ten minutes each.  Upon completion, 
membranes were incubated with appropriate secondary antibodies for 1 hour at room 
t actin) or 3 hours at 4°C (all others).  All membranes were washed three 
times for 5 minutes with PBS-T and incubated with an HRP-conjugated chemiluminescence 
detection kit (ECL Plus Western Blotting Detection Reagents, Amersham Biosciences, 
Buckinghamshire, UK).  Autoradiography film was exposed to this chemiluminescent 
signal, developed, and the bands were quantified via densitometry using ImageJ software.  





Table 3.  List of antibodies used.   
   
 
1.12.  Statistical Analyses 
All data are presented as mean ± SEM.  After verifying equality of variances, differences 
between treatment groups were determined using one-way/two-way ANOVA.  Significant 
differences between group means were established using the Tukey HSD posthoc test.  
Statistical analyses were performed using Systat 12 (Systat Software, Chicago, IL) and 
portrayed using Graphpad Prism (Graphpad Software, Inc., La Jolla, CA). 
SECTION 2.  EXPERIMENTAL DESIGN  
 To test the hypothesis that KU-32 intervention will improve morphological, 
psychophysical, electrophysiological, and bioenergetic indices of DSPN at more chronic 
stages, a 16-week intervention study was designed using SW mice (Figure 20).  Although 
these mice were expected to be more resilient to the effects of chronic experimental T1DM 
as compared to C57BL/6 mice, some disease-associated mortality was still anticipated and 
considered in the study design.  Hence, STZ-diabetes was induced in 42 of 73 mice (~ 58%) 
at week 0, while 31 mice (~ 42%) were kept non-diabetic.  To alleviate sex and body weight 
bias upon drug efficacy, only male mice were used and all mice were weight-matched.  
After 4 weeks, periodic Hargreaves and Von Frey testing were conducted to monitor 
Antibody Use Manufacturer Catalog 
PGP 9.5 IHC AbD Serotec 7863-0504 
Hsp72 IB Stressgen ADI-SPA-812 
GAP-43 IB Neuromics RA22115 
pSer(41)GAP-43 IB Santa Cruz Biotechnology SC-17109-R 
pSer(473)Akt IB Cell Signaling Technology 4060S 
-actin IB Santa Cruz Biotechnology SC-47778 
Goat anti-Rabbit HRP IB Santa Cruz Biotechnology SC-2004 
Goat anti-Mouse HRP IB Santa Cruz Biotechnology SC-2005 
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progressive hypoalgesia.  At 16 weeks, representative STZ-diabetic (n = 4) and non-diabetic 
(n = 4) mice were euthanized to confirm NCV deterioration and for benchmark tissue 
collection.  FBG and HbA1C readings were taken to verify altered metabolic states.  Select 
control (n = 13) and STZ-diabetic (n = 14) mice were administered (IP) 20 mg/kg KU-32 or 
corresponding vehicle equivalents (all other mice) on a weekly basis for ten weeks.  Weekly 
Hargreaves and von Frey testing commenced one week prior to injections (week 15) and 
lasted until study completion at 26 weeks.  Injections were conducted each week after 
behavioral testing so as to minimize possible influences of injection site soreness on 
behavioral responses.  At 26 weeks, NCV, FBG, and HbA1C measurements were collected 
for all mice and tissues were harvested and stored as described.  Mitochondrial bioenergetic, 
iENF density, and molecular assessments were conducted shortly after study completion. 
Control saline vehicle injection (1X PBS) (n = 31)
Diabetic 200 mg/kg streptozotocin (STZ) (n = 42)





Tissue harvest and analysis
iENF density analysis
Mitochondrial bioenergetics
Study CompletionInitiate Hargreaves and von Frey testing
FBG and HbA1C
NCV validation of DSPN (n = 4 mice/group)
Initiate weekly KU-32 dosing, 20 mg/kg
Vehicle + Vehicle  (n = 13)
STZ + Vehicle     (n = 15)
Vehicle + KU-32    (n = 13)








SECTION 3.  RESULTS 
3.1.  KU-32 Does Not Alter Overall Glycemic Control 
 After 26 weeks of untreated STZ-diabetes, body weight was significantly decreased and 
both FBG and HbA1C were significantly elevated relative to untreated non-diabetic mice 
(Table 4).  As expected, KU-32 intervention at 16 weeks had no impact upon body weight, 
FBG, and HbA1C levels as compared to untreated diabetic and non-diabetic controls.  These 
results are similar to those in our previous 12-week intervention studies in C57BL/6 mice 
and indicate that variations in mouse strain and drug schedule are insufficient to improve 
overall glycemic control.12  It is interesting to note that during the drug intervention period, 
almost half (7 of 15) of untreated diabetic mice abruptly died (4) or required early 
euthanizing (3) due to a poor BCS.  In contrast, none of the KU-32-treated animals abruptly 
died and only 3 of 14 mice were euthanized early due to a poor BCS.  
Table 4.  Effects of STZ-diabetes and KU-32 on metabolic parameters.   
  
Treatment Body Weight (g) n FBG (mg/dl) HbA1C (%) n 
Veh + Veh 46.9 ± 5.0 11 101 ± 19 4.6 ± 0.6 6 
Veh + KU-32 44.3 ± 3.2 9 109 ± 29 4.6 ± 0.4 6 
STZ + Veh 36.0 ± 6.6* 8 533 ± 114* 11.8 ± 1.1* 6 
STZ + KU-32 37.7 ± 4.0* 11 571 ± 55* 11.9 ± 0.3* 6 
 *, p < 0.001 versus Veh + Veh  
 
3.2.  KU-32 Rescues Electrophysiological Deficits 
 After 16 weeks of diabetes, MNCV decreased 17% from 58.6 ± 1.0 to 48.9 ± 2.0 m/s    
(p < 0.001; n = 4), whereas SNCV reductions were more modest from 40 ± 0.1 to 36.2 ± 1.1 
m/s (p < 0.05; n = 4).  After 26 weeks of untreated diabetes, MNCV and SNCV remained 
significantly lower than untreated non-diabetic controls (Figure 21).  In untreated diabetics, 
MNCV decreased to 41.3 ± 4.1 m/s by 26 weeks (30% total reduction).  KU-32 intervention 
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at 16 weeks not only prevented further MNCV decline but also reversed the pre-existing 
deficit to within normal control levels.  Similarly, KU-32 rescued diabetic SNCV deficits at 
16 weeks (37.4 ± 0.8 m/s) to within normal control levels by 26 weeks.  These NCV results 
reflect those observed in previous 12-week intervention studies in C57BL/6 mice, with the 
exception that SNCV reductions in diabetic SW mice were only half that of diabetic 
C57BL/6 mice.12  This is most likely attributed to differences between mouse strains.  
 
 
Figure 21.  KU-32 rescues NCV deficits.  Ten weeks of KU-32 treatment significantly 
improved diabetes-induced MNCV (solid bars; left axis) and SNCV (striped bars; right 
axis).  *, p < 0.05 versus Veh + Veh; ^, p < 0.05 versus STZ + Veh. 
 
3.3.  KU-32 Improves Sensory Hypoalgesia 
 After 4 weeks of STZ-diabetes, mechanical and thermal pain thresholds were assessed 
on alternate weeks.  These measurements were collected once every 4 weeks until week 15, 
where both tests were performed each week until study completion at 26 weeks.   
3.3.1.  Improvements to Mechanical Hypoalgesia 
 While the mechanical (pricking) pain thresholds (force in grams) necessary to trigger 
paw withdrawal in untreated non-diabetic mice remained steady at ~ 5.5 g, untreated 
diabetic mice demonstrated a significant increase in stimuli intensity requirements by 4 
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weeks (Figure 22).  These thresholds progressively worsened until 18 weeks, where force 
requirements plateaued at ~ 9.5 g for the remainder of the study.  Relative to untreated 
diabetic mice, KU-32 induced a time-dependent recovery in diabetic mechanical sensitivity 
after only one week of treatment.  After six weeks, mechanical thresholds for KU-32-treated 
diabetic mice were indistinguishable from untreated non-diabetic mice.  KU-32 had no 
adverse effects in non-diabetic mice.   





































Figure 22.  KU-32 restores normal mechanical thresholds.  Responses to pricking stimuli 
(von Frey monofilament) applied at an increasing intensity (force in grams) were assessed.  
These mechanical pain thresholds gradually increased and maxed at ~ 18 weeks in untreated 
diabetic mice.  KU-32 intervention at 16 weeks restored these mechanical thresholds back to 
non-diabetic levels. *, p < 0.05 versus time-matched Veh + Veh; ^, p < 0.05 versus time-
matched STZ + Veh. 
 
3.3.2.  Improvements to Thermal Hypoalgesia 
 STZ-diabetes caused a significant increase in paw withdrawal latency to intensifying 
thermal stimuli (thermal pain thresholds) by 5 weeks (Figure 23).  While paw withdrawal 
latencies averaged 5.5 s for non-diabetic mice throughout this study, untreated diabetic mice 
plateaued at ~ 10 s between 14 and 24 weeks.  While KU-32 had no adverse effects in 
untreated non-diabetic mice, the drug induced a significant, time-dependent improvement in 
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diabetic paw withdrawal latencies throughout the study.  Thermal thresholds for KU-32-
treated diabetic mice became indistinguishable from non-diabetics only at 10 weeks of drug 
treatment.  Though KU-32 improved both thermal and mechanical thresholds, the rate of 
recovery differed substantially.  This suggests that KU-32 may affect myelinated and 
unmyelinated nociceptive nerve fibers differently.   





























Figure 23.  KU-32 reestablishes normal thermal thresholds.  Paw withdrawal latencies 
(seconds) to intensifying thermal stimuli were assessed.  These latencies gradually increased 
and plateaued between 14 and 24 weeks in untreated diabetic mice.  Over 10 weeks, KU-32 
restored thermal thresholds back to non-diabetic levels.   *, p < 0.05 versus time-matched 
Veh + Veh; ^, p < 0.05 versus time-matched STZ + Veh. 
 
3.4.  KU-32 Partly Improves Cutaneous Innervation  
3.4.1.  Improvements to iENF Density 
 Recovery of normal thermal thresholds can occur without any improvements to iENF 
density.22-24  To explore KU-
and 26 weeks (Figure 24).  Prior to drug intervention at 16 weeks, diabetic mice exhibited a 
31% reduction in iENF density.  This deficit allowed us to determine whether KU-32 could 














Week 16 Week 26
 
 
Figure 24.  KU-32 improves cutaneous innervation.  (A) Representative IHC images for 
16- and 26-week treatment groups; scale bar = 40 µm.  Arrows show examples of iENFs 
(white) and dermal nerve fibers (red) that were counted.  (B) Analysis of iENF densities.  





improvements in thermal pain thresholds.  After 26 weeks of untreated diabetes, iENF 
density was 29% less than untreated controls (unchanged compared to 16-week diabetics).  
KU-32 intervention in diabetic mice significantly improved iENF density to within 11% of 
untreated controls.  These effects were not observed in previous intervention studies due to a 
lack of measureable iENF loss and excessive mortality in STZ-diabetic C57BL/6 mice.11-12  
KU-32 had no effect on iENF density in non-diabetic mice. 
3.4.2.  Correlations Between iENF Density and Thermal Hypoalgesia 
 After plotting each animal
significant inverse correlation was established between untreated diabetic and non-diabetic 
mice (Figure 25).  K-means cluster analysis revealed that while most KU-32-treated 
diabetic mice (7) statistically clustered with non-diabetic mice, a subpopulation of KU-32-
treated diabetic mice (4) remained more closely associated with untreated diabetic mice.  
These KU-32-treated diabetic mice had significantly fewer fibers than the other drug-treated 
mice (p < 0.006, Mann-Whitney test), but still showed significant improvements in thermal 
pain thresholds.  Why this recovery occurred without iENF density improvements remains 
unclear.  One possibility may lie with the genetic heterogeneity of the outbred strain, but a 
larger sample size is needed to determine this.  Other explanations may involve alterations to 
thermal nociceptor expression or nociceptive information relay.  Although we can not 
distinguish whether KU-32 invigorates new fiber growth or suppresses degeneration, 
morphological improvements are still evident and provide great promise towards treating 
more humanistic hallmarks of DSPN.  However, given the lack of additional nerve fiber loss 
between 16 and 26 weeks of diabetes, it seems reasonable that KU-32 may enhance neurite 





Figure 25.  Thermal thresholds correlate to reductions in iENF density.  Thermal paw 
withdrawal latency (s) was plotted against iENF density for each animal and subjected to k-
means cluster analysis.  Encircled regions indicate cluster membership and show that only a 
small subset of KU-32-treated diabetic mice (n = 4) demonstrated significant recoveries in 
thermal thresholds without improving iENF density.   
 
3.4.3.  Drug Intervention Does Not Alter Dermal Nerve Fiber Density 
 The percent area occupied by PGP 9.5-immunopositive dermal nerve fibers were 
normalized to the total dermal area.  Although diabetes trended toward decreasing dermal 
fiber area, no significant differences were observed between treatment groups (Veh + Veh, 
5.9 ± 1.0%; Veh + KU-32, 5.7 ± 1.9%; STZ + Veh, 4.8 ± 1.7%; STZ + KU-32, 5.2 ± 1.1%). 
3.5.  KU-32 Improves Mitochondrial Function in Diabetic Sensory Neurons 
 Adult sensory neurons were isolated from L4-L6 DRG at week 26 since they generate 
the myelinated and unmyelinated nerve fibers mainly affected by DSPN and KU-32.  A key 
advantage to working with adult sensory neurons is that they have been exposed to the 
physiological milieu of experimental T1DM and exhibit molecular deficits associated with a 
diabetogenic phenotype.25-27  Using intact sensory neurons also avoids artifacts commonly 
associated with mitochondrial isolation from DRG.  However, one drawback is that the 
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primary cultures are not pulsed with anti-mitotics, which helps alleviate Schwann cell and 
fibroblast contamination, which are normally eradicated during the establishment of 
embryonic primary cultures.28  Even so, this enriched neuronal preparation promotes neurite 
outgrowth and temporarily retains an adult neuronal phenotype.29   












Figure 26.  KU-32 improves mitochondrial function in diabetic sensory neurons.   
(A) Graph of XF96 Seahorse data showing oligomycin and FCCP effects on OCR in adult 
sensory neurons isolated from each treatment group (n = 4-5 wells derived from 3 mice per 
group) at 26 weeks.  (B) Area under the curve (AUC) analysis indicates significantly altered 
ATP-coupled respiration (solid bars) as determined by oligomycin-sensitivity and decreased 
MRC (hatched bars) as determined by FCCP-sensitivity.  Both parameters were significantly 
enhanced in KU-32-treated diabetic mice compared to untreated diabetics.  *, p < 0.05 
versus time-matched Veh + Veh; ^, p < 0.05 versus time-matched STZ + Veh. 
 
 Sensory neurons isolated from 26-week untreated diabetic mice exhibited an ~ 80% 
decrease in oligomycin-sensitive OCR (rate 7; Figure 26A).  This was over twice that of 
sensory neurons from untreated controls (~ 35%).  Since oligomycin inhibits ATP synthase, 
these data suggest that diabetic sensory neurons devote most of their basal O2 consumption 
to ATP synthesis, which may be a compensatory measure for compromised electron 
transport through the respiratory complexes.  Sensory neurons from KU-32-treated diabetic 
mice demonstrated a significant improvement in oligomycin-sensitive OCR to ~ 40%, which 




synthesis efficiency or reduce overall ATP requirements in chronically stressed diabetic 
sensory neurons.  After FCCP (protonophore) injection, sensory neurons from KU-32-
treated diabetic mice exhibited a much higher and significant rebound in MRC compared to 
untreated diabetic sensory neurons (rate 11; Figure 26A).  However, neither diabetic group 
successfully generated an SRC to reinforce metabolic support, suggesting that diabetic 
sensory neurons already operate at maximal capacity.  Even so, the improved MRC indicates 
that KU-32 promotes resiliency in sensory neurons subjected to prolonged metabolic stress.  
In all cases, statistical significance between treatment groups was determined by integrating 
the area under the curve (AUC) for rates 4-7 (oligomycin-sensitive) and rates 8-11 (FCCP-
sensitive) (Figure 26B). 
 Since completing this study, we have adopted a new method to assess non-mitochondrial 
oxygen consumption through a final coinjection of rotenone  and antimycin A , which 
inhibits respiratory complexes I and III and halts mitochondrial respiration.30  Regardless of 
whether non-mitochondrial OCRs are altered in DSPN, it does not detract from the fact that 
oligomycin- and FCCP-sensitive differences in OCRs occurred between treatment groups.  
In addition, 1 mM pyruvate is not incorporated into the bicarbonate-free DMEM medium 
prior to XF96 analysis to establish a more pronounced MRC and SRC across all treatment 
groups.30  Even so, all sensory neurons in this study had free access to 5.5 mM glucose-rich 
medium and endogenous pyruvate stores, which permits an appropriate measure of basal and 
drug-sensitive OCR changes.  The fact that OCRs remained largely consistent throughout 
each measurement loop suggests that these resources were never fully depleted during these 
measurements, which further validates the results of this study.    
 
                                                 
 1 mM working concentration 
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SECTION 4.  DISCUSSION AND CONCLUDING REMARKS  
 These results support our previous proposal that pharmacologic Hsp90 modulators can 
provide sensory neurons and peripheral nerves with the edge needed to endure the austere 
physiological milieu associated with DSPN.  In our previous work, we demonstrated that our 
novel C-terminal Hsp90 modulator, KU-32, improves several clinical indices of negative 
symptoms associated with small and large fiber dysfunction without affecting metabolic 
control of the disease.12  We also established that these effects were dependent upon the 
functional expression of inducible Hsp70 (Hsp70.1 and Hsp70.3 in mice).12  In this study, 
we have shown that KU-32 significantly improves electrophysiological, psychophysical, 
morphological, and bioenergetic indices of DSPN at more chronic stages of development, 
thus supporting our hypothesis.  Most importantly, this pharmacotherapeutic strategy may 
represent the first effective treatment option for the negative symptoms of DSPN.  However, 
-32 afford these neuroprotective 
effects in D  
4.1.  KU-  
 It is unclear as to whether KU-32 elicits an HSR in diabetic sensory neurons and 
peripheral nerves or simply alters normal Hsp90 interactions via allosteric modulation.  
While KU-32 does induce a robust HSR (especially Hsp70) in cultured embryonic sensory 
neurons, evidence of HSR induction in adult diabetic tissues has been inconsistent.12, 31  
Then again, the fact that most DRG differentiate and adopt distinct phenotypes as they 
mature [e.g. fiber type, fiber length, sensory modality(ies), and neuropeptide expression] 
may partly explain these differences.32-34  Variations in KU-32-induced recovery rates for 
mechanical and thermal hypoalgesia in diabetic mice support the notion of differential drug 
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effects by fiber type.  It must also be considered that most tissues from intervention studies 
are collected at study completion, which is 6-10 weeks after the first KU-32 injection and 
nearly one week after the final injection.12  In contrast to in vitro drug treatments, in vivo 
pharmacokinetics can also significantly alter the amount and extent of drug exposure in 
diabetes-relevant tissues.35  Hence, if KU-32 only induces a transient HSR immediately after 
an injection or only during the initial weeks of treatment, then evidence of a robust HSR 
could be missed.   
 Alternatively, it should be considered that an HSR may not be required.  Novobiocin 
(Figure 27 -terminal nucleotide-binding domain and disrupt 
normal co-chaperone interactions, though this has not been proven.36-38  The benzamide 
upon dimerization and promoting proteotoxicity.36-37  Structure-activity relationship (SAR) 
studies have shown that replacing the benzamide sidechain with an acetamide reduces 
toxicity.36, 39  KU-32 is a descendent of A4-inspired novobiocin analogs, which possess this 
acetamide substitution.8-10  It is thought that these analogs bind to Hsp90 in a similar manner 
as novobiocin, but induce only allosteric modulation versus dimer disruption.36, 38-39  While 
this could dislodge HSF1 to elicit an HSR, it could also alter normal protein interactions 
with Hsp90.  Either way, the Hsp90-dependent and independent roles of Hsp70 could be 
enhanced, suggesting that a robust HSR may not be crucial for drug efficacy.40   
 
 
Figure 27.  Structures of novobiocin, A4, and KU-32.  Modified regions of novobiocin for 
A4-inspired analogs (e.g. KU-32) are indicated in red.8-10, 36-39 
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4.2.  Hypothetical Mechanisms of Action 
withstand prolonged periods of metabolic distress and growth inhibition.  This could aid the 
development of new and effective neuroprotective agents that target similar obstacles 
encountered in DSPN and other neurodegenerative disorders.40  KU-32 represents a novel 
pharmacotherapeutic approach that capitalizes upon lessons learned from Hsp involvement 
in oncogenesis to empower sensory neurons and peripheral nerves with increased resiliency 
and neurite outgrowth.  Potential mechanisms surrounding KU-
will be discussed drawing upon lessons learned from Hsp actions in oncogenesis. 
4.2.1.  Mechanisms for Improving iENF Density and Thermal Hypoalgesia 
 KU- ts to iENF density in diabetic SW mice strongly correspond to its 
reestablishment of normal thermal pain thresholds.  As mentioned, somatosensory nerve 
fibers are thought to linger in a state of perpetual growth and could be responsive to local 
manipulation.41  The lack of further iENF loss between 16 and 26 weeks in untreated 
diabetic mice would argue that KU-32 likely enhances nerve fiber growth rather than just 
slowing the rate of progressive fiber degeneration.  Since KU-32 has no affect on systemic 
metabolic parameters, it seems reasonable to suspect that these neuroprotective effects are 
attributed to enhanced neurotrophic support.12   
 Oncogenesis requires the acquisition of self-sufficient growth signaling, which supports 
cancer cell survival, proliferation, and migration (metastasis).42  In several types of cancer 
(e.g. gastrointestinal, lung, breast, prostate, gynecological, pancreatic, and osteosarcomas), 
this requirement is fulfilled by enhancing IGF-I signaling.43-47  This occurs by either 
increasing IGF-I secretion, improving ligand binding interactions, or promoting the 
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expression of IGF-I signaling components.47-48  Several IGF-I signaling components rely 
upon Hsps for post-translational modifications, transport, and functional integrity.  Hsp90 
client proteins include the IGF-IR, IRS-1, IRS-2, PI3K, PDK1, Akt, PKC- - -1, 
ERK-1, MEK-1 (MAPK/ERK kinase 1), and GSK- Figures 12 and 13; CHAPTER I).44-46, 
49-61  Hsp90 also binds raptor to enhance mTOR signaling.62  Even so, most of this client 
protein data comes from cancer studies and must be verified in normal tissues.44-46, 49-61 
 The chemotherapeutic potential for targeting IGF-I signaling has not gone unrealized, 
and has resulted in the development of several IGF-IR inhibitors.63  Alas, many cancer 
strains have developed resistance to this treatment by augmenting IR-A expression.48, 64  
This has led to the development of RTK inhibitors that dually target the IGF-IR and the 
IR.48, 64  Of note, IR maturation also depends heavily upon Hsp90-mediated trafficking of 
the pro-receptor through the ER.65  During this process, Hsp90 exports dysfunctional IRs to 
the cytoplasm for degradation.66  Hence, targeting Hsp90 in these drug-resistant strains may 
simultaneously affect both IR and IGF-IR signaling.   
In contrast, enhancing Hsp support could boost insulin and IGF-I neurotrophic signaling 
in diabetic sensory neurons and peripheral nerves.  IGF-IR levels spike in the distal axons of 
degenerating sural nerves in T1DM and T2DM patients, suggesting that a natural response 
to late stages of DSPN is to invigorate IGF-I signaling.67  It is interesting to note that Hsp90 
and Hsp70 localize to regenerating growth cones of sciatic nerves following nerve crush.68  
 more, Hsp70 expression levels increase in the more distal regions (isolated from the 
soma), suggesting Hsp70 can be locally translated in response to neurotrauma.68  Further, 
Hsp70 expression levels inexplicably deplete alongside IGF-IR in the small nociceptive 
DRG and Schwann cells of STZ-diabetic rats.69  While inducible Hsp70 depletion has no 
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impact upon DSPN progression, it is required for KU- 12  Hence, 
it seems reasonable that restoring local Hsp70 support to more distal regions of nociceptive 
nerve fibers could amplify endogenous neurotrophic signaling.  This is supported by 
findings in IGF-I intervention studies in STZ-diabetic rodents, which elicits very similar 
neuroprotective effects as KU-32 (Table 5).70-73 
Table 5.  Neuroprotective effects of KU-32 and IGF-I in STZ-diabetes.12, 70-73   
   
Neuroprotective Effect KU-32 IGF-I 
Improves iENF Density + + 
Stimulates Neuritogenesis  + 
Reduces Distal Axon Atrophy  + 
Improves Thermal Hypoalgesia + + 
Improves Mechanical Hypoalgesia + * 
Improves MNCV + + 
Improves SNCV + + 
Improves Mitochondrial Bioenergetics +  
Improves Mitochondrial Inner Membrane Potential  + 
(+) effective; (*) stabilizes hyperalgesia; and (blank) unknown effects 
Unfortunately, molecular evidence of increased IGF-I signaling has been inconclusive in 
26-week pooled nerve samples, as represented by pSer(473)Akt in Figure 28.  As such, we 
speculated that KU-32 could have more distinct effects at the more distal regions of diabetic 
peripheral nerves (i.e. foot pads).  Since all foot pad samples from this study were fixed for 
iENF density analysis, additional foot pad samples were acquired from a follow-up 16-week 
intervention SW study conducted by Jiacheng Ma and homogenized.  Although 
immunoblots f -actin 
(loading control) levels, some general trends were noticed.  Inducible Hsp70 levels generally 
decreased in diabetic foot pads (as expected), but there was no evidence of a robust HSR.  
pSer(473)Akt levels were also unaffected by KU-32 as well as diabetes.  However, a notable 
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trending increase in pSer(41)GAP-43 appeared in KU-32-treated diabetic and non-diabetic 
mice, but not GAP-43.  As previously discussed, GAP-43 is a protein that is 
locally expressed in neuronal growth cones and non-myelinating SCs during regeneration.41, 
74-78  GAP-43 phosphorylation by PKC promotes morphogenic activity and prevents growth 
cone retraction in DRG.79  While it is unknown whether Hsps directly interact with GAP-43, 
insulin- and IGF-I-responsive PKCs, such as PKC- - 59-
60  While these IB results suggest that KU-32 may enhance pSer(41)GAP-43, but not Hsp70 
or pSer(473)Akt in diabetic foot pads, more evidence is needed.  Importantly, there were no 
adverse signs of excessive collateral branching or hyperalgesia in either KU-32 treatment 
group.  Hence, while pSer(41)GAP-43 may favor neurite outgrowth, there are most likely 
other regulatory factors at play.  More work is needed to confirm these results and to further 
explore potential KU-32 affects upon the IGF-I/PKC/GAP-43 signaling axis.  










Foot Pads at 21 Weeks
 
 
Figure 28.  Representative IB of peripheral nerve and foot pad homogenates.  (Top) 
Pooled sciatic, tibial, and sural nerve homogenates from 16-week intervention SW mice at 
-actin.  (Bottom) Foot 
pad homogenates from a separate, 16-week intervention SW mice were analyzed for 
inducible Hsp70 (Hsp72), pSer(41)GAP-43, pSer(473)Akt, GAP- -actin. 
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4.2.2.  Mechanisms for Improving Mitochondrial Function and Other Indices 
 High-energy axonal functions, such as growth cone motility, molecular transport, and 
excitation, require a dedicated and sufficient supply of ATP.29  Substantial changes to the 
mitochondrial proteome have been reported in STZ-diabetic and high glucose-stressed 
sensory neurons and SCs, which alter mitochondrial membrane potentials, respiratory chain 
activities, and bioenergetics.25, 29, 80-83  Thus, improving mitochondrial support and function 
in diabetic sensory neurons could significantly improve multiple aspects of DSPN.    
 In cancer, tumor biomass expansion and signaling are partially driven by advantageous 
metabolic alterations.84  To meet biosynthetic demands, cancer cell mitochondria must 
function efficiently under extreme conditions, including nutrient deprivation and oxidative 
stress.84  This requires adequate biomaterial flux, protein folding and stabilization, and the 
neutralization of impending proteotoxic threats.84  Increases in mitochondria-localized 
Hsp90 and its homolog TRAP-1 (TNF receptor-associate protein-1) in tumor cells serve to 
stabilize and repair damaged mitochondrial proteins (e.g. respiratory complex II), thus 
sustaining mitochondrial operations.84  Mitochondria-localized Hsp90 can also bind 
cyclophilin D to prevent mitochondrial membrane permeabilization and apoptosis.85  Along 
these lines, Hsp70 induction inhibits the activation and translocation of pro-apoptotic Bax to 
the mitochondria and stabilizes anti-apoptotic Bcl-2.86-87  Furthermore, Hsp90 and Hsp70 
largely facilitate mitochondrial protein trafficking.60, 88-89  These Hsps deliver preproteins to 
the mitochondrial membrane transporter TOM70 (translocase of outer mitochondrial 
membrane 70-kDa).90-91  TOM70 imports these preproteins into the mitochondria for 
mtHsp70 (mitochondrial Hsp70)-mediated transport to Hsp60.90-91  Hsp60 then folds these 
preproteins into their mature conformations.90-91  In this manner, nearly 99% of the 
 
 136 
mitochondrial proteome is dependent upon Hsp90 and Hsp70.92  Hence, Hsp90 and Hsp70 
promote structural and functional integrity in cancer cell mitochondria, making them more 
adept to handling chronic metabolic stress. 
 We have shown that KU-32 significantly improves mitochondrial bioenergetics at more 
chronic stages of DSPN, which likely contributes to electrophysiological, psychophysical, 
and morphological effects as well.  In proteomic studies in high glucose-stressed embryonic 
rat DRG, KU-32 greatly increased the translation of several mitochondrial respiratory 
components and bolstered endogenous antioxidant defenses (e.g. manganese SOD, an Hsp90 
client protein).81  With that said, a definitive mechanistic cause for improved mitochondrial 
bioenergetics in diabetic sensory neurons is still under investigation.  If the enhanced 
neurotrophic signaling hypothesis holds true, then Hsp90 modulation should likely affect 
pSer(473)Akt.  After all, Hsp90 over-expression alone can increase pSer(473)Akt levels in 
HEK293 cells.57  In DRG, IGF-I-induced pSer(473)Akt improves mitochondrial inner 
membrane potential ( , inhibits Bim/Bax translocation, triggers CREB-mediated pro-
survival transcription, and deactivates caspase-9, FKHR (forkhead in rhabdomyosarcoma), 
and GSK- 25, 69, 93-100  Alas, the IB results seemingly refute this possibility, unless KU-
effects are indeed more transient.  To thoroughly assess this possibility, more tissues have to 
be collected immediately after each weekly KU-32 injection.  This requires a substantially 
larger population size (n) and a better understanding of KU-
(addressed in CHAPTER III).   
4.2.3.  Other Mechanistic Considerations 




(e.g. NGF or NT-3) are being affected.  Of note, most of these pathways result in the 
downstream activation of identical signaling molecules, which synergistically afford 
neuroprotective effects.101-102  Hence, if Hsp90 modulation enhances the activation of 
downstream neurotrophic signaling molecules, then the neurotrophic factors themselves may 
be less important.  Hence more, this pharmacotherapeutic approach may likely bypass the 
painful side effects linked to exogenous NGF treatments.101   
 Given the vastness of the Hsp90 and the Hsp70 interactomes, it should be considered 
that each of the neuroprotective effects of KU-32 could be attributed to multiple molecular 
signaling alterations.  While this is not ideal from a drug development perspective, it is 
possible.  To effectively rule this out requires a broad assessment of the proteome/RNAome 
at several regions of diabetic peripheral nerves, given that Hsp70 can be locally expressed.68  
This type of analysis is problematic for distal somatosensory nerve fibers in foot pads since 
they can not be readily isolated from the surrounding tissues.  Hence, costly analytical 
techniques, such as high content screening or RNA microarrays, would be plagued by tissue 
contamination issues; this is a concern for IB as well.  To exclusively analyze protein 
expression in the nerve fibers of the dermis/epidermis requires IHC.   
 Proteomics can be used to assess disease and drug-induced alterations in protein levels in 
adult sensory neurons and remaining portions of sciatic, tibial, and sural nerves.  However, 
previous pulse SILAC (stable isotope labeling of amino acids in culture) methods used to 
assess KU- 81  This poses 
survivability issues in adult primary cultures.  More importantly, failure to fully reproduce 
the physiological milieu of experimental T1DM would likely alter protein expression.  Thus, 
an alternative proteomic approach is needed.  iTRAQ (isobaric tags for relative and absolute 
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quantification) enables protein/peptide labeling in tissue homogenates, which enables 
snapshot comparisons between various treatment groups.103  While this technique does not 
eliminate contamination issues, changes in whole nerve and DRG protein levels could be 
characterized.  This would help govern subsequent molecular analyses and determine 
regions differences overall protein expression.  This is important given the dying back 
pattern of nerve attrition in DSPN.  However, this generates two concerns:  (1) which time 
points should be assessed and (2) if KU-32 has distinct effects in different nerve fibers, will 
background noise suppress real changes in affected nerve fibers.  The bottom line is that 
employing a pharmacotherapeutic approach that targets molecular chaperones runs the 
lly understand KU-
effects will require either proteomics or genetic knockdown studies (if possible) upon 
discovery of a putative neuroprotective mechanism.  
 There are additional risks associated with targeting heat shock proteins in DSPN.40  The 
first is the risk for drug-drug interactions with insulin and/or adjunctive therapies for 
glycemic control.  If KU-32 does boost neurotrophic signaling, it could also generate risks 
similar to mismanaged insulin therapy if metabolic insulin signaling is also affected.  In this 
regard, it must first be noted that complete annihilation of insulin production is lethal and 
our previous 12-week intervention studies in C57Bl/6 mice demonstrated that STZ-diabetic 
mice still retained ~ 40% of normal circulating insulin levels.12  While KU-32 has not been 
administered alongside insulin or other diabetes adjunctive therapies, we have shown that 
FBG and HbA1C levels are unaffected by KU-32 treatments in diabetic and non-diabetic 
animals.  This effectively negates possible enhancement of metabolic insulin signaling.  The 
second risk is the promotion of cancer.  While this is a practical concern, all intervention 
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studies to date involving KU-32-treated diabetic and non-diabetic mice have been devoid of 
signs of overt toxicity or tumorigenesis.12  With that said, clinical effects can often differ 
from preclinical studies with regard to drug pharmacodynamics and pharmacokinetics.  If 
KU-32 exhibits any undesirable side effects, these could be overcome by readjusting 
primary treatment regimens, insulin and adjunctive therapies, or by developing an Hsp90 
modulator with less robust effects.12   
4.3.  Concluding Remarks 
 In summary, pharmacologic Hsp90 modulation significantly improves psychophysical, 
electrophysiological, morphological, and bioenergetic indices at more chronic stages of 
DSPN development.  The finding that KU-32 promotes iENF recovery argues against a 
purely neurochemical correction for NCV improvements, which may transcend interspecies 
mechanistic differences to help expedite drug development.104-105  However, the molecular 
mechanisms underlying these neuroprotective effects require further attention.  KU-32 
represents a novel pharmacotherapeutic approach that draws upon oncogenic methods to 
improve resiliency to hyperglycemic and neurotrophic insults that contribute to DSPN.  
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CHAPTER III:  KU-32 PHARMACOKINETIC ANALYSES 
 
SECTION 1.  EXPERIMENTAL DESIGN  
 Despite marked improvements in several standard indices of DSPN, there was a need to 
characterize KU-  (IP-PK) profile in DSPN-relevant 
tissues to verify successful drug distribution and elimination from these tissues.  We further 
sought to characterize KU- er oral gavage (OG-PK) to develop 
comparable dose ranges for future oral intervention studies.   
To test the hypothesis that both intraperitoneal and oral KU-32 administration will result 
in successful drug delivery to DSPN-relevant tissues in a route-dependent manner, we 
conducted four experiments.  In Experiment 1, drug tissue levels in 20 mg/kg KU-32 IP-
treated wild-type C57BL/6 (WT B6) and Hsp70.1/70.3 double knockout (Hsp70 KO) mice 
were compared to determine if previous reported differences in KU-32-responsiveness  
between these strains were the result of unequal drug distribution.1-2  In Experiment 2, 
pharmacokinetic profiles for DSPN-relevant tissues were assessed following 20 mg/kg KU-
32 IP treatments in WT B6 and Hsp70 KO mice.  In Experiment 3, drug tissue levels were 
measured after an 8-week intervention study in Swiss-Webster (SW) mice  to confirm total 
drug elimination in STZ-diabetic and non-diabetic tissues at the point the next weekly 
treatment would typically occur.1  Finally, in Experiment 4, pharmacokinetic profiles for 
DSPN-relevant tissues and blood plasma were examined after 10 or 20 mg/kg KU-32 OG 
treatments in SW mice.  KU-32 analyte levels in tissue/plasma were measured using liquid 
chromatography-tandem (triple quadrupole) mass spectrometry (LC/MS/MS). 
                                                 
 Both WT B6 and Hsp70 KO studies consisted of 12 weeks of STZ-diabetes followed by 6 weekly 20 mg/kg 
KU-32 IP treatments.  In contrast to KU-32-responsive diabetic WT B6 mice, KU-32 intervention in diabetic 
HSP70 KO mice had no effect on standard indices of DSPN. 
 Treatments entailed 6 weekly 2, 10, or 20 mg/kg KU-32 IP treatments after 8 weeks of STZ-diabetes. 
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SECTION 2.  MATERIALS AND METHODS 
2.1.  Animals 
 Three strains of mice were used for these experiments.  Male, six-week old, outbred SW 
mice were purchased from Harlan Laboratories (Indianapolis, IN) and acclimated for two 
weeks prior to use.  Male and female WT B6 and Hsp70 KO (C57BL/6 background) mice 
were obtained from in-house breeding colonies.  WT B6 mice were initially purchased from 
Harlan Laboratories, and Hsp70 KO mice were originally acquired from the Mutant Mouse 
Resource Center (San Diego, CA).  Animals were maintained on a 12 hour light/dark cycle 
at 70°F and 70% humidity and given ad libitum access to Purina diet 5001 chow and water.  
All procedures were conducted according to IACUC regulations and protocols as well as the 
standards and regulations for care and use of laboratory rodents established by the NIH.   
2.2.  Drug Formulations and Treatments 
 All KU-32 treatments were based on the weight (kg) of the mouse on the day prior to 
injection.  KU-32 was synthesized and prepared as a 5 mg/ml stock (0.1 M Captisol) as 
previously described (CHAPTER II).  In addition, a 2.5 mg/ml KU-32 stock (0.1 M Captisol) 
was also prepared for 10 mg/kg KU-32 OG treatments to allow consistent vehicle loading 
for both OG treatments.  For each KU-32-treated animal, an aliquot of fresh 5 mg/ml KU-32 
(0.1 M Captisol) or 2.5 mg/ml KU-32 (0.1 M Captisol) stock needed for each dose was 
dispensed into a sterile 1.7-ml microcentrifuge tube.  To help facilitate IP injections, sterile 
1X PBS (200 µl) was added to each tube, bringing the final working concentrations to:  
2 mg/kg KU-32 (in ~ 215 µl of ~ 7 mM Captisol); 10 mg/kg KU-32 (~ 275 µl of ~ 27 mM 
Captisol); and 20 mg/kg KU-32 (~ 350 µl of ~ 43 mM Captisol).  Vehicle-treated controls 
for IP experiments were given mass-dependent volume equivalents of 0.1 M Captisol plus 
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200 µl of sterile 1X PBS, or ~ 350 µl of ~ 43 mM Captisol (vehicle equivalent for 20 mg/kg 
KU-32 treatments).  To minimize dilution effects on drug absorption, no additional saline 
was added to OG treatments.  Hence, final working concentrations for OG treatments were:  
10 mg/kg KU-32 (in ~ 125 µl of 0.1 M Captisol) and 20 mg/kg KU-32 (in ~ 125 µl of 0.1 M 
Captisol).  Vehicle-treated controls for OG experiments were given mass-dependent volume 
equivalents of 0.1 M Captisol, or ~ 125 µl of 0.1 M Captisol (vehicle equivalent for both 
10 mg/kg KU-32 and 20 mg/kg KU-32 OG treatments).   
 IP treatments were conducted using a sterile 1-ml syringe fitted with a sterile 27-gauge, 
3/4-inch long hypodermic needle (BD, Franklin Lakes, NJ).  Injection sites were pre-cleaned 
with 70% ethanol.  For OG treatments, mice were anesthetized by open-drop exposure to 
isoflurane.  During this procedure, animals were placed on a perforated plastic platform 
inside a slightly vented desiccation chamber, which contained a 2 x 2-inch gauze doused 
with 30% v/v isoflurane/propylene glycol underneath.  Each bolus was then loaded into a 
primed  1-ml syringe fitted with a reusable curved feeding needle (20-gauge; 1.5-inch long; 
and 2.25-mm ball diameter) (Cadence Science, Staunton, VA), inserted gently down the 
from anesthesia (~ 15 seconds), mice were returned to their home cages.  To minimize food 
influences on drug absorption, animals were fasted four hours before and one hour after OG 
treatment; animals always had ad libitum access to water.  For better comparisons between 
drug delivery routes, IP-treated animals in Experiments 1 and 2 were likewise fasted.  Only 
SW mice from the 8-week intervention study were treated without fasting.  
                                                 
 Needles were primed with appropriate solutions of 5 mg/ml KU-32, 2.5 mg/ml KU-32, or 0.1 M Captisol 
stock to avoid gastric distension and physical discomfort and to ensure complete dose delivery.  Each dose was 
slowly drawn into the needle/syringe and any air trapped in the tip of the needle was expelled prior to injection.  
Pressure during gavage ceased upon initial contact of the plunger tip with the end of the syringe barrel. 
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2.3.  Experiments 
2.3.1.  Experiment 1:  KU-32 Tissue Levels in WT B6 and Hsp70 KO Mice 
 The first experiment was conducted using WT B6 and Hsp70 KO mice (Table 6).  Each 
animal was administered a single IP injection of either 20 mg/kg KU-32 or a Captisol/saline 
vehicle equivalent.  Vehicle-treated controls were included for quality assurance purposes.  
All animals were euthanized 2 or 4 hours after treatment for tissue collection (described in 
Euthanasia and Tissue/Plasma Collection).  KU-32 levels were measured in the dorsal 
of both strains at each time point. 
Table 6.  Treatment groups for Experiment 1.   
     
WT B6 Treatments Time Point n  Hsp70 KO Treatments Time Point n 
Veh 2 h 1  Veh 2 h 1 
Veh 4 h 1  Veh 4 h 1 
20 mg/kg KU-32 2 h 3  20 mg/kg KU-32 2 h 3 
20 mg/kg KU-32 4 h 3  20 mg/kg KU-32 4 h 3 
 
2.3.2.  Experiment 2:  Intraperitoneal Pharmacokinetic Time Profiles for KU-32 
 In the second experiment, 2- and 4-hour data from Experiment 1 were augmented by two 
earlier time points using Hsp70 KO mice (Table 7).  These mice were intraperitoneally 
injected with 20 mg/kg KU-32 or a Captisol/saline vehicle and euthanized 30 or 60 minutes 
later for tissue collection.  Since 2- and 4-hour KU-32 tissue levels (Experiment 1) were 
indistinguishable between WT B6 and Hsp70 KO mice, strain data were pooled at each time 
point.  Hence, IP-PK time profiles were established using 0.5-hour (n = 3 mice), 1-hour 
(n = 3 mice), 2-hour (n = 6 mice), and 4-hour (n = 6 mice) time points in DRG, foot pads, 
and pooled nerves.  Vehicle-treated controls were also included for quality assurance.  Since 
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our pilot study revealed no detectable traces of KU-32 at 8 hours (data not presented), IP-PK 
time profiles were not extended beyond 4 hours. 
Table 7.  Augmented treatment groups for Experiment 2.   
    
Hsp70 KO Treatments Time Point n 
Veh 0.5 h 1 
Veh 1 h 1 
20 mg/kg KU-32 0.5 h 3 
20 mg/kg KU-32 1 h 3 
 
2.3.3.  Experiment 3:  KU-32 Tissue Levels After an 8-Week Intervention Study  
 In this 8-week intervention study, STZ-diabetes was induced in SW mice and monitored 
using the same methods and BCS considerations described in CHAPTER II.  After 8 weeks, 
STZ-diabetic and non-diabetic animals identified for tissue analysis received six weekly IP 
treatments of 2, 10, or 20 mg/kg KU-32 (Table 8).  All animals were euthanized 7-9 days 
after the sixth (final) treatment and the DRG, foot pads, and pooled nerves were collected.   
Table 8.  Treatment groups for Experiment 3.  
      
SW Treatments n 
Veh + 20 mg/kg KU-32 7 
STZ + 2 mg/kg KU-32 6 
STZ + 10 mg/kg KU-32 7 
STZ + 20 mg/kg KU-32 5 
 
2.3.4.  Experiment 4:  Oral Gavage Pharmacokinetic Time Profiles for KU-32 
 In the final experiment, SW mice were orally administered 10 mg/kg KU-32, 20 mg/kg 
KU-32, or Captisol/saline vehicle-equivalent doses (Table 9).  Vehicle-treated controls were 
included for quality assurance purposes.  All animals were euthanized 1, 2, 4, 8, or 24 hours 
after gavage.  In addition to DRG, foot pads, and pooled nerves, OG-PK time profiles for 
blood plasma were also established.   
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Table 9.  Treatment groups for Experiment 4.   
    
SW Treatments Time Point n  SW Treatments Time Point n 
10 mg/kg KU-32 1 h 4  20 mg/kg KU-32 1 h 4 
10 mg/kg KU-32 2 h 4  20 mg/kg KU-32 2 h 4 
10 mg/kg KU-32 4 h 4  20 mg/kg KU-32 4 h 4 
10 mg/kg KU-32 8 h 4  20 mg/kg KU-32 8 h 4 
10 mg/kg KU-32 24 h 4  20 mg/kg KU-32 24 h 4 
Veh 1 h 2     
  
2.4.  Euthanasia and Tissue/Plasma Collection 
 All animals were euthanized in accordance with NIH guidelines, IACUC regulations, 
and approved animal use protocols.  For Experiments 1, 2, and 4, mice were euthanized by 
CO2 asphyxiation, followed by cardiac excision and then decapitation.  After standard NCV 
measurements in the 8-week intervention study (as described in CHAPTER II), mice from 
Experiment 3 mice were euthanized via cardiac excision and then decapitation.   
 All tissues were collected immediately after euthanasia.  Sciatic, tibial, and sural nerves 
were dissected and pooled from both hind limbs, flash frozen on dry ice, and then stored at  
- 80°C.  The plantar integument (foot pad) for each hindpaw was also dissected, pooled, 
flash frozen on dry ice, and stored at  80°C.  L4-L6 DRG were excised from the lumbar 
intervertebral foramena using a dissecting microscope (roots trimmed during extraction), 
pooled for each mouse, flash frozen on dry ice, and stored at  80°C.  In Experiment 4, 
blood samples were collected after cardiac excision and promptly vortexed with 50 µl of 
0.3 M ethylenediaminetetraacetic acid (EDTA) containing 1X complete protease inhibitor 
cocktail (Roche Diagnostics, Indianapolis, IN).  Samples were centrifuged at 1,500 x g for 
15 minutes at 4°C and plasma was collected, flash frozen on dry ice, and stored at  80°C.  
Pooled nerves, foot pads, DRG, and plasma were also collected from wholly untreated mice 
(no vehicle) to serve as negative controls (tissue and plasma blanks) and for standard curve 
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generation in LC/MS/MS analyses (n = 30 mice).  All tissues were later weighed in fresh, 
dry 2-ml microcentrifuge tubes at room-temperature in preparation for LC/MS/MS.  These 
tissues were immediately refrozen on dry ice and re-stored at  80°C alongside frozen 
plasma samples.   
2.5.  KU-32 Measurements and Pharmacokinetic Analyses 
2.5.1.  KU-32 Extraction 
 While the extraction procedure for KU-32 was largely conserved across all sample types 
and experiments, different extraction solvent volumes were used based on the amount of 
sample available and each distinct matrix.1  These methods are described below.  Drug 
extractions and LC/MS/MS analyses were performed with technical consult and equipment 
Biotechnology Innovation and Optimization Center. 
2.5.1.1.  KU-32 Extraction from Pooled Sciatic, Tibial, and Sural Nerves 
 All 2-ml microcentrifuge tubes containing frozen pooled nerve samples and standards 
were slowly warmed to room temperature (RT).  Millipure H2O was carefully added to each 
tube using a mass scale to achieve a 25 mg tissue/g H2O suspension.  All tissues were then 
pulverized by intense sonication for 30 seconds at RT.  Each homogenate was vortexed for 
10 seconds and a 200-µl aliquot was transferred to a safe-lock 2-ml microcentrifuge tube.  
For each standard, 5 µl of appropriate 1X KU-32 (50% dimethyl sulfoxide; DMSO) stock 
solution was added, vortexed for 10 seconds, and incubated for 5 minutes at RT to generate 
1, 10, 50, 100, 250, 500, and 1,000 ng KU-32/g tissue standards.  Each 1X KU-32 stock was 
vortexed for 10 seconds prior to use and 5 µl of 50% DMSO was added to each sample for 
consistency and vortexed for 10 seconds.  All standards and samples were then spiked with 
 
 150 
5 µl of 50 ng/ml trideutero KU-32 (d3KU-32) (50% DMSO) internal standard and vortexed 
for 10 seconds to give a 50 ng d3KU-32/g tissue mixture; d3KU-32 stock was also vortexed 
for 5 seconds before use.  Approximately 1 ml of methyl tert-butyl ether (MTBE) was added 
to each tube, vortexed for 5 minutes, and centrifuged at 12,000 rpm for 5 minutes at RT.  
Roughly 950 µl of the organic layer was transferred to a new 1.7-ml microcentrifuge tube 
and evaporated to dryness using a speed vacuum (high temperature) for ~ 20 minutes.  Each 
sample and standard was then reconstituted in 50 µl of 20% v/v (CH3CN/H2O), vortexed for 
10 seconds, and centrifuged at 12,000 rpm for 5 minutes at RT.  Upon completion, 45-µl of 
supernatant was transferred to autosampler vials with glass inserts for LC/MS/MS analysis.   
2.5.1.2.  KU-32 Extraction from Foot Pads 
 All 2-ml microcentrifuge tubes containing pooled frozen foot pad samples and standards 
were slowly warmed to RT.  Millipure H2O was carefully added to each tube using a mass 
scale to achieve a 100 mg tissue/g H2O suspension.  Tissues were then pulverized by intense 
sonication for 90 seconds at RT.  Each homogenate was vortexed for 10 seconds and a 
125-µl aliquot was transferred to a safe-lock 2-ml microcentrifuge tube.  For each standard, 
12.5 µl of appropriate 1X KU-32 (50% DMSO) stock solution was added, vortexed for 
10 seconds, and incubated for 5 minutes at RT to generate 1, 10, 50, 100, 250, 500, and 
1,000 ng KU-32/g tissue standards.  Each 1X KU-32 stock solution was vortexed for 
10 seconds before use and 12.5 µl of 50% DMSO was added to each sample for consistency 
and vortexed for 10 seconds.  All tubes were spiked with 12.5 µl of 50 ng/ml d3KU-32 
(50% DMSO) internal standard and vortexed for 10 seconds to give a 50 ng d3KU-32/g 
tissue mixture; d3KU-32 stock solution was vortexed for 5 seconds before use.  Roughly 
625 µl of MTBE was added to each tube, vortexed for 5 minutes, and centrifuged at 
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12,000 rpm for 5 minutes at RT.  About 600 µl of the organic layer was transferred to a 
fresh 1.7-ml microcentrifuge tube and evaporated to dryness using a speed vacuum (high 
temperature) for ~ 20 minutes.  Each sample/standard was reconstituted in 50 µl of 20% v/v 
(CH3CN/H2O), vortexed for 10 seconds, and centrifuged at 12,000 rpm for 5 minutes at RT.  
Upon completion, 45-µl of supernatant was transferred to autosampler vials with glass 
inserts for LC/MS/MS analysis.   
2.5.1.3.  KU-32 Extraction from Dorsal Root Ganglia 
2.5.1.3.1.  KU-32 Extraction from DRG (IP Experiments) 
 All 2-ml microcentrifuge tubes containing frozen DRG samples and standards were 
slowly warmed to RT.  Millipure H2O was carefully added to each tube using a mass scale 
to achieve a 25 mg tissue/g H2O suspension.  Tissues were then pulverized by intense 
sonication for 30 seconds at RT.  Each homogenate was vortexed for 10 seconds and a 40-µl 
aliquot was transferred to a safe-lock 2-ml microcentrifuge tube.  For each standard, 1 µl of 
appropriate 1X KU-32 (50% DMSO) stock solution was added, vortexed for 10 seconds, 
and incubated for 5 minutes at RT to generate 1, 10, 50, 100, 250, 500, and 1,000 ng 
KU-32/g tissue standards.  Each 1X KU-32 stock solution was vortexed for 10 seconds 
before use and 1 µl of 50% DMSO was added to each sample for consistency and vortexed 
for 10 seconds.  All tubes were spiked with 1 µl of 50 ng/ml d3KU-32 (50% DMSO) 
internal standard and vortexed for 10 seconds to give a 50 ng d3KU-32/g tissue mixture; 
d3KU-32 stock solution was vortexed for 5 seconds before use.  Roughly 200 µl of MTBE 
was added to each tube, vortexed for 5 minutes, and centrifuged at 12,000 rpm for 5 minutes 
at RT.  About 180 µl of the organic layer was transferred to a fresh 1.7-ml microcentrifuge 
tube and evaporated to dryness using a speed vacuum (high temperature) for ~ 20 minutes.  
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Each sample/standard was reconstituted in 40 µl of 20% v/v (CH3CN/H2O), vortexed for 10 
seconds, and centrifuged at 12,000 rpm for 5 minutes at RT.  Upon completion, 35-µl of 
supernatant was transferred to autosampler vials with glass inserts for LC/MS/MS analysis.   
2.5.1.3.2.  KU-32 Extraction from DRG (OG Experiment) 
 Due to DRG sample mass limitations, the extraction procedure for the OG experiment 
was modified relative to IP experiments.  All 2-ml microcentrifuge tubes containing frozen 
DRG samples and standards were slowly warmed to RT.  Millipure H2O was added to each 
tube using a mass scale to achieve a 10 mg tissue/g H2O suspension.  Tissues were then 
pulverized by intense sonication for 30 seconds at RT.  Each homogenate was vortexed for 
10 seconds and a 40-µl aliquot was transferred to a safe-lock 2-ml microcentrifuge tube.  For 
each standard, 4 µl of appropriate 0.1X KU-32 (50% DMSO) stock solution was added, 
vortexed for 10 seconds, and incubated for 5 minutes at RT to generate 1, 10, 50, 100, 250, 
500, and 1,000 ng KU-32/g tissue standards.  Each KU-32 stock solution was vortexed for 
10 seconds before use and 4 µl of 50% DMSO was added to each sample for consistency 
and vortexed for 10 seconds.  All tubes were then spiked with 4 µl of 5 ng/ml d3KU-32 
(50% DMSO) internal standard and vortexed for 10 seconds to give a 50 ng d3KU-32/g 
tissue mixture; d3KU-32 stock solution was vortexed for 5 seconds before use.  Roughly 
200 µl of MTBE was then added to each tube, vortexed for 5 minutes, and centrifuged at 
12,000 rpm for 5 minutes at RT.  About 180 µl of the organic layer was transferred to a 
fresh 1.7-ml microcentrifuge tube and evaporated to dryness using a speed vacuum (high 
temperature) for ~ 20 minutes.  Each sample/standard was reconstituted in 40 µl of 20% v/v 
(CH3CN/H2O), vortexed for 10 seconds, and centrifuged at 12,000 rpm for 5 minutes at RT.  
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Upon completion, 35-µl of supernatant was transferred to autosampler vials with glass 
inserts for LC/MS/MS analysis.   
2.5.1.4.  KU-32 Extraction from Blood Plasma 
 All 2-ml microcentrifuge tubes containing frozen plasma samples and standards were 
slowly warmed to RT.  Each tube was vortexed for 10 seconds and a 50-µl aliquot was 
transferred to a safe-lock 2-ml microcentrifuge tube.  For each standard, 5 µl of appropriate 
10X KU-32 (50% DMSO) stock solution was added, vortexed for 10 seconds, and incubated 
for 5 minutes at RT to give 1, 10, 50, 100, 250, 500, and 1,000 ng KU-32/ml plasma 
standards.  Each KU-32 stock solution was vortexed for 10 seconds before use and 5 µl of 
50% DMSO was added to each sample for consistency and vortexed for 10 seconds.  All 
tubes were spiked with 5 µl of 500 ng/ml d3KU-32 (50% DMSO) internal standard and 
vortexed for 10 seconds to give a 50 ng d3KU-32/ml plasma mixture; d3KU-32 stock 
solution was vortexed for 5 seconds before use.  Roughly 250 µl of MTBE was added to 
each tube, vortexed for 5 minutes, and centrifuged at 12,000 rpm for 5 minutes at RT.  
About 225 µl of the organic layer was transferred to a 1.7-ml microcentrifuge tube and 
evaporated to dryness using a speed vacuum (high temperature) for ~ 20 minutes.  Each 
sample/standard was then reconstituted in 50 µl of 20% v/v (CH3CN/H2O), vortexed for 
10 seconds, and centrifuged at 12,000 rpm for 5 minutes at RT.  Upon completion, 45-µl of 
supernatant was transferred to autosampler vials with glass inserts for LC/MS/MS analysis.   
2.5.1.5.  Tissue and Plasma Blanks 
 Tissue and plasma blanks were prepared from wholly untreated mice.  These blanks 
were used for purging and as negative controls between standard and sample processing 
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during LC/MS/MS analysis.  Blanks were processed similar to the standards with the 
exception that KU-32 and d3KU-32 spikes were substituted with 50% DMSO only.     
2.5.2.  Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) 
 KU- S/MS System 
(AB SCIEX, Framingham, MA).  Chromatographic separation was performed using a 5-µm 
Agilent Zorbax SB-C18 column (2.1 x 50 mm) (Agilent Technologies, Santa Clara, CA) and 
a linear gradient of CH3CN:H2O:HCO2H [(5:95:0.1) to (95:5:0.1) over 8 minutes] with a 
300 µl/min flow rate.  Average analyte retention time was 3.43 minutes.  The effluent was 
then introduced to a Sciex API3200 Linear Ion Trap (LIT) detector (Framingham, MA) 
using turbo ion spray in the positive ion mode.  During this process, effluent ions were 
focused by the Q0 quadrupole prior to entering the Q1 quadrupole.  The Q1 quadrupole 
served as an ion filter optimized for 408.223 m/z (KU-32) and 411.140 m/z (d3KU-32) 
collection.  Upon arriving at the Q2 collision chamber [LINAC® (linear accelerator) 
collision cell], ions were fragmented by nitrogen gas collision.  KU-32 (192.100 m/z) and 
d3KU-32 (193.200 m/z) analytes were then filtered by the Q3 quadrupole before entering 
the LIT detector to generate quantifiable signals.  Standard curves were constructed for each 
run using 0-1,000 ng KU-32/g tissue or 0-1,000 ng KU-32/ml plasma standards.  Analyte 
recovery ranged between 65-75%, which was determined by comparing d3KU-32 analyte 
spectra from the zero standard in relation to like spectra from a d3KU-32 (50% DMSO)-
spiked 20% v/v (CH3CN/H2O) control .  KU-32:d3KU-32 analyte ratios and standard curves 
were used to determine original KU-32 concentrations for each sample.  Limit of detection 
(LOD) calculations for Experiment 3 were based on the linear calibration curves for each 
                                                 
 Established as 100% recovery since created post-extraction  
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LC/MS/MS run:  LOD = 3Sa/b, where Sa is the residual standard deviation  and b is the 
slope of the calibration curve.3-4 
2.6.  Statistical Analyses and Pharmacokinetic Calculations 
Statistical analyses were performed using JMP Pro 11.0.0 (SAS Institute Inc, Cary, NC) 
and portrayed using Graphpad Prism 6 (Graphpad Software, Inc., La Jolla, CA).  Initial 
assessments of KU-32 analyte concentration data revealed strong evidence of non-normality 
(Shapiro- -
er 
two-way ANOVA use.5-6  This was not surprising given the small sample sizes for each 
treatment group (n = 3-6 samples/group).  Alternatively, the Kruskal-Wallis test was used to 
determine differences between group medians, followed by the Wilcoxon Each Pair test for 
nonparametric multiple comparisons to identify significant differences between specific 
group pairs.6-7  The Bonferonni correction (post hoc test) was used to correctly adjust the 
-levels to account for inflated error associated with the multiple comparisons.7  This was 
-level of 0.05 by the number of pairwise comparisons 
made with 20 mg/kg KU-32 OG at -level of 0.025 for 
two comparisons (20 mg/kg KU-32 IP and 10 mg/kg KU-32 OG)  or retaining 0.05 for a 
single pair comparison (10 mg/kg KU-32 OG).7  The p-values expressed in all figures reflect 
these -levels, and all data are presented as mean ± SEM.   
IP-PK and OG-PK time profiles (Experiments 2 and 4) for each sample type were 
established by plotting mean KU-32 analyte concentrations over time.  For further analysis, 
mean analyte concentrations were converted to a natural log scale.8-13  Linear regression 
                                                 
 sy.x  
 No comparisons were made for 20 mg/kg KU-32 IP:10 mg/kg KU-32 OG  
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analysis was then performed for each treatment group and the linear regression segments 
were plotted.8-13  The r2-values for each linear regression segment were used to determine 
whether the drug elimination data supported first-order kinetics.8-13  Drug elimination rate 
constants (ke) were established as the opposite slope of these linear regression segments.8-13  
Drug elimination half-lives for each treatment group and sample type were calculated as:  
t1/2 = ln(2)/ke.8-13  Based on the linear equations of each linear regression segment, one-phase 
exponential decay equations were derived and plotted on the unaltered PK time profiles. 
SECTION 3.  RESULTS 
3.1.  Inducible Hsp70 Deletion Does Not Affect Drug Distribution 
While KU-32 was detected in the pooled nerves, foot pads, and DRG of 20 mg/kg 
KU-32 IP-treated WT B6 and Hsp70 KO mice, no significant differences were found 
between strains at the 2- and 4-hour time points (Figure 29); lowest p-value (0.0809) was 
established for the 2-hour foot pad comparison.  Despite clear differences between tissue 
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Figure 29.  Comparison of KU-32 tissue levels in WT B6 and Hsp70 KO mice.  KU-32 
levels for the DRG, foot pads, and pooled nerves of WT B6 and Hsp70 KO mice were 
measured two and four hours after a single 20 mg/kg KU-32 IP injection.  No significant 
differences (p < 0.05) between strains were found; error bars denote SEM. 
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3.2.  Intraperitoneal Pharmacokinetic Time Profiles for KU-32 
Temporal IP-PK analyses revealed major drug distribution and elimination differences 
between pooled nerves, foot pads, and DRG.  Surprisingly, the highest levels of KU-32 were 
found at the initial time point at 30 minutes (Ci-30) for all tissues (Table 10; Figure 30A-C), 
indicating that maximum drug concentrations for these tissues had already been reached and 
that drug absorption into the blood and tissue distribution occur remarkably fast.  Additional 
analyses were performed using natural log plots of mean KU-32 analyte levels over time 
(Figure 30E-G).  The r2-values for linear regression segments [0.952 (pooled nerves); 0.934 
(foot pads), and 0.995 (DRG)] supported first-order elimination kinetics for all tissues.8-9  
While the elimination rate constant (ke) for pooled nerves was nearly identical to the DRG, 
the ke for foot pads was 41% less than that of pooled nerves, resulting in a 67% longer 
half-life (t1/2) in foot pads.  Given these half-life and Ci-30 data, it was determined that 99.9% 
of total drug distributed to these tissues was eliminated 6.4 hours (pooled nerves), 10.4 hours 
(foot pads), and 6.6 hours (DRG) after treatment.  These data suggest that foot pads are 
exposed to KU-32 roughly 60% longer than pooled nerves and DRG.  Unfortunately, while 
AUC calculations are best-suited for comparing the overall extent of drug exposure between 
tissues (and delivery routes), these calculations required additional (earlier) time points to 
accurately capture the maximum drug concentrations (Cmax) and initial distribution from Co 
(concentration at time point zero) to the true Cmax.  
Table 10.  IP-PK parameters.   
     
Tissue (IP Treatment) Ci-30 (ng/g) ke (h-1) t1/2 (h) 
Pooled Nerves  (20 mg/kg KU-32) 5,720 1.18 0.590 
Foot Pads  (20 mg/kg KU-32) 3,680 0.696 0.996 
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Figure 30.  IP-PK and OG-PK time profiles for KU-32.  Mean KU-32 analyte levels and 
one-phase exponential decay equations for (A) pooled nerves, (B) foot pads, (C) DRG, and 
(D) plasma were plotted over time following 10 mg/kg KU-32 (OG) or 20 mg/kg KU-32 
(OG and IP) treatments; error bars denote ± SEM.  Natural log conversions of mean KU-32 
analyte levels and linear regression segments for (E) pooled nerves, (F) foot pads, (G) DRG, 
and (H) plasma were plotted over time.  Dashed lines represent IP treatments and solid lines 
portray OG treatments.  *, p < 0.025 between 20 mg/kg KU-32 OG and 20 mg/kg KU-32 IP; 




Figure 31.  KU-32 levels after an 8-week intervention study.  KU-32 analyte levels in the 
(A) pooled nerves, (B) foot pads, and (C) DRG after an 8-week intervention study in SW 
mice.  All tissues were collected 7-9 days after the sixth (final) weekly IP treatment at the 















































3.3.  KU-32 Levels After an 8-Week Intervention Study 
Eight-week STZ-diabetic and non-diabetic SW mice were given 2, 10, or 20 mg/kg 
KU-32 IP treatments once per week for six weeks.  One week after the final treatment, 
LC/MS/MS analysis showed virtually no detectable KU-32 present in pooled nerves, foot 
pads, and DRG (Figure 31).  These data suggest that KU-32 was either never distributed to 
these tissues or that KU-32 was entirely eliminated before sampling.  Drug elimination data 
from Experiment 2 support the latter, predicting that 99.9% of all drug distributed to these 
tissues is eliminated within 11 hours of treatment.  Conversely, the data here reinforce the 
findings of Experiment 2, suggesting that weekly IP treatments at this dose are insufficient 
to cause drug accumulation in these tissues, thus ruling out drug accumulation as a possible 
explanation for the progressive neuroprotective effects elicited by KU-32.1 
In most cases, KU-32 analyte levels were well below the limit of detection (LOD) for 
LC/MS/MS (defined in the LC/MS/MS section).  However, there were three cases in which 
KU-32 was detected:  two in pooled nerves [1x STZ-diabetic (10 mg/kg KU-32) and 
1x Non-Diabetic (20 mg/kg KU-32)] and one in DRG [1x STZ-diabetic (2 mg/kg KU-32)].  
The reasons for these outliers are unknown but may be linked to individual variations in 
drug absorption, distribution, and elimination.  This is partly supported by the non-normality 
and high variance observed across treatment groups.  While it is tempting to speculate that 
disease-induced reductions in vascular support could affect drug elimination, it seems 
unlikely for two reasons.  First, while the extremities are the most common site for vascular 
deterioration in diabetes mellitus14, KU-32 was not found in time-matched foot pads.  
Second, trace levels of KU-32 were found in the pooled nerves of non-diabetic mice, which 
should have normal vasculature to facilitate elimination.  Regardless, these levels comprise 
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less than 2% of initial drug concentrations measured at 30 minutes in Experiment 2, which is 
far less than the standard deviation for these points.  Fortunately, the detection of KU-32 in 
STZ-diabetic tissues does confirm that at least some drug is distributed to diabetic tissues.  
Even so, further temporal IP-PK studies in STZ-diabetic mice are needed to assess particular 
disease influences on KU-32 absorption, distribution, and elimination. 
3.4.  Oral Gavage Pharmacokinetic Time Profiles for KU-32 
 Temporal OG-PK analyses revealed several dose-dependent distribution and elimination 
differences between pooled nerves, foot pads, and DRG and dose-dependent differences in 
drug absorption and elimination in the plasma.  The highest KU-32 levels were found at the 
initial 60-minute time point (Ci-60) for all tissues and plasma, again suggestive of rapid drug 
absorption into the blood and distribution to the tissues (Table 11; Figure 30A-D).  This 
rapid drug absorption was corroborated by Dr. Maged Zeineldin (Molecular Biosciences), 
who performed identical PK analyses on intestinal samples also collected from these mice.  
He found that KU-32 levels were highest in the superior duodenum, but quickly diminished 
upon passing posteriorly through the jejunum and ileum (unpublished results).  However, 
with the analyses performed, it was not possible to determine if KU-32 was fully depleted 
before reaching these regions or if physiological differences affected absorption.   
Table 11.  OG-PK parameters.   
    
Tissue (OG Treatment) Ci-60 (ng/g) ke (h-1) t1/2 (h) 
Pooled Nerves  (10 mg/kg KU-32) 999 0.874 0.793 
Pooled Nerves  (20 mg/kg KU-32) 2,220 0.557 1.25 
Foot Pads  (10 mg/kg KU-32) 940 0.322 2.15 
Foot Pads  (20 mg/kg KU-32) 1,870 0.271 2.56 
DRG  (10 mg/kg KU-32) 1,270 0.264 2.62 
DRG  (20 mg/kg KU-32) 1,830 0.237 2.93 
Plasma  (10 mg/kg KU-32) 1,130 0.673 1.03 




 Further analyses were performed using natural log plots of mean KU-32 analyte levels 
over time (Figure 30E-H).  The linear regression segments established for these plots had 
r2-values of:  0.993 (10 mg/kg KU-32) and 0.970 (20 mg/kg KU-32) for pooled nerves; 
0.969 (10 mg/kg KU-32) and 0.977 (20 mg/kg KU-32) for DRG; 0.992 (10 mg/kg KU-32) 
and 0.991 (20 mg/kg KU-32) for foot pads; and 0.978 (10 mg/kg KU-32) and 0.944 
(20 mg/kg KU-32) for plasma, suggesting that elimination followed first-order kinetics.8-9  
As expected, there were dose-dependent differences in drug absorption, distribution, and 
elimination.  Initial tissue levels (Ci-60) for the pooled nerves, foot pads, and plasma of 
20 mg/kg KU-32 OG-treated mice were nearly twice that of 10 mg/kg OG-treated mice.  
Intriguingly, the Ci-60 for DRG of 20 mg/kg KU-32 OG-treated mice was 44% higher than 
those of 10 mg/kg OG-treated mice.  Drug elimination rate constants were consistently 
higher for tissues of 10 mg/kg OG-treated mice [57% (pooled nerves), 18% (foot pads); and 
11% (DRG) higher] than those of 20 mg/kg KU-32 OG-treated mice.  
 In considering half-life and Ci-60 data, it was determined that 99.9% of all drug 
distributed to the tissues of 10 mg/kg KU-32 OG-treated mice is eliminated 8.9 hours 
(pooled nerves), 22.4 hours (foot pads), and 27.1 hours (DRG) after treatment.  Likewise, 
99.9% of all drug distributed to the tissues of 20 mg/kg KU-32 OG-treated mice is 
eliminated 13.5 hours (pooled nerves), 26.5 hours (foot pads), and 30.2 hours (DRG) after 
oral gavage.  Similarly, calculations with plasma half-life and Ci-60 data showed that 99.9% 
of all drug absorbed into the blood is eliminated 11.3 hours (10 mg/kg KU-32) and 11.9 
hours (20 mg/kg KU-32) after gavage.  Hence, the duration of drug exposure for foot pads 
and DRG seems to be over twice that of pooled nerves and plasma. 
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SECTION 4.  DISCUSSION AND CONCLUDING REMARKS  
4.1.  KU-32 Pharmacokinetic Time Profile Comparisons 
 The results obtained show that KU-32 is rapidly absorbed and distributed to DSPN-
relevant tissues within 30 minutes of IP treatment or one hour of gavage.  Temporal IP-PK 
and OG-PK analyses suggest that 99.9% of all drug distributed to the pooled nerves, foot 
pads, and DRG is eliminated within ~ 30 hours of treatment.  These inferences are consistent 
with findings from the 8-week intervention study, which showed virtually no detectable 
levels of KU-32 present in the tissues of non-diabetic and diabetic mice one week after final 
treatment.  With that said, there were still distinct differences in drug distribution and 
elimination between delivery routes, tissues, and doses.  Possible explanations for these 
observations are discussed herein. 
 Since peripheral nerve fibers stem from the neuronal cell body (soma) located within the 
DRG, one might expect KU-32 to readily diffuse throughout the neuron, regardless of its 
site of entry and relative hydrophobicity, thereby resulting in similar drug concentrations 
and elimination kinetics for DRG that perhaps lag behind those of pooled nerves.15  This 
seems to be true for the DRG and pooled nerves of 20 mg/kg KU-32 IP-treated mice, which 
do demonstrate comparable Ci-30, ke, and t1/2 values after temporal PK analyses (Table 10).  
This was not the case for OG-treated mice (Table 11).  Drug elimination half-lives for the 
DRG of OG-treated mice (10 and 20 mg/kg KU-32) were 2-3 times greater than those of 
pooled nerves.  In comparing drug elimination half-lives for DRG and pooled nerves 
between delivery routes (20 mg/kg KU-32 OG versus 20 mg/kg KU-32 IP), it was found 
that tissues of OG-treated mice had half-lives that were 2.3 hours (DRG) and 0.7 hours 
(pooled nerves) longer than those of IP-treated mice.  Hence, it takes an additional 7.1 hours 
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(pooled nerves) and 23.6 hours (DRG) to eliminate 99.9% of the total drug distributed to 
these same tissues in OG-treated mice.   
 While it was reasonable to expect variations in initial drug distribution based on drug 
dose and delivery routes, the reasons for differences in elimination kinetics are unknown.8-10, 
12-13  For DRG, we first suspected that differences in extraction solvent:sample mass ratios 
used during the pulverization step of KU-32 extraction could cause variations in KU-32 
analyte recovery.  Drug extraction from the DRG of OG-treated mice was performed using 
10 mg tissue/g H2O, whereas extraction from the DRG of IP-treated mice was conducted 
using 25 mg tissue/g H2O.  Given KU-
extra solvent could enhance the amount of total free drug recovered in solution.  Moreover, 
lesser amounts of tissue pulp in near equivalent volumes of water between protocols should 
lessen the likelihood of KU-32 repartitioning back into the pulverized tissues.  While this 
might be possible, it seems unlikely given that each homogenate was intensely vortexed 
immediately prior to aliquot collection and that tissue mass-dependent equivalents of 
d3KU-32 internal standard were recovered at similar rates between delivery routes.  Thus, 
the question remained, why does KU-32 elimination kinetics for DRG (and foot pads and 
pooled nerves) differ so much between delivery routes?   
 To answer this, plasma IP-PK and OG-PK time profiles were compared.  While plasma 
samples were not collected during these IP experiments, we have previously reported plasma 
KU-32 levels after 2 mg/ml KU-32 (5% Captisol) IP injections in Balb/c mice (Figure 32).1  
This study also showed rapid drug absorption into the blood with maximum absorption 
levels occurring within 15 minutes of treatment.1  In 10 mg/kg KU-32 and 20 mg/kg KU-32 
OG-treated mice, drug elimination half-lives for plasma were consistent at about 1.1 hours, 
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and plasma drug concentrations appeared to be dose-dependent.  In the Balb/c study, the 
drug elimination half-life for plasma was ~ 1.8 hours.  However, dosing must be considered.   
 
Figure 32.  KU-32 IP-PK time profiles for plasma and whole brain.  1 ml of 2 mg/ml 
KU-32 (5% Captisol) was injected intraperitoneally in Balb/c mice. Plasma and whole brain 
samples were harvested at the indicated times and analyzed using LC/MS/MS.1  
 
 Approximately 150 µl of 5 mg/ml KU-32 stock solution was needed for each 20 mg/kg 
KU-32 OG treatment, meaning that ~ 0.75 mg of KU-32 was administered into each animal.  
In contrast, 1 ml of 2 mg/ml KU-32 stock solution gives a total of 2 mg KU-32 injected into 
each Balb/c mouse.1  Setting aside vehicle differences, the net amount of KU-32 delivered in 
OG treatments was 37.5% of that used for the IP treatments.  Incredibly, the amount of 
KU-32 circulating in the blood after one hour of OG treatment is over twice that ever 
achieved in IP-treated Balb/c mice.1  Given that the Ci-30 levels reported herein for pooled 
nerves, foot pads, and DRG were all above 3,000 ng/g for 20 mg/kg KU-32 IP-treated mice, 
it seems likely that the majority of IP-administered drug diffuses directly into the tissues 
rather than first partitioning into the blood for distribution.  Conversely, OG requires drug 
absorption across the gut for systemic blood circulation and then tissue distribution.  It 
seems possible that IP drug delivery could result in more superficial drug penetration into 
DSPN-relevant tissues.  Further, diffusion back out of superficial tissue layers may occur 
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more rapidly once initial drug distribution is complete.  In contrast, more systemic blood 
circulation (via OG) may afford more thorough penetration into deeper tissue layers.  It is 
important to note that L4-L6 DRG are largely encased in the lumbar intervertebral foramena 
of the spinal column, which only allows the nerve roots to protrude out into the periphery.15-
16  This makes the DRG less susceptible to IP drug treatments.17  However, DRG also lack a 
protective capsular membrane as seen in the blood-brain barrier.17  Given that the DRG are 
still highly perfused by capillaries, they are more susceptible to orally bioavailable drugs.17  
In regard to peripheral nerves, the vasa nervorum may provide better access to inner nerve 
fibers by bypassing the protective nerve sheathes (Figure 33).18  For foot pads, higher drug 
plasma levels would likely increase more remote cutaneous drug distribution via capillaries.  
Overall, these reasons may partly explain why drug elimination half-lives for DRG, pooled 




Figure 33.  Vasa nervorum.  Radicular vessels (RV) stemming from regional extrinsic 
vessels (EV) comprise the vasa nervorum, or the microvasculature supplying the peripheral 
nerves.  Also shown are the epineurium (Epi), perineurium (Peri), and endoneurium (Endo) 





4.2.  Inducible Hsp70 and KU-32 Pharmacokinetics  
 In support of the ongoing hypothesis that inducible Hsp70 is essential for KU-
neuroprotective effects in DSPN, we have shown that KU-32 distribution to the pooled 
nerves, foot pads, and DRG are indistinguishable between WT B6 and Hsp70 KO mice.1-2, 
19-20  While 2-hour foot pad data did seem to deviate between strains, the difference was 
insignificant (p = 0.0809).  Should this deviation become significant with increased sample 
sizes , KU-32 levels would likely become higher for the foot pads of Hsp70 KO mice.  Such 
a distinction would be irrelevant, however, given that more KU-32 would be available to 
tissues of Hsp70 KO mice.  Hence, our previous report of KU-32 inefficacy in STZ-diabetic 
Hsp70 KO mice was not the result of less drug distribution and availability in these tissues, 
but rather a mechanistic consequence of inducible Hsp70 deletion.1-2 
4.3.  Concluding Remarks and Future Directions  
 In summary, we have shown that KU-32 is rapidly distributed to DSPN-relevant tissues 
and readily available for local Hsp90 modulation almost immediately after IP and gavage 
treatments.  The finding that KU-32 is readily eliminated from these tissues within the 
normal dosing timeframe argues against the notion that mounting drug concentrations are 
related to KU- tive effects.  Interestingly, OG drug delivery 
seemed to increase the drug elimination half-lives in all examined tissues relative to IP 
treatments.  However, the resounding question still remains, are these concentrations 
achieved by OG sufficient to elicit the same neuroprotective effects observed with IP 
treatments?  In this regard, dose-dependent improvements in electrophysiological and 
psychophysical indices of DSPN in 8-week intervention studies have been demonstrated 
                                                 
 As described in the Statistical Analyses and Pharmacokinetic Calculations section, small sample sizes as 
well as data non-normality and high variance were all major limitations. 
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using an IP dose range of  2-20 mg/kg KU-32.1, 21  Hence, it seems likely that repeated 
exposure to even low amounts of KU-32 could be beneficial.  However, this is contingent 
upon how the disease impacts drug distribution to these DSPN-relevant tissues.   
 In CHAPTER II, we demonstrated that pharmacologic Hsp90 modulation improves 
psychophysical, electrophysiological, morphological, and bioenergetic indices at more 
chronic stages of DSPN development.  Previous studies have also shown that KU-
neuroprotective effects in DSPN are contingent upon the expression of inducible Hsp70.1-2  
Herein, we have established that KU-32 distribution and elimination in DSPN-relevant 
tissues are unaffected by inducible Hsp70 deletion.  While this local drug availability in 
DSPN-relevant tissues of Hsp70 KO mice does support the mechanistic importance of 
inducible Hsp70 for KU-32 effectiveness, the molecular mechanisms underlying these 
neuroprotective effects still remain elusive.  However, the confirmation that KU-32 is 
locally available within the DRG, pooled nerves, and foot pads, combined with the prospect 
for remote Hsp90 modulation and Hsp70 translation in neurons, opens the door to multiple 
mechanistic possibilities.22   
 In the future, it will be important to explore whether KU-32 can effectively enhance 
IGF-I-induced neurite outgrowth and mitochondrial bioenergetic improvements in sensory 
neurons (DRG) isolated from intervention study mice.  Given the extent of Hsp90 client 
protein involvement in the IGF- -I 
signaling during late stages of DSPN, and the highly similar neuroprotective effects elicited 
by both KU-32 and IGF-I intervention in STZ-diabetic rodents (CHAPTER II), boosting 
endogenous IGF-I signaling may be a valid mechanism of action for KU-32.22-44  The 
realization that KU-32 is orally bioavailable and displays different temporal PK patterns 
 
 169 
compared to IP treatments in DSPN-relevant tissues clearly warrants further investigation in 
OG KU-32 intervention studies.  Further, additional PK studies are needed to determine 
whether KU-32 disposition is affected by diabetes and its other associated complications.   
  In conclusion, KU-32 represents a novel pharmacotherapeutic approach that can 
effectively treat more humanistic hallmarks of DSPN at acute and chronic stages of 
development.  These neuroprotective qualities, in conjunction with desirable PK attributes, 
provide great promise as the first effective treatment option for DSPN.  
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